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E-cadherin is a cell-to-cell adhesion protein encoded by the gene CDH1. Germline 
inactivating mutations in CDH1 underpin hereditary diffuse gastric cancer (HDGC), an 
autosomal dominant disease that strongly increases an individual’s likelihood of 
developing diffuse gastric cancer (DGC) and invasive lobular breast cancer (ILBC). 
Current clinical intervention strategies for CDH1 mutation carriers are limited, with the 
only available approaches being endoscopic surveillance or prophylactic gastrectomy. 
There is a pressing need to develop chemoprevention strategies to supplement the current 
approaches. 
 
As E-cadherin is a tumour suppressor protein and lost from the cancer cell, it is not a 
conventional drug target. This issue can, however, be circumvented using a synthetic 
lethal approach. Synthetic lethality is defined as a genetic interaction in which a 
combination of mutations in two or more genes leads to cell death but no death with 
either mutation alone. Therapeutically, this approach allows for the specific targeting of 
cells harbouring tumour suppressor gene mutations. 
 
We have previously applied a synthetic lethal strategy to identify candidate therapeutic 
drugs in a non-malignant isogenic pair of MCF10A cell lines, one with and one without 
CDH1 expression (MCF10A CDH1-/-). From this testing, a panel of lead drugs were 
identified, however, the synthetic lethal effects were relatively modest and also reduced 
the viability of E-cadherin-expressing MCF10A cells. This led to our interest in 
developing synergistic, synthetic lethal drug combinations, where co-treatment of an 
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additional drug may increase the synthetic lethal response whilst minimising toxicity to 
wild-type MCF10A cells. 
 
Prior to drug testing, a range of endpoint (CellTiter-Glo, resazurin reduction, and nuclei 
counting) and real-time (IncuCyte and xCELLigence) cell viability assays were compared 
to develop an optimum drug screening platform for the MCF10A isogenic cells. We 
identified nuclei counting and IncuCyte assays as the most cost-effective and accurate 
approaches. These assay methodologies were used alongside the Chou-Talalay median 
effect analysis to assess drug synergy at 50% viability loss (ED50) via a combination 
index (CI), whereby a CI score below 0.9 represents a synergistic interaction. 
 
A range of drugs were delivered simultaneously to the MCF10A isogenic pair in order to 
discover synergistic combinations that were synthetic lethal with CDH1. The lipid-
lowering agents statins were identified as a drug class that specifically reduced MCF10A 
CDH1-/- cell viability whilst modestly affecting wild-type MCF10A cells up to a 
concentration of 5 μM. Co-treatment of atorvastatin with our previously identified lead 
synthetic lethal drugs, entinostat, vorinostat, and saracatinib, maintained synthetic 
lethality and showed evidence of a synergistic interaction, producing MCF10A CDH1-/- 
ED50 CI values of 0.37, 0.50, and 0.47, respectively. The most potent synergistic and 
synthetic lethal effect, however, was produced by atorvastatin in combination with the 
progesterone receptor and glucocorticoid receptor antagonist mifepristone, with MCF10A 
and MCF10A CDH1-/- ED50 CI values of 0.49 and 0.08, respectively. 
 
The atorvastatin and mifepristone combination exclusively arrested MCF10A CDH1-/- 
cells in the G1 phase of the cell cycle. This effect was shown to be independent of 
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mevalonate and Hippo signalling – key pathways known to be affected by statin 
treatment. In addition to the non-malignant MCF10A breast cell line, the atorvastatin and 
mifepristone combination produced a synergistic loss of cell viability in two E-cadherin-
deficient breast cancer cell lines, the ILBC-derived line IPH-926 (ED50 CI = 0.69) and 
the triple-negative breast cancer (TNBC)-derived MDA-MB-231 line (ED50 CI = 0.61). 
To the best of our knowledge, the combination of a statin and mifepristone has not been 
previously described in the literature. 
 
In summary, this study has discovered statins as a synthetic lethal drug class in a non-
malignant cell line lacking CDH1 expression. Co-treatment of atorvastatin and 
mifepristone produced an enhanced synthetic lethal response, a synergistic drug 
relationship that was maintained across malignant breast cell lines devoid of CDH1 
expression. These findings may serve as a foundation for the development of novel DGC 
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This thesis comprises six main chapters with appendices. 
 
Chapter one is a general introduction. This chapter discusses E-cadherin dysregulation in 
cancer, with an emphasis on diseases caused by germline E-cadherin mutations. Relevant 
E-cadherin-dependent signalling pathways are also presented, as well as the concept of 
synthetic lethality and drug synergy. Finally, this chapter concludes with an outline of the 
project’s aims. 
 
Chapter two outlines the materials and methods used in this project. 
 
Chapter three is the first of three results chapters. In addition to presented data, each 
results chapter contains an introduction and discussion sub-chapter. This results chapter 
presents data comparing a range of endpoint and real-time cell viability assays. The 
favoured endpoint assay (nuclei counting) and real-time assay (IncuCyte) are used in the 
subsequent results chapters. 
 
Chapter four is the second results chapter. This chapter presents data from a screen for 
synergistic drug combinations that are synthetic lethal in E-cadherin-deficient cells. 
 
Chapter five is the third results chapter. This chapter aims to characterise both the 
synergistic and synthetic lethal mechanisms of the lead drug combination, atorvastatin 
and mifepristone, identified in chapter four. 
 
 xx 
Chapter six outlines potential future directions of this research. This chapter describes a 
pathway of additional experiments that may lead to clinical use of the atorvastatin and 









1. GENERAL INTRODUCTION 
1.1 E-CADHERIN DYSREGULATION IN CANCER 
The transition from benign tumours to invasive, metastatic cancer cells is known to involve 
changes in cell motility and intercellular contact mechanisms (Semb and Christofori, 1998).  It 
is therefore not surprising that dysregulation of E-cadherin (CDH1), a protein involved in 
epithelial cell-to-cell adhesion complexes, has been implicated in the development of many 
cancers types (Hollestelle et al., 2013). Downregulation of CDH1 expression is a common 
feature of numerous epithelial tumours including gastric, breast, prostate, ovarian, lung, oral, 
colorectal, and hepatocellular carcinoma (Batlle et al., 2000; Guilford et al., 1998; van Roy and 
Berx, 2008). In addition, germline inactivating CDH1 mutations define hereditary diffuse 
gastric cancer (HDGC), an inherited cancer syndrome predisposing individuals to increased 
rates of diffuse gastric cancer (DGC) and invasive lobular breast cancer (ILBC) (Guilford et al., 
1998; van der Post et al., 2015). 
 
1.1.1 Gastric Cancer  
Gastric cancer is the fourth most common cause of cancer worldwide; by 2030 deaths from 
gastric cancer globally are predicted to have risen from the 15th to the 10th leading cause of 
mortality from all causes (Mathers and Loncar, 2006).  In New Zealand, current age-
standardised rates of gastric cancer equate to 7.6 per 100,000 for males and 4.0 for females 
(Torre et al., 2016).  Although the vast majority of gastric cancers are sporadic, approximately 
1-3% of cases arise as a result of inherited gastric cancer predisposition syndromes (La Vecchia 
et al., 1992; Varley et al., 1995; Vasen et al., 1996). 
 
 3 
Gastric cancer is typically characterised using Lauren’s classification, where two histotypes are 
described – intestinal and diffuse (a mixed type is also observed) (Lauren, 1965). Intestinal 
gastric cancer is more common than the diffuse type, with incidence rates of 8.6 per 100,000 
and 4.7 per 100,000, respectively (Ekstrom et al., 2000). However, these rates are changing – 
the rate of intestinal cases is declining, whilst diffuse cases are increasing by approximately 
3.7% per year (Guggenheim and Shah, 2013; Henson et al., 2004).  
 
1.1.2 Hereditary Diffuse Gastric Cancer (HDGC) 
In 1998, linkage analysis demonstrated that germline mutations of the E-cadherin gene (CDH1) 
are the genetic cause of HDGC (Guilford et al., 1998).  HDGC is an autosomal dominant 
inherited syndrome that leads to an increased risk for both diffuse gastric and lobular breast 
cancers.  A recent analysis of 75 families with pathogenic CDH1 mutations has estimated a 
cumulative penetrance risk of diffuse gastric cancer (DGC) by age 80 years of 70% for males 
and 56% for females (Hansford et al., 2015). CDH1 mutation carriers develop cancer after 
somatic inactivation of the CDH1 second allele. The trigger and molecular mechanism by which 
the second CDH1 allele is inactivated appears to be diverse and includes methylation, mutation, 
and loss of heterozygosity (Barber et al., 2008; Oliveira et al., 2009). Bisulfite analysis of 
stomach adenocarcinoma tissue from CDH1 mutation carriers suggests 50% of early stage 
cancers have had the second allele inactivated by promoter hypermethylation (Humar et al., 
2009).  
 
CDH1 mutation carriers develop multiple stage T1a signet ring cell carcinomas (SRCC) from 
an early age (Figure 1.1) (Charlton et al., 2004; Norton et al., 2007). These T1a foci present in 
large numbers as either isolated cells or small clusters in the lining of the stomach, with a 
median number of 20 and maximum of 500 foci observed in resected tissue (Charlton et al., 
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2004; Guilford et al., 2010). Fortunately, T1a foci display a low proliferative index; showing 
low Ki67 staining and fewer mitotic cells than adjacent healthy tissue (Barber et al., 2008; 








Figure	  1.1	  Stage	  T1a	  signet	  ring	  cell	  carcinoma	  (SRCC)	  in	  a	  germline	  CDH1	  mutation	  carrier	  
Left:	  a	  total	  gastrectomy	  specimen	  from	  a	  15	  year	  CDH1	  mutation	  carrier	  showing	  the	  anatomical	  location	  of	  
318	  stage	  T1a	  foci.	  Black	  circles	  are	  carcinoma	  foci,	  to	  scale,	  except	  foci	  <1	  mm	  are	  shown	  arbitrarily	  as	  1	  mm	  
for	   visibility.	   Right:	   An	   example	   of	   a	   9	   mm	   H&E	   stained	   focus	   showing	   the	   location	   between	   the	   mucosal	  
surface	  and	  the	  muscularis	  mucosae.	  Signet	  ring	  cells	  can	  be	  observed	   in	  the	  bottom	  left	   frame.	  Reproduced	  
from	  Hereditary	  diffuse	   gastric	   cancer:	   predominance	  of	  multiple	   foci	   of	   signet	   ring	   cell	   carcinoma	   in	  distal	  
stomach	  and	  transitional	  zone,	  Charlton	  et	  al.,	  53,	  814-­‐20,	  2004	  with	  permission	  from	  BMJ	  Publishing	  Group	  
Ltd.	  
 
Progression from indolent T1a lesions to advanced HDGC presents as linitis plastica with 
diffuse infiltration of the gastric wall. SRCC tend to migrate below an intact mucosa, 
consequently early stage DGC is difficult to detect by standard gastroscopy and tends to be 
asymptomatic at early stages (van der Post et al., 2015). HDGC is therefore often diagnosed at a 
late stage with a poor prognosis, with a 5-year survival rate below 30% (Koea et al., 2000; 
Stiekema et al., 2013). At present, prophylactic total gastrectomy (PTG) is the single option to 
remove an inherited risk of gastric cancer and is recommended after age 20 years (van der Post 
et al., 2015).  
 
The low proliferative status of T1a lesions means the progression to advanced DGC is a slow 




identified no lesions above T1a stage (Charlton et al., 2004). This suggests that advanced 
HDGC is a rare event, whereby the vast number of T1a foci remain dormant until a chance 
mutation drives cancer progression. One such gene, SRC, has been identified as a key driver of 
this process (Humar et al., 2007). The biology at play presents a potential therapeutic window 
for CDH1 mutation carriers, where drug treatment may be used to obliterate the reservoir of T1a 
foci prior to the acquisition of deleterious mutations and advanced disease. This 
chemoprevention option would provide a much-needed, novel alternative to PTG surgical 
intervention.  
 
1.1.3 Invasive Lobular Breast Carcinoma (ILBC) 
Breast cancer is the leading cause of cancer-related death in females worldwide, with an 
estimated 1.7 million cases and 521,900 deaths occurring in 2012 (Torre et al., 2016). CDH1 
expression is often decreased in the invasive ductal carcinoma (IDC) subtype, and lost entirely 
in invasive lobular breast carcinoma (ILBC) – the second most common invasive breast cancer 
subtype that comprises 10-15% of all breast cancer cases (Arpino et al., 2004; Christgen and 
Derksen, 2015; Singhai et al., 2011; Vos et al., 1997). Carriers of pathogenic CDH1 mutations 
are at an increased risk of developing ILBC (approximately 40% lifetime risk) (Pharoah et al., 
2001). 
 
ILBCs are typically oestrogen receptor positive (ER+), belonging to the luminal or normal-like 
molecular subtype, and have a slow proliferation rate (Bertucci et al., 2008; Christgen and 
Derksen, 2015). ERBB2 amplification and loss of expression of the tumour suppressor TP53 is 
rare, however, activating PIK3CA mutations are prominent (30-50% of ILBC cases) (Bertucci et 
al., 2008; Christgen and Derksen, 2015; Christgen et al., 2013; Christgen et al., 2016). An 
aggressive ILBC variant, termed pleomorphic ILBC, comprises 1-5% of ILBCs and harbours a 
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contrasting molecular complexion to classical ILBC. Pleomorphic ILBCs are usually oestrogen 
receptor negative (ER-) and occasionally ERBB2-positive, with inactivating TP53 mutations 
observed in most cases (Ercan et al., 2012; Simpson et al., 2008). As such, TP53 is considered 
the ‘gatekeeper’ between the slow-growing classical and aggressive pleomorphic ILBC variants.  
 
The prognosis for ILBC patients is currently debated in the literature. Some studies have 
reported a 5-year disease-free survival rate as similar to or slightly greater than that seen for 
other breast cancer subtypes such as IDC (Biglia et al., 2013; Korhonen et al., 2013). However, 
these findings are contested due to anti-oestrogen therapies showing poorer response in ILBC 
patients than IDC patients – an interesting observation considering ILBCs have a greater 
proportion of ER+ specimens than IDCs (90% vs. 50%, respectively) (Lehmann, 2015; Rakha et 
al., 2008). It has therefore been suggested that the long-term ILBC prognosis may be worse than 
IDC (Arpino et al., 2004; Lehmann, 2015; Pestalozzi et al., 2008). 
 
1.2 E-CADHERIN FUNCTION 
E-cadherin is the founding member of the cadherin superfamily, which includes 32 major 
cadherins (CDH), 65 protocadherins (PCDH), and 17 cadherin-related (CDHR) members (Gul 
et al., 2017). E-cadherin is a transmembrane calcium-dependent cell-to-cell adhesion 
glycoprotein, located at the adherens junction in the epithelium (Figure 1.2).  It consists of five 
cadherin repeats in the extracellular domain, one transmembrane domain, and an intracellular 
domain that binds p120-catenin and β-catenin (van Roy and Berx, 2008).  As β-catenin is 
capable of binding to α-catenin (a regulator of actin polymers), E-cadherin thus mediates the 
connection between the cell and filaments in the cytoskeleton (Onder et al., 2008). E-cadherin-
actin signalling at the adherens junction recruits and activates myosin II, a protein that generates 
contractile tension forces at the junction and influences actin organisation (Lecuit and Yap, 
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2015). Indeed, we have shown a contrasting cytoskeletal framework between E-cadherin-
expressing and E-cadherin-deficient cells, with disorganised actin fibre and microtubule 
patterning apparent following E-cadherin loss (Chen et al., 2014a). 
	  
Figure	  1.2	  E-­‐cadherin	  association	  with	  cytoskeletal	  filaments	  at	  the	  adherens	  junction	  
“Mechanisms	  for	  the	  E-­‐cadherin	  molecular	  complex	  to	  associate	  with	  actin	  of	  the	  actomyosin	  apparatus.	  Actin	  
filaments	  may	  bind	  directly	  to	  α-­‐catenin,	  interact	  with	  α-­‐catenin-­‐associated	  proteins,	  or	  bind	  to	  proteins	  such	  
as	  myosin	  VI,	  which	  can	  associate	  with	  E-­‐cadherin	  independently	  of	  α-­‐catenin.”	  Reprinted	  by	  permission	  from	  
RightsLink	   Permissions	   Springer	   Customer	   Service	   Centre	   GmbH:	   Springer	   Nature,	   Nature	   Cell	   Biology,	   E-­‐
cadherin	  junctions	  as	  active	  mechanical	  integrators	  in	  tissue	  dynamics,	  Lecuit	  and	  Yap,	  Copyright	  (2015).	  	  	  
 
In addition to cytoskeletal binding, E-cadherin forms extracellular contacts with neighbouring 
cells via homophilic ligation. These cell-to-cell contacts tend to accumulate in groups in the 
lateral cell membrane, termed ‘lateral clusters’, and stabilise an apical-basal polarity within the 
epithelium (Rodriguez-Boulan and Macara, 2014; Yap et al., 2015). A polarised phenotype 
allows epithelial cells to perform a range of functions such as expansion or constriction of 
apical or lateral membranes, processes central to tubulogenesis and the formation of columnar 
or squamous epithelia; and orientation of the mitotic spindle, which allows cell division to occur 
parallel or perpendicular to the epithelial plane (Lechler and Fuchs, 2005; Rodriguez-Boulan 
and Macara, 2014; Sawyer et al., 2010). E-cadherin therefore plays an important role in cell 
differentiation, stemness, and migration (Onder et al., 2008). Downregulation of CDH1 is 
central to a process known as the epithelial-mesenchymal transition (EMT) in which epithelial 
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on the asymmetric distribution of clustered E-cadherin at junctions46. 
These coupled patterns of movement therefore indicate that E-cadherin 
adhesion and actomyosin are physically linked to one another, allowing 
actomyosin to transmit forces to the adhesion system.
The physical connection between cadherin complexes and the con-
tractile apparatus is principally mediated by association with the F-actin 
component of actomyosin. Multiple mechanisms link E-cadherin to 
F-actin (Fig. 1b). A key role is played by α-catenin47,48, which can directly 
bind actin filaments49 and also supports less direct interactions through 
proteins such as vinculin48,50,51 and EPLIN (also known as LIMA1)52.
Other molecular mechanisms also participate, such as the unconven-
tional motor myosin VI, which can associate directly with E-cadherin53 
and is recruited to apical cadherin junctions (zonulae adherente) in 
polarized epithelia54. Although we do not yet understand why such a 
wide range of proteins are able to link cadherins to cortical F-actin, one 
interesting possibility is that they may be making distinct contributions 
to the mechanical properties of the junctions. For example, although 
myosin VI is a processive motor that moves towards the minus-ends 
of actin filaments, under resistive load — such as it might experience 
at adherens junctions — it can potentially convert to an actin-binding 
anchor55 that might serve to reinforce cadherin–actin associations under 
stress. Alternatively, they may reinforce mechanical coupling with forces 
that have different orientations to the junctions (for instance, perpen-
dicular (or normal) versus tangential to junctions)51. More generally, this 
emphasizes the notion that multiple actin pools exist which interact with, 
and organize, subsets of cadherins within the junctions56–58.
However, E-cadherin adhesions also contribute to the biogenesis of 
the junctional actomyosin cortex itself (Fig. 1c). E-cadherin adhesions 
are sites of Rho signalling59,60, which activates myosin II, and the cad-
herin–catenin complex participates in coordinating the balance of Rho 
activators (guanine nucleotide exchange factors (GEFs)) and inactivators 
(GTPase-activating proteins (GAPs)) at adherens junctions60. Rho sig-
nalling is mediated by the ROCK protein kinase, which also associ-
ates with E-cadherin at cell–cell junctions61,62. Other proteins that can 
interact with ROCK to promote its junctional accumulation, such as 
the actin-binding protein Shroom, also have important roles in control-
ling junctional tension and morphogenesis61,63. Additionally, E-cadherin 
adhesions promote actin assembly at the junctional cortex by recruiting 
actin regulators (for example, Arp2/3 (ref. 64), formins (ref. 65), CD2AP 
(ref. 66) and cortactin (ref. 67)) and the signalling pathways that activate 
them. These associations between signalling molecules and actin regu-
lators at E-cadherin-based junctions help generate the actin networks 
that are necessary for actomyosin contractility. Thus, the integration of 
adhesion and contractility that is seen at adherens junctions6 involves 
a contribution from E-cadherin to building the contractile apparatus 
itself, an effect that is most evident for junctional actomyosin. Although 
it is not known whether cadherin-based actin assembly also affects the 
medial–apical networks, it can extend outwards from junctions68.
This capacity for cadherin adhesion actively to build, as well as pas-
sively bind to, actomyosin complicates the analysis of junctional mechan-
ics. In parsing this problem, it is important to appreciate that the timescale 
of analysis influences the apparent mechanical properties of cell–cell 
interactions. The total mechanical stresses (force/surface area) in the 
plane of the junctions between cells consist of elastic, viscous and active 
stresses69–71. Elastic stresses depend on the extent of deformations, whereas 
viscous stresses depend on the rate of deformations and active stresses 
depend on myosin II motor activity, actin dynamics and crosslinking. 
On short timescales (seconds), elastic behaviour dominates and allows 
long-range propagation of tension within and between cells in a tissue72. 
The junctional73–75 and medial–apical actomyosin networks12,37,76 make 
contributions to such elastic stresses, as do passive connections between 
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Figure 1 Actomyosin at epithelial junctions. (a) Schematic of actomyosin 
organization in simple epithelial cells. Cells in a monolayer are depicted as 
hexagons when viewed in the apical plane. Myosin minifilaments interact with 
F-actin networks both at the cortices of cell–cell junctions and in the edi l–
apical pole of the cells. (b) Mechanisms for the E-cadherin molecular complex 
to associate with F-actin of the actomyosin apparatus. Actin filaments may 
bind directly to α-catenin, interact with α-catenin-associated proteins, such as 
vi culin or EPLIN, r bind to proteins such as myosin VI, which can associate 
with E-cadherin independently of α-catenin. (c) Cadherin adhesions support 
biogenesis of the junction l actomyosin apparatus by promoting ac in assembly 
(for example, through nucleation by engaging Arp2/3, formins and associated 
proteins such s cortactin) and Rho-dependent activation of myosin II.
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ates with E-cadherin at cell–cell junctions61,62. Other proteins that can 
interact with ROCK to promote its junctional accumulation, such as 
the actin-binding protein Shroom, also have important roles in control-
ling junctional tension and morphogenesis61,63. Additionally, E-cadherin 
adhesions promote actin assembly at the junctional cortex by recruiting 
actin regulators (for example, Arp2/3 (ref. 64), formins (ref. 65), CD2AP 
(ref. 66) and cortactin (ref. 67)) and the signalling pathways that activate 
them. These associations between signalling molecules and actin regu-
ators at E-cadherin-based junctions help generate the actin networks 
that are necessary for actomyosin contractility. Thus, the integration of 
adhesion and contractility that is seen at adherens junctions6 involves 
a contribution from E-cadherin to building the contractile apparatus 
itself, an effect that is most evident for junctional actomyosin. Although 
it is not known whether cadherin-based actin assembly also affects the 
medial–apical networks, it can extend outwards from junctions68.
This capacity for cadherin adhesion actively to build, as well as pas-
sively bind to, actomyosin complicates the analysis of junctional mechan-
ics. In parsing this problem, it is important to appreciate that the timescale 
of analysis influences the apparent mechanical properties of cell–cell 
interactions. The total mechanical stresses (force/surface area) in the 
plane of the junctions between cells consist of elastic, viscous and active 
stresses69–71. Elastic stresses depend on the extent of deformations, whereas 
viscous stresses depend on the rate of deformations and active stresses 
depend on myosin II motor activity, actin dynamics and crosslinking. 
On short timescales (seconds), elastic behaviour dominates and allows 
long-range propagation of tension within and between cells in a tissue72. 
The junctional73–75 and medial–apical actomyosin networks12,37,76 make 
contributions to such elastic stresses, as do passive connections between 
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Figure 1 Actomyosin at epithelial junctions. (a) Schematic of actomyosin 
organization in simple epithelial cells. Cells in a monolayer are depicted as 
hexagons when viewed in the apical plane. Myosin minifilaments interact with 
F-actin networks both at the cortices of cell–cell junctions and in the medial–
apical pole of the cells. (b) Mechanisms for the E-cadherin molecular complex 
to associate with F-actin of the actomyosin apparatus. Actin filaments may 
bind directly to α-catenin, interact with α-catenin-associated proteins, such as 
vinculin or EPLIN, or bind to proteins such as myosin VI, which can associate 
with E-cadherin independently of α-catenin. (c) Cadherin adhesions support 
biogenesis of the junctional actomyosin apparatus by promoting actin assembly 
(for example, through nucleation by engaging Arp2/3, formins and associated 
proteins such as cortactin) and Rho-dependent activation of myosin II.
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Figure 1 Actomyosin at epithelial junctions. (a) Schematic of actomyosin 
organization in simple epithelial cells. Cells in a monolayer are depicted as 
hexagons when viewed in the apical plane. Myosin minifilaments interact with 
F-actin netw rks both at th  cortices of cell–cell junctions and in the medi l–
apical pole of he cells. (b) Mecha isms for the E-cadher  molecular complex 
to associate with F-actin of the actomyosin apparatus. Actin fil ments m y 
bind directly to α-catenin, interact with α-catenin-associated proteins, such as 
vinculin or EPLIN, or bind to proteins such as myosin VI, which can associate 
with E-cadherin independently of α-catenin. (c) Cadherin adhesions support 
biogenesis of t e j nctional actomyosin apparatus by promoting actin assembly 
(for example  through nucleation by engaging Arp2/3, formins and associated 
proteins such a  cortactin) and Rho-dependent activation of myosin II.
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cells acquire a highly motile, invasive phenotype that is associated with metastasis and drug 
resistance (Onder et al., 2008). The Wnt, phosphoinositide 3-kinase (PI3K)/Akt, Rac, and 
Hippo signalling pathways are key mediators of these biological processes (Huber et al., 2005; 
Kalluri and Weinberg, 2009; Yang and Weinberg, 2008). Due to their relevance later in this 
project, the Rac and Hippo pathways are explained in further detail below. 
 
1.2.1 The Rac Pathway 
The ubiquitously expressed protein Rac1 belongs to the Rac subfamily of Rho small GTPases. 
Other members of the Rac subfamily include Rac2, Rac3, and RhoG, although expression of 
these proteins is generally restricted to specific tissues (Haataja et al., 1997; Roberts et al., 
1999; Vincent et al., 1992).  As a GTPase, Rac1 cycles between an inactive (GDP-bound) and 
active (GTP-bound) state to relay signals from membrane-based receptors, including receptor 
tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs), and cytokine receptors. 
Functionally, Rac1 has been shown to promote cell growth, inhibit apoptosis, and regulate gene 
expression, with Rac1 deletion shown to be embryonic lethal due to defective germ layer 
development (Sugihara et al., 1998; Wennerberg and Der, 2004).  In addition, Rac1’s ability to 
reorganise the actin cytoskeleton to alter cell polarity and promote motility has led to extensive 
investigation in the context of cancer (Etienne-Manneville and Hall, 2002). 
 
Further to crosstalk with RTKs, GPCRs, and cytokine receptors, Rac1 has been shown to be 
activated following E-cadherin homophilic ligation (Kovacs et al., 2002).  This is achieved by 
E-cadherin recruiting both Rac1 and the lipid kinase PI3K to adhesive contacts, where the 
production of phosphatidylinositol 3,4,5-trisphosphate (PIP3), via PI3K, is sufficient to activate 
the co-localised Rac1 (Figure 1.3) (Kovacs et al., 2002; Rodriguez-Boulan and Macara, 2014).  
It is possible that the intermediary role played by PI3K in this scenario may explain the high 
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frequency of activating PI3K mutations in CDH1-deficient ILBC, as this would allow Rac1 to 
drive malignancy in the absence of cell-to-cell contacts. Further to PI3K signalling, cytosolic 
p120-catenin has been shown to drive Rho/Rock signalling in E-cadherin-deficient ILBC mouse 
cell lines (Schackmann et al., 2011).  
 
Figure	  1.3	  Rac1	  activation	  at	  cell-­‐to-­‐cell	  contacts	  
“When	   cadherin-­‐mediated	   homophilic	   interactions	   occur,	   GDP-­‐Rac1	   is	   converted	   to	   GTP-­‐Rac1	   through	   the	  
action	  of	  a	  guanine	  nucleotide	  exchange	  factor	  (GEF),	  downstream	  of	  PI3K.	  Activated	  Rac1	  positively	  regulates	  
E-­‐cadherin-­‐mediated	   cell-­‐to-­‐cell	   adhesion.”	   Reprinted	   by	   permission	   from	   RightsLink	   Permissions	   Springer	  
Customer	  Service	  Centre	  GmbH:	  Springer	  Nature,	  Nature	  Reviews	  Molecular	  Cell	  Biology,	  Rho-­‐family	  GTPases	  
in	  cadherin-­‐mediated	  cell	  –	  cell	  adhesion,	  Fukata	  and	  Kaibuchi,	  Copyright	  (2001).	  
 
 
1.2.2 The Hippo Pathway 
The Hippo pathway, also known as the Salvador-Warts-Hippo pathway, is an evolutionarily 
conserved pathway involved in the maintenance of cellular proliferation during tissue 
development and regeneration. Following mutational analysis in Drosophila melanogaster, the 
Hippo pathway has been suspected as a key player in carcinogenesis (Harvey et al., 2013; 
Tapon et al., 2002). 
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Central to the Hippo pathway is a conglomerate of serine/threonine kinases - MST1 and MST2, 
LATS1 and LATS2, and adaptor proteins MOB1A and MOB1B. This protein complex induces 
phosphorylation of the oncoproteins YAP and TAZ, which serves to both prevent YAP and 
TAZ translocation to the nucleus, via 14-3-3 protein binding, and also prime them for ubiquitin-
mediated degradation. If unphosphorylated, however, YAP and TAZ translocate to the nucleus 
and subsequently stimulate cell growth via regulation of the transcription factors TEAD1-4 and 
SMAD1-3 (Figure 1.4) (Johnson and Halder, 2014).   
 
Mutations in Hippo pathway proteins that induce hyperactivation of YAP or TAZ are known to 
drive increased cellular proliferation (Harvey et al., 2013).  Additionally, in vitro, the 
overexpression of YAP in cancer cell lines was shown to promote apoptotic resistance in 
response to chemotherapeutic agents and anoikis (Overholtzer et al., 2006; Zhang et al., 2011; 
Zhao et al., 2012). It is therefore noteworthy that few somatic or germline mutations have been 
identified in Hippo pathway genes in common human cancers (Harvey et al., 2013), suggesting 
that altered Hippo activity may be downstream to other mutational events in carcinoma. 
 
In the context of epithelial cell biology, E-cadherin has been reported to sequester YAP and 
TAZ to adherens junctions (Schroeder and Halder, 2012).  In doing so, E-cadherin regulates the 
function of YAP and TAZ by preventing their nuclear entry and, additionally, preventing their 
access to phosphatases which antagonise the activity of YAP and TAZ inhibitory kinases 
(Schroeder and Halder, 2012).  With E-cadherin absent, it is possible that YAP and TAZ would 
be liberated from the cell periphery, promoting entrance to the nucleus and thus initiating the 
neoplastic process. Indeed, nuclear localisation of YAP has been reported in ILBC cell lines in 








Figure	  1.4	  The	  Hippo	  pathway	  
“a)	  When	  the	  Hippo	  pathway	  is	  on,	  MST1	  or	  MST2	  phosphorylate	  SAV1,	  and	  together	  they	  phosphorylate	  and	  
activate	  MOB1A,	  MOB1B,	  LATS1,	  and	  LATS2,	  which	  then	  phosphorylate	  YAP	  and	  TAZ.	  Phosphorylated	  YAP	  and	  
TAZ	  are	  sequestered	   in	   the	  cytoplasm	  by	   the	  14-­‐3-­‐3	  protein	  and	  shunted	   for	  proteasomal	  degradation.	  As	  a	  
result,	  TEADs	  associate	  with	  the	  transcriptional	  cofactor	  VGL4	  and	  suppress	  target	  gene	  expression.	  b)	  When	  
the	  Hippo	  pathway	   is	  off,	   the	  kinases	  MST1,	  MST2,	  LATS1,	  and	  LATS2	  are	   inactive,	   so	  YAP	  and	  TAZ	  are	  not	  
phosphorylated	   and	   instead	   accumulate	   in	   the	  nucleus	  where	   they	  displace	  VGL4	   and	   form	  a	   complex	  with	  
TEADs,	  which	  promotes	  the	  expression	  of	  target	  genes.”	  Reprinted	  by	  permission	  from	  RightsLink	  Permissions	  
Springer	   Customer	   Service	   Centre	   GmbH:	   Springer	   Nature,	   Nature	   Reviews	   Drug	   Discovery,	   Johnson	   and	  




1.3 SYNTHETIC LETHALITY 
The inactivation of tumour suppressor genes, such as E-cadherin, is one of the more clear-cut 
molecular events occurring during tumourigenesis, but one that obviously cannot be exploited 
by conventional drug development (as no protein is translated from the inactivated gene).  One 
approach, however, that is not precluded by the absence of the tumour suppressor is known as 
synthetic lethality.   
 
Initially observed in Drosophila and explored extensively in yeast, synthetic lethality is 
classically defined as a genetic interaction in which a combination of mutations in two or more 
genes leads to cell death (Figure 1.5) (Bender and Pringle, 1991; Canaani, 2013; Dobzhansky, 
1946). In a therapeutic setting, the term can refer to the use of a targeted drug to cause cell death 
exclusively in tumours carrying specific gene alterations. The targeting of cells that carry 
mutations in common tumour suppressor genes provides a means to achieve a high degree of 
tumour specificity, enabling better efficacy than standard chemotherapeutic approaches with, 
theoretically, fewer side effects.  
 
In the context of this thesis, synthetic lethality is used to describe a greater loss of cell number 
in E-cadherin-deficient cells than E-cadherin-expressing cells, relative to respective control 










Figure	  1.5	  The	  concept	  of	  synthetic	  lethality	  
Synthetic	   lethality	  occurs	  when	  a	  mutation	   in	  either	   two	  genes	   individually	  has	  no	  effect	  but	   combining	   the	  
mutations	  leads	  to	  cell	  death.	  Drug	  treatment	  to	  inhibit	  synthetic	  lethal	  partners	  of	  tumour	  suppressor	  genes	  
may	   lead	   to	   novel	   cancer	   therapeutic	   options.	   Ashworth,	   A:	   J	   Clin	  Oncol	   26	   (22),	   2008:	   3785-­‐90.	  Reprinted	  
with	  permission.	  Copyright	  (2018)	  American	  Society	  of	  Clinical	  Oncology.	  All	  rights	  reserved.	  
 
In recent years, researchers have performed compound screens on model knockout cell lines to 
identify drugs that target cells harbouring tumour suppressor gene mutations (Bryant et al., 
2005; Farmer et al., 2005; Kau et al., 2003; Neshat et al., 2001; Podsypanina et al., 2001). A 
successful demonstration of synthetic lethality is the development of poly (ADP-ribose) 
polymerase (PARP) inhibitors that showed an increased sensitivity in cells containing 
BRCA1/BRCA2 mutations (Ashworth, 2008; Bryant et al., 2005). Following this discovery, the 
PARP inhibitor olaparib has been approved by the FDA and European commission for patients 
with platinum-sensitive, recurrent, high-grade serous ovarian cancer with BRCA1 or BRCA2 
mutations (Tangutoori et al., 2015). Numerous other PARP inhibitors are currently in clinical 
trials for BRCA mutation carriers, heralding a success for synthetic lethal therapeutics and 
welcoming a new chapter of personalised medicine.  
 
Our research group has applied a similar strategy and recently performed a screen with over 
4,000 known drugs in an attempt to identify synthetic lethal phenotypes in E-cadherin-negative 
cells (Telford et al., 2015). Testing was performed in a non-tumourigenic mammary epithelial 
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cell line, MCF10A, and an isogenic counterpart harbouring a zinc-finger nuclease-generated 
four base pair deletion in exon 11 of the CDH1 gene (MCF10A CDH1-/-). A non-tumourigenic 
cell line was selected to best represent ‘normal’ human cells. From this initial screen, a range of 
potential drug candidates for E-cadherin-deficient cancers were identified (Table 1.1), with 
histone deacetylase inhibitors (HDACi) and the SRC inhibitor (SRCi) saracatinib taken on for 
successful validation (Telford et al., 2015).   
 
 







Table	   1.1	   Known	   drugs	   with	   greater	   inhibitory	   effect	   on	   MCF10A	   CDH1-­‐/-­‐	   cells	   compared	   with	   MCF10A	   cells.	  
Adapted	  from	  Telford	  et	  al.	  (2015).	  
Drug Name Drug Class 
Mocetinostat HDAC inhibitor 
Entinostat HDAC inhibitor 
Quisinostat HDAC inhibitor 
Pracinostat HDAC inhibitor 
LAQ824 HDAC inhibitor 
Panobinostat HDAC inhibitor 
Crizotinib ROS1-like tyrosine kinase inhibitor 
PI-103 PI3K inhibitor 
GSK2126458 PI3K inhibitor 
PIK-75 PI3K inhibitor 
CGP 71683 NPY5R inhibitor 
Tyrphostin A9 PDGFR and EGFR inhibitor 
AZD8055 mTOR inhibitor 
Obatoclax mesylate BCL2 inhibitor 
Brefeldin A Guanidine nucleotide exchange factor inhibitor 
LY2784544 JAK family inhibitor 
FCCP Uncoupler of mitochondrial oxidative phosphorylation 
JNJ-7706621 CDK and aurora kinase inhibitor 
Danusertib Aurora kinase, BCR-Abl, c-RET, and FGFR inhibitor 
PD-166285 hydrate Broad-spectrum tyrosine kinase inhibitor 
10-DEBC hydrochloride AKT inhibitor 
Saracatinib SRC inhibitor 







1.3.1 Histone Deacetylase Inhibitors (HDACi) 
Histone deacetylation is one of many common epigenetic modifications required for chromatin 
organisation and gene expression regulation.  Whilst acetylated histone residues typically lead 
to transcriptional activation and gene expression, histone deacetylation has been associated with 
the formation of a ‘condensed’ chromatin state linked to transcriptional repression and gene 
silencing (Glozak and Seto, 2007).  Enzymes involved in maintaining these chromatin 
modifications with opposing activities are the histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (Mills, 2010).   
 
There are eighteen characterised mammalian HDAC isozymes (Gupta et al., 2012).   Eleven of 
these have been termed ‘classical HDACs’ because they share a high degree of structural 
homology and common catalytic mechanism through which they deacetylate both histone and 
non-histone proteins (Shakespear et al., 2011).  These classical HDACs are further sub-divided 
into four classes (classes I, IIa, IIb, and IV) on the basis of domain organisation (Table 1.2) 
(Gupta et al., 2012).   
 






















IIb 6 10 
IV 11 
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Aberrant gene expression attributed to epigenetic alterations is crucial for tumour development 
and is also implicated in response to chemotherapy (Mutze et al., 2010).  As a consequence of 
this, HDACs have emerged as promising targets for the treatment of cancers.  There are 
currently five HDACi (vorinostat, romidepsin, belinostat, panobinostat, and pracinostat) that are 
FDA-approved and used as anti-cancer agents, whilst many others are in various stages of 
clinical trials for monotherapy or combination chemotherapy treatments (Gupta et al., 2012; 
Manal et al., 2016).  In addition to cancer therapeutics, HDACi have also shown promise for the 
treatment of other human diseases, such as inflammatory and metabolic disorders, 
immunological, cardiovascular, and infectious diseases (Gupta et al., 2012). The wide range of 
diseases that can be treated with HDACi partnered with a reported good tolerability profile in 
patients is driving the development of novel therapeutic HDACi (Mottamal et al., 2015 and 
references therein).  
 
Most HDACi are comprised of three structural components: an affinity-determining zinc-
binding region, a linker region, and a surface recognition domain (cap region) that plugs the 
entrance to the catalytic site of the HDAC (Figure 1.6) (Gupta et al., 2012). Improvements in 
affinity, potency, and selectivity are achieved via modifications to the recognition group that 
targets surface residues surrounding the active site (Gupta et al., 2012). Successful HDACi 
modifications have been demonstrated to great effect with the recently FDA-approved 
pracinostat, a more orally active and therapeutically effective analogue of vorinostat (Novotny-






Figure	  1.6	  Structural	  components	  of	  a	  histone	  deacetylase	  inhibitor	  (HDACi)	  
The	  affinity	  determining	  ‘zinc-­‐binding	  region’	  is	  attached	  to	  the	  HDAC	  catalytic	  site	  blocking	  ‘cap	  region’	  via	  a	  
‘linker	   region’,	   as	   depicted	   by	   the	   pan-­‐HDACi	   vorinostat.	   Adapted	   from	  Gupta	   et	   al.	   (2012).	   Reprinted	  with	  
permission.	  Copyright	  2018	  Bentham	  Science.	  
 
1.3.2 SRC Inhibitors (SRCi) 
SRC is a 536 amino acid non-receptor tyrosine kinase that conveys signals from membrane-
based receptors to numerous intracellular survival pathways, including the PI3K and MAPK 
signalling pathways (Roskoski, 2015; Thomas and Brugge, 1997). The tyrosine kinase 
receptors, such as EGFR (ERBB1) and HER2 (ERBB2), GPCRs, integrins, and E-cadherin, are 
among the list of receptors known to regulate SRC activity (Roskoski Jr, 2004; Thomas and 
Brugge, 1997).  
 
Structurally, from the N- to C-terminus, SRC contains a 14-carbon myristoyl group, a unique 
domain, an SH3 domain, an SH2 domain, an SH2-kinase linker, a protein-tyrosine kinase 
domain (SH1), and a C-terminal regulatory segment (Figure 1.7) (Brown and Cooper, 1996; 
Roskoski, 2015; Thomas and Brugge, 1997). N-terminal myristoylation, occurring at the 14-
carbon myristoyl group, is required for SRC to attach to cell membranes and subsequently 
function (Brown and Cooper, 1996). The SH3 and SH2 domains facilitate binding to left-
handed helices and C-terminal phosphotyrosine residues, respectively (Adzhubei et al., 2013; 
Boggon and Eck, 2004; Liu et al., 2012). The SH3 domain can therefore bind to the SH2-kinase 





conformation (SRC’s inactive state) (Boggon and Eck, 2004).  Mutations at residues preventing 
this intramolecular binding result in SRC hyperactivation and have been shown to induce 
anchorage-independent cell growth (Cooper et al., 1986; Kmiecik and Shalloway, 1987).    
 
 
Figure	  1.7	  Structure	  of	  SRC	  
From	  the	  N-­‐	  to	  C-­‐	  terminus,	  SRC	  contains	  a	  14-­‐carbon	  myristoyl	  group,	  a	  unique	  domain,	  an	  SH3	  domain,	  an	  
SH2	   domain,	   an	   SH2-­‐kinase	   linker,	   a	   protein-­‐tyrosine	   kinase	   domain	   (SH1),	   and	   a	   C-­‐terminal	   regulatory	  
segment.	   The	   catalytic	   loop	   (CL)	   region	   and	   activation	   segment	   (AS)	   are	   highlighted	   in	   the	   SH1	   domain.	  
Reprinted	   from	   Pharmacological	   Research,	   94,	   Roskoski,	   Src	   protein-­‐tyrosine	   kinase	   structure,	  mechanism,	  
and	  small	  molecule	  inhibitors,	  9-­‐25,	  Copyright	  (2015),	  with	  permission	  from	  Elsevier.	  
 
 
Four FDA-approved SRCi (bosutinib, dasatinib, ponatinib, and vandetanib) define the current 
war chest used to combat SRC hyperactivated tumours in the clinic (Roskoski, 2015). Of this 
list, only vandetanib is approved for targeting solid tumours (medullary thyroid cancer) and is 
known to inhibit numerous surface-based receptors in addition to SRC, a likely consequence of 
its initial development as a VEGFR inhibitor (Hennequin et al., 2002). A lead synthetic lethal 
SRCi identified in our known drug screen, saracatinib, is not FDA-approved but currently in 
clinical trials for a range of solid tumour malignancies (Roskoski, 2015). Akin to other SRCi, 
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Fig. 1. Organization of human Src. CL, catalytic loop; AS, activation segment.
proteins exhibit 99.6% identity with most of the variation occurring
near the N-terminus. The chicken viral Src (v-Src) protein Exhibits
95.8% identity with chicken Src. The protein kina e domains of
the chicken/human proto-oncogenes (residues 267/270–520/523)
exhibit only two differences: chicken Met354 corresponds to
human Thr357 and chicken Asp502 corresponds to human Glu505.
Thus, results from studies of the protein kinase domain of chicken
Src are expected to accurately reflect those of the human enzyme.
The C-terminal tails (residues 521/524–533/536) of
chicken/human Src are identical, but they are completely dif-
ferent from those of Rous v-Src. The Rous viral oncogene protein
(v-Src) lacks seven-residues at its carboxyterminus, which include
an autoinhibitory tyrosine phosphorylation site, thus accounting
for its increased basal activity. Human Src and the Rous v-Src
protein kinase domains exhibit 11 residue differences. The chicken
numbering system is used in much of the early literatur , even
when studies were performed with the human enzyme. In this
paper, unless specified therwise, human residue numbers are
used for both human and chicken Src reflecting efforts targeting
the human enzyme for drug discovery. Three amino acids in the
avian protein are deleted after human Src residue 25. To go from
the human Src residue to that of chicken, subtract three.
Myristoylation facilitates the attachment of Src to membranes,
and myristoylation is required for Src operation in cells [3]. The
seven N-terminal amino acids beginning with glycine are required
for the myristoylation of Src and v-Src [9,10]. Mutational studies
show that a correlation exists between N-myristoylation, subse-
quent membrane association, and the ability of v-Src protein kinase
to transform cells into a neoplastic state. The catalytic subunit
of the serine/threonine protein kinase A (PKA) and the Abl non-
receptor protein-tyrosine kinase are myristoylated, but they are
largely cytosolic [11,12]. Myristoylation is thereby not sufficient to
ensure protein kinase membrane localization.
SH3 domains (≈60 amino acid residues) bind to sequences that
can adopt a left-handed helical conformation [13]. The SH3 domain
is a !-barrel consisting of five antiparallel !-strands and two  promi-
nent loops called the RT and n-Src loops (Fig. 2). These loops lie
at either end of a surface composed of aromatic and hydrophobic
residues that make up the recognition site for protein sequences
bearing a PxxP motif. These sequences adopt a polyproline type II
helical conformation that complexes with the SH3 domain. The pro-
lines interact with aromatic side chains on the SH3 surface. Not all
type II left-handed helices contain multiple prolines [13]. For exam-
ple, the linker between the Src SH2 domain and kinase domain that
interacts with the SH3 domain contains Pro249 in a type II helix.
This residue interacts with N138 and Y139 of the SH3 domain of
human Src.
SH2 domains (≈100 amino acid residues) bind to distinct amino
acid sequences C-terminal to phosphotyrosine [14]. Songyang and
Cantley analyzed the binding of a library of phosphopeptides to
SH2 domains to define preferred docking sequences [15]. The SH2
domains of Fgr, Fyn, Lck, and Src select pYEEI in preference to other
sequences. X-ray crystallographic studies of the Src SH2 domain
indicate that (i) the phosphotyrosine ligand binds to an invariant
arginine and (ii) the isoleucine at the P + 3 position binds within a
hydrophobic pocket [16]. The acidic residues at the pY + 1 and pY + 2
Fig. 2. Secondary structures of (A) inactive and (B) active Src. The SH3 domain is
cyan, and the SH2 domain is magenta. C-t, C-terminus; N-t, N-terminus. The figures
of  inactive human Src (A) and active chicken Src (B) were prepared from PDB ID:
2SRC and 3DWQ, respectively.
This figure and Figs. 4, 5 and 9 were prepared using the PyMOL Molecular Graphics
System Version 1.5.0.4 Schrödinger, LLC.
positions of the SH2 binding partner interact with basic residues on
the surface of the SH2 domain.
The Src SH2 domain (Fig. 2) consists of a central three-stranded
!-sheet with a single helix packed against each side ("1 and "2).
The SH2 domain forms two recognition pockets: one co-ordinates
phosphotyrosine and the other binds one or more hydrophobic
residues C-terminal to the phosphotyrosine. The phosphotyrosine
pocket contains a conserved arginine residue (Arg178 in human
Src). The Src SH2 domain, however, can bind to a variety of
sequences that do not conform to this optimal pYEEI sequence, and
other parts of proteins beyond the vicinity of the phosphotyrosine
contribute to the formation of the binding interface. The human
Src SH2 domain binds intramolecularly to C-terminal pTyr530 that
results in inhibition of protein kinase activity. The sequence of
this intramolecular site is pYQPG, which is a nonoptimal Src SH2-
binding sequence. As a result, this binding can be readily displaced
by more optimal phospholigands that can lead to enzyme activa-
tion.
One of the two  most important regulatory phosphorylation sites
in Src is Tyr530, six residues from the C-terminus. Under basal con-
ditions in vivo, 90–95% of Src is phosphorylated at Tyr530 [17],
which binds intramolecularly with the Src SH2 domain. SH2 and
SH3 binding partners are able to displace the intramolecular asso-
ciation that stabilizes the dormant form of the enzyme [3]. The
Tyr530Phe mutant is more active than the wild type enzyme and
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1.4 DRUG SYNERGY 
Our previous discovery of HDACi and SRCi drugs inducing synthetic lethal phenotypes in E-
cadherin-deficient cells is of great interest, however, the observed effects are modest and in 
need of enhancement if such treatments were to be used in the chemoprevention setting. This 
has led to our interest in investigating synergistic drug combinations which can produce greater 
synthetic lethal effects.  
  
Derived from the Attic Greek word synergia, meaning ‘working together’, the term ‘synergy’ is 
applied to drug studies where a combination of drugs can interact to enhance the effects, or side 
effects, of the involved individual drugs.  Conversely, drug ‘antagonism’ denotes a response 
whereby drugs interact in a fashion reducing the effects of the involved drugs.  In a therapeutic 
context, synergistic drug combinations allow for increased efficacy at reduced drug 
concentrations, ultimately minimising the risk of drug side effects to the patient whilst 
maximising therapeutic potential. 
 
To investigate the interaction of a drug combination, it must first be predicted what therapeutic 
response would be observed from an ‘additive effect’, an interaction where neither drug synergy 
nor antagonism is observed.  The Chou-Talalay combination index equation is currently 
regarded as the gold standard for determining such drug-based interactions in vitro, cited in 
excess of 5,000 publications (Chou, 2010; Chou and Talalay, 1984).  This combination index 
incorporates facets of Chou’s ‘median-effect equation’, a concept regarded in drug studies as 
the ‘unified theory’ due to its amalgamation of enzyme-ligand binding kinetic equations such as 
Henderson-Hasselbach, Michaelis-Menten, Hill, and Scatchard equations (Chou, 1980). In 
essence, the Chou-Talalay combination index equation uses the observed cell proliferation 
inhibition from each individual drug treatment to predict an inhibitory response of combined 
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treatment in an additive context (an effect denoted by a combination index score of 1; CI = 1).  
A combination index lower than 1 (CI < 1) denotes a drug combination producing a greater 
inhibitory effect than the predicted (additive effect) value; conversely, a combination index 
greater than 1 (CI > 1) denotes a drug combination producing a weaker inhibitory effect than the 
predicted (additive effect) value (Table 1.3).     
 





















Combination Index (CI) Drug Interaction 
> 1 Antagonistic 
1 Additive 
< 1 Synergistic 
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1.5 PROJECT AIMS 
This project was comprised of three main aims.  
 
(i) To compare the performance of different endpoint and real-time cell viability assays in order 
to effectively validate candidate synthetic lethal drugs in an isogenic pair of non-malignant 
MCF10A breast cell lines, one with and one without CDH1 expression (MCF10A CDH1-/-). 
 
(ii) To identify a synergistic drug combination that inhibits proliferation preferentially in 
MCF10A CDH1-/- cells (i.e. a synergistic drug combination that inhibits E-cadherin’s synthetic 
lethal partners).  
 
(iii) To characterise the lead drug combination’s effect on proliferation in the MCF10A isogenic 
















2. MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Reagents 
β-mercaptoethanol – Sigma-Aldrich, USA 
0.05% trypsin solution - Prepared in lab (Appendix C.2) 
0.5% trypsin/EDTA – Thermo Fisher Scientific, USA 
30% acrylamide/bis solution 37.5:1 – Bio-Rad, USA 
Absolute ethanol - Scharlau, Spain 
Actrapid penfil neutral insulin - Novo Nordisk Pharmaceuticals Ltd, New Zealand 
Ammonium persulfate (APS) – BDH Laboratory Supplies, UK 
Anti-YAP1 (phospho S127) antibody – Abcam, UK 
Anti-YAP1 antibody – Abcam, UK 
Anti-α-tubulin antibody – Sigma-Aldrich, USA 
Atorvastatin - SelleckChem, USA 
Bovine insulin – Sigma-Aldrich, USA 
Cell Culture Lysis 5X Reagent – Promega, USA 
CellTiter-Glo Luminescent Cell Viability Assay - Promega, USA 
Cholera toxin - Sigma-Aldrich, USA 
cOmplete Mini (EDTA-free) Protease Inhibitor Tablets (Ref: 11836170001) – Sigma-Aldrich, 
USA 
Dimethyl sulfoxide (DMSO) - Sigma-Aldrich, USA 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) – Thermo Fisher 
Scientific, USA 
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Entinostat - SelleckChem, USA 
Epidermal growth factor (EGF) - PeproTech, USA 
Flavopiridol - SelleckChem, USA 
Foetal bovine serum (FBS) – Thermo Fisher Scientific, USA 
Freezing medium - Prepared in lab (Appendix C.3) 
FTI-277 – Tocris Bioscience, UK 
GGTI-298 – Tocris Bioscience, UK 
Hoechst 33342 – Thermo Fisher Scientific, USA 
Horse serum - Thermo Fisher Scientific, USA 
HS-173 - SelleckChem, USA 
Hydrocortisone - Sigma-Aldrich, USA 
IRDye 680LT Goat (ployclonal) anti-Rabbit IgG (H+L) – LI-COR, USA 
IRDye 800CW Goat (polyclonal) anti-Mouse IgG (H+L) – LI-COR, USA 
Isopropanol – Scharlau, Spain 
K03861 - SelleckChem, USA 
Lovastatin - SelleckChem, USA 
LY294002 – SelleckChem, USA 
Mifepristone - SelleckChem, USA 
Olaparib – SelleckChem, USA 
Paraformaldehyde - BDH Laboratory Supplies, UK 
PD0325901 – SelleckChem, USA 
PF-573228 - SelleckChem, USA 
PHA-793887 - SelleckChem, USA 
Phosphate buffered saline (Dulbecco A) tablets – Oxoid Limited, UK 
Phosphate buffered saline solution (PBS) - Prepared in lab (Appendix C.1) 
PI-103 – SelleckChem, USA 
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Pierce BCA Protein Assay Kit – Thermo Fisher Scientific, USA 
PIK-75 - SelleckChem, USA 
Precision Plus All Blue Prestained Protein Standard – Bio-Rad, USA 
Propidium iodide - Thermo Fisher Scientific, USA 
Resazurin - Sigma-Aldrich, USA 
RNase A - Thermo Fisher Scientific, USA 
Roswell Park Memorial Institute 1640 Medium (RPMI 1640) – Thermo Fisher Scientific, USA 
RPMI 1640 (ATCC Modification) – Thermo Fisher Scientific, USA 
Saponin – Sigma-Aldrich, USA 
Saracatinib – SelleckChem, USA 
Simvastatin - SelleckChem, USA 
Sodium dodecyl sulphate (SDS) – BDH Laboratory Supplies, UK 
Sorafenib - SelleckChem, USA 
SYTOX - Thermo Fisher Scientific, USA 
TAE226 – SelleckChem, USA 
Taxol - Sigma-Aldrich, USA 
Tetramethylethylenediamine (TEMED) – Riedel-de Haen, Germany 
Trim milk powder – Pams, NZ 
Tris ultrapure – BioFroxx, Germany 
Tunicamycin – Sigma-Aldrich, USA 
Tween-20 – Sigma-Aldrich, USA 
Ultra-pure DNase/RNase-Free Distilled Water - Thermo Fisher Scientific, USA 
Verteporfin – Cayman Chemical, USA 
Vorinostat - SelleckChem, USA 
Zaragozic acid A – Cayman Chemical, USA 
Zoledronic acid - SelleckChem, USA 
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2.1.2 Equipment 
500 mL filter system – Corning, USA 
96 well black walled, clear flat bottom plates - Corning, USA 
96 well white walled, clear flat bottom plates - Greiner Bio-One, Austria 
96 well xCELLigence E-plates - ACEA Biosciences, USA 
BD FACSCanto II – BD Biosciences, USA 
BD Falcon 5 mL polystyrene round-bottom tube – BD Biosciences, USA 
CO2 cell culture incubator - Binder, Germany 
Cytation 5 Imaging Reader – BioTek, USA 
Cytell Cell Imaging System – GE Healthcare, UK 
Dual chamber cell counting slides - Bio-Rad, USA 
Immobilon PVDF transfer membrane – Merck, USA 
IncuCyte FLR - Essen BioScience, USA 
Milli-Q Ultrapure Water Purification System - Millipore, USA 
Mini-PROTEAN II electrophoresis cell – Bio-Rad, USA 
Mini Trans-Blot electrophoretic transfer cell – Bio-Rad, USA 
Mr. Frosty Cryo 1 °C Freezing Container – Thermo Fisher Scientific, USA  
Odyssey Fc Imaging System – LI-COR, USA 
POLARstar OPTIMA - BMG Labtech, USA 
TC10 Automated Cell Counter - Bio-Rad, USA 
Tissue culture hood - EMAIL, Australia 
Water bath - Semco, USA 




CellProfiler – Broad Institute, USA  
CompuSyn – ComboSyn, Inc., USA  
FlowJo – FlowJo, USA 
Gen5 Software – BioTek, USA 
Image Studio Software – LI-COR, USA 
ImageJ - National Institute of Health, USA  
IncuCyte Confluence V1.5 - Essen BioScience, USA 






2.2.1 Cell Culture 
2.2.1.1 Complete Growth Medium 
MCF10A cells were cultured in a 1:1 mixture of Dulbecco’s Modified Eagle Medium and F12 
medium (DMEM/F-12), supplemented with 5% horse serum, 0.5 μg/mL hydrocortisone, 100 
ng/mL cholera toxin, 10 μg/mL human insulin, and 20 ng/mL EGF. Pre-mixed complete media 
was filter sterilised using a 0.22 μm polyethersulfone filter and aliquoted into 50 mL Falcon 
tubes. 
 
MDA-MB-231 cells were cultured in RPMI 1640 medium, supplemented with 10% FBS. The 
ATCC-formulated Leibovitz’s L-15 medium was not used as cells were incubated in the 
presence of 5% CO2.  
 
IPH-926 cells were cultured in RPMI 1640 (ATCC modification) medium, supplemented with 
20% FBS and 10 μg/mL bovine insulin. 
 
2.2.1.2 Cell Culture Maintenance 
MCF10A, MCF10A CDH1-/-, MDA-MB-231, and IPH-926 cells were grown in 75 mL cell 
culture flasks in a humidified incubator at 37 °C with 5% CO2 in their respective complete 
growth medium (Chapter 2.2.1.1).  
 
Prior to passaging, whole growth medium, 0.05% trypsin, and PBS were pre-warmed in a 37 °C 
water bath. Old growth medium was aspirated from the flask and cells were washed with 3 mL 
PBS, which was then aspirated and 3 mL 0.05% trypsin added. The cells were then returned to 
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the incubator (MCF10A and MCF10A CDH1-/- cells for approximately 25 min; MDA-MB-231 
and IPH-926 cells for approximately 5 min).  4 mL complete growth medium was then added to 
inactivate the trypsin and cells were transferred to a 15 mL Falcon tube and pelleted via 
centrifugation.  The supernatant was aspirated and the cell pellet was resuspended in 4 mL 
complete growth medium.  MCF10A and MCF10A CDH1-/- cells were counted and plated at 
respective densities of 3.0x105 and 4.5x105 cells in 75 mL culture flasks. MDA-MB-231 and 
IPH-926 cells were subcultured at ratios of 1:3 and 1:1, respectively. Flasks were then returned 
to the humidified incubator. 
 
2.2.1.3 Cell Counting 
Cells were counted on a dual chamber counter slide using the TC10 Automated Cell Counter. 
Each slide chamber was filled with approximately 10 μL of resuspended cells. Two 
measurements of cell density were taken from each chamber and averaged to determine the 
density of resuspended cells. 
 
2.2.1.4 Thawing Cell Lines 
Cells removed from liquid nitrogen storage were quickly thawed in a 37 °C water bath. 
Recovered cells were then resuspended in 9 mL of warm complete growth medium, pelleted via 
centrifugation, and the supernatant discarded to remove remaining DMSO. Pelleted cells were 
resuspended in warm complete growth medium and transferred to a 75 mL cell culture flask, 
then placed in a humidified incubator at 37 °C and 5% CO2. Complete growth medium was 
changed in the cell culture flasks the following day. 
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2.2.1.5 Cryogenic Preservation 
After trypsinisation, pelleted cells were resuspended in freezing medium (Appendix C.3), 
aliquoted into 1 mL cryovials, and transferred to a Mr. Frosty Cryo 1 °C Freezing Container and 
placed in a -80 °C freezer for 24 h. This allowed cells to be cooled at a rate of 1 °C per minute 
before being transferred into liquid nitrogen for long-term storage.  
 
2.2.2 Cell Viability Assays 
2.2.2.1 Drug Treatment Protocol 
All drugs except zoledronic acid were reconstituted in DMSO to create stock solutions. 
Zoledronic acid was reconstituted in mQH2O. Drugs were aliquoted and stored at  -80 °C. 
Individual aliquots were diluted in complete growth medium to create working stocks prior to 
use in an experiment. 
 
Cells were seeded in 96-well, black-walled, clear-bottomed, tissue culture plates in 100 μL 
complete growth medium and left to equilibrate at room temperature for 30 min before 37 °C, 
5% CO2 incubation. Cell seeding densities are shown in Table 2.1. After overnight incubation, 
cells were treated with 10 μL drug or 0.1% DMSO for controls. All endpoint experiments were 




















2.2.2.2 CellTiter-Glo Luminescent Cell Viability Assay 
For luminescent assays, CellTiter-Glo was added at 20% final concentration. Earlier 
optimisation had shown this concentration to consistently reproduce the manufacturer’s 
recommended 1:1 vol/vol ratio (results not shown). Luminescent readings were obtained using a 
POLARstar Optima after 10 min incubation at room temperature with shaking.  
 
2.2.2.3 Resazurin Reduction Cell Viability Assay 
For resazurin reduction assays, resazurin was made to 440 μM stock solutions in PBS and 
aliquoted for storage at -20 °C. Resazurin solution was added to cells at 20% final 
concentration, and plates were incubated for 3 h at 37 °C prior to reading fluorescence at 550 
nm excitation and 590 nm emission using a POLARstar Optima.  
 
2.2.2.4 Nuclei Counting Cell Viability Assay 
For nuclei counting assays, a one-step, no-wash, mild permeabilisation and fixation protocol 
was adopted from Chan et al. (2013),  using a final concentration of 0.25% paraformaldehyde, 
0.075% saponin, and 1 μg/mL Hoechst 33342. Plates were then incubated for at least 2 h in the 
Cell line Seeding Density (cells per well) 
MCF10A 4x103 




dark at room temperature. Plates were imaged at six fields per well under 4x magnification 
using the Cytation 5 Imaging Reader and imaged nuclei were enumerated using Gen5 software 
to obtain a total cell count. Alternatively, plates were imaged at 4 fields per well under 4x 
magnification using the Cytell Cell Imaging System and imaged nuclei were enumerated using 
CellProfiler to obtain a total cell count. For direct comparison between total cell count and 
measured confluency performed in the IncuCyte FLR, 10 nM SYTOX was used in place of 
Hoechst for nuclei enumeration because this IncuCyte model only has a single, green 
fluorescence filter.  
 
2.2.2.5 xCELLigence Real-Time Assay 
Experiments conducted on the RTCA-MP xCELLigence system were performed in accordance 
with instructions of the supplier. 100 μL of cell culture medium was added into each well of the 
E-plate 96, followed by a brief background impedance measurement on the RTCA-MP station.  
MCF10A and MCF10A CDH1-/- cells were seeded at a density of 4x103 cells per well in 90 μL 
complete growth medium.  After 30 min equilibration at room temperature, the E-plate was 
returned to the RTCA-MP station.  Cell proliferation as determined by the impedance 
measurement was recorded in 15 min intervals.  At 24 h post-seeding, the assay was paused and 
cells were treated with 10 μL drug or 0.1% DMSO for controls.  The assay was then resumed, 
taking impedance measurements every 15 min for a further 120 h.  The electrical impedance 
measured by the RTCA software is reflected as the cell index (CI) value and is proportional to 
the number and attachment strength of the cells.  All xCELLigence experiments were performed 
in duplicate.  
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2.2.2.6 IncuCyte Real-Time Assay 
Cells were seeded in 96-well, black-walled, clear-bottomed, tissue culture plates in 100 μL 
complete growth medium and left to equilibrate at room temperature for 30 min before 37 °C, 
5% CO2 incubation. Cell seeding densities are shown in Table 2.1. After overnight incubation, 
cells were treated with 10 μL drug or 0.1% DMSO for controls, and the plate was inserted into 
the IncuCyte FLR for real-time imaging, with three fields imaged per well under 4x 
magnification every 2 h for a total of 48 h. Data were analysed using the IncuCyte Confluence 
version 1.5 software, which quantified cell surface area coverage as confluence values. All 
IncuCyte experiments were performed in triplicate. 
 
2.2.2.7 Drug Synergy Analysis 
Drug synergy/antagonism interactions were analysed using nuclei counting cell viability values 
and isobologram analysis via CompuSyn software. Isobologram analysis quantifies drug-drug 
interactions using a combination index (CI) value, whereby CI > 1.1 indicates antagonism, CI = 
0.9-1.1 indicates additivity, and CI < 1 indicates synergy. 
 
2.2.3 Cell Cycle Analysis 
Cells were seeded at 1.5x105 cells per well into 6-well plates in 2 mL complete growth medium 
and left to equilibrate to room temperature for 30 min before 37 °C, 5% CO2 incubation. After 
24 h, growth medium was aspirated and replaced with 2 mL drug diluted in complete growth 
medium, with 0.1% DMSO diluted in 2 mL complete growth medium for vehicle controls and 2 
mL complete growth medium for cell-only controls. Plates were then incubated for an 
additional 24 h. Following incubation, growth medium was transferred from each well into a 15 
mL Falcon tube. Wells were washed with 0.5 mL PBS, with wash added to respective 15 mL 
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Falcon tubes. 250 μL 0.05% trypsin solution was added to each well and plates incubated until 
cellular detachment. Cells were transferred into their respective Falcon tubes and wells were 
washed with 0.5 mL PBS, with wash added to the respective tubes. Cells were pelleted by 
centrifugation, supernatant discarded, and cells resuspended in 1 mL PBS. Cells were pelleted 
again via centrifugation and supernatant discarded. 800 μL ice-cold 70% ethanol solution was 
then added dropwise onto pellet whilst vortexing and cells were stored at -20 °C. The fixed, 
permeabilised cells were pelleted via centrifugation, supernatant discarded, 0.5 mL PBS added, 
and pelleted again via centrifugation. Supernatant was discarded, 50 μL RNAse A (from a 100 
μg/mL working stock) was added to cell pellet, followed by addition of 400 μL propidium 
iodide solution (from a 50 μg/mL working stock). Cells were vortexed into solution, transferred 
to 5 mL polystyrene round-bottom FACS tubes, wrapped in foil, and stored at 4 °C for 3 h. 
Samples were then processed using a FACS Canto II, with 50,000 total cell events recorded for 
cell cycle analysis via FlowJo software. 
 
2.2.4 Western Blotting 
2.2.4.1 Protein Lysate Preparation 
Cells were seeded at 1.5x105 cells per well into 6-well plates in 2 mL complete growth medium 
and left to equilibrate to room temperature for 30 min before 37 °C, 5% CO2 incubation. After 
24 h, growth medium was aspirated and replaced with 2 mL drug diluted in complete growth 
medium, with 0.1% DMSO diluted in 2 mL complete growth medium for vehicle controls and 2 
mL complete growth medium for cell-only controls. Plates were then incubated for an 
additional 24 h. Following incubation, growth medium was aspirated, cells were washed twice 
with PBS, and then lysed using 100 μL passive lysis buffer containing 1x cOmplete Protease 
Inhibitor Cocktail (Appendix C.11). Lysate was transferred to a centrifuge tube and vortexed 
prior to centrifugation to pellet cell debris. Supernatant was then collected and protein 
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concentration quantified using a bicinchoninic acid (BCA) assay as per the manufacturer’s 
protocol. 
 
2.2.4.2 Gel Electrophoresis 
Protein samples were mixed at a 1:1 ratio with 2x Laemmli buffer (Appendix C.5) and heated at 
95 °C for 5 min, then centrifuged for 1 min to remove bubbles after boiling. 20 μg of protein 
was loaded on a 10% SDS-PAGE gel (Appendix C.6) and submerged in 1x running buffer 
(Appendix C.7) in the Mini-PROTEAN II electrophoresis cell. 12 μL Precision Plus All Blue 
Prestained Protein Standard was loaded to determine band sizes. The gel was run at a constant 
100 V for 2 h. 
 
2.2.4.3 Protein Transfer to PVDF Membrane 
A polyvinylidene fluoride (PVDF) membrane was briefly soaked in 100% methanol before 
washing with mQH2O and soaking in 1x cold transfer buffer (Appendix C.8) for 15 min. 
Proteins were transferred from the gel to the PVDF membrane using the Mini Trans-Blot 
Electrophoretic Transfer Cell. The gel and membrane were sandwiched between filters, 
submerged in cold transfer buffer, and transferred using a constant 100 V for 1 h. 
 
2.2.4.4  Primary Antibody Incubation 
The PVDF membrane was washed three times for 10 min in Tris-buffered saline with Tween-20 
(TBST; Appendix C.10). The membrane was then blocked using 5% w/v trim milk powder in 
TBST at room temperature for 1 h. Primary antibody was diluted in 5% w/v trim milk powder 
in TBST and incubated with the PVDF membrane at 4 °C on a rocking platform overnight. 
Primary antibody dilutions are listed in Table 2.2. 
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2.2.4.5 Secondary Antibody Dilution 
Following overnight primary antibody incubation, the PVDF membrane was washed four times 
for 10 min in TBST. Secondary antibody was then added and the membrane was incubated for 
1.5 h at room temperature in the dark. Secondary antibody dilutions were performed as per the 
manufacturer’s protocol, with dilution ratios outlined in Table 2.3. Three 10 min TBST washes 
and one TBS (Appendix C.9) wash was performed, with the membrane in the dark. The 
membrane was then imaged using an Odyssey Fc Imaging System.  
 
 











Target Antibody Dilution Product code 
YAP Rabbit mAb 1:1,000 ab52771 
YAP pSer127 Rabbit mAb 1:1,000 ab76252 
α-tubulin Mouse mAb 1:2,500 T6199 
Target Antibody Dilution Product code 
Rabbit Goat pAb 1:10,000 IRDye 680LT 





















3. OPTIMISATION OF REAL-TIME 
AND ENDPOINT CELL VIABILITY 
ASSAYS 
3.1 INTRODUCTION 
In vitro viability assays are essential tools for drug development, allowing for the assessment of 
drug efficacy prior to subsequent in vivo analyses. Whether performed as a single plate 
experiment or as part of a high-throughput screen, the concept remains the same - cells are 
incubated with a particular compound(s) then assessed for viability to quantify drug-induced 
cell toxicity.     
 
Numerous commercial cell viability assays that exploit different cellular processes to quantify 
cytotoxicity are now available, each highlighting the variability that can be obtained from 
different methodologies (Chan et al., 2013; Kepp et al., 2011; Quent et al., 2010). 
Consequently, the selection and application of an effective assay(s) should be a major 
consideration in any drug-based experimental design. 
 
A widely used approach to determine drug-induced cytotoxicity involves measuring cellular 
metabolic activity at the conclusion of an experiment. Such approaches include the 3-[4,5-
dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide (MTT) assay, resazurin reduction, and 
the CellTiter-Glo assay, each harnessing a different aspect of cellular metabolism as a means of 
quantifying live cells. The MTT assay relies upon the mitochondrial activity of live cells to 
convert a yellow MTT substrate into purple formazan crystals, detectable via spectrophotometry 
(Mosmann, 1983). The resazurin reduction assay, used in alamarBlue and CellTiter-Blue 
assays, is a more sensitive alternative to MTT and uses the intracellular reduction potential of 
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living cells to convert resazurin to the fluorescent product resorufin (O'Brien et al., 2000). 
CellTiter-Glo adopts the use of firefly luciferase, which reacts with available cellular adenosine 
triphosphate (ATP) to produce a bioluminescent signal proportional to the number of live cells 
present in the assay (Crouch et al., 1993). The nuclei counting method, which is a direct 
measure of viability, is considered to be the most accurate (Chan et al., 2013); however, the 
ease of mix-and-measure metabolic-based approaches makes them a common feature in high-
throughput drug screens.  
 
Unlike endpoint approaches, real-time assay systems allow for the tracking of cellular growth 
over the entire time course of an experiment. This is particularly effective for assessing the 
impact of cytostatic compounds, where subtle growth inhibitory effects are easily noticeable but 
may be missed using endpoint-based methods. Real-time assays are typically performed using 
equipment capable of capturing images at regular intervals and quantifying cellular surface area 
coverage as a measure of proliferation, such as the IncuCyte FLR. Such methods also facilitate 
visualisation of drug-induced cell morphology changes. Alternatives to this approach include 
the xCELLigence, which uses electrical impedance to measure both cellular adhesion strength 
and surface area coverage as a combined proxy of cellular proliferation. 
 
In this study, we compared the performance of five different cell-based viability assays. Three 
endpoint assays (resazurin reduction, CellTiter-Glo, and nuclei enumeration) and two real-time 
assays (IncuCyte and xCELLigence) were used to investigate the effectiveness of each approach 




3.2.1 Metabolic and Nuclei Counting Endpoint Assays 
Firstly, the performance of two metabolic based assays were compared alongside nuclei 
counting. The resazurin reduction and CellTiter-Glo assays were chosen ahead of the MTT 
assay as previous studies have reported reduced sensitivity with MTT compared to other 
endpoint methods (Hamid et al., 2004; Haselsberger et al., 1996). To compare the efficacy of 
each assay, MCF10A and MCF10A CDH1-/- cells were treated with a previously identified 
synthetic lethal drug, vorinostat, for 48 hours and assessed for cell viability using each method 
(Telford et al., 2015). A dose-dependent effect was observed in all three methods with 
increasing vorinostat concentration in both cell lines. In both MCF10A and MCF10A CDH1-/- 
cells, 0.63 μM vorinostat treatment showed negligible viability inhibition, with no marked 
differences observed between the two metabolic assays. At dosages of 1.25 and 2.5 μM 
vorinostat, however, the CellTiter-Glo assay gave significantly higher viabilities than the 
resazurin reduction assay (P < 0.05; Figure 3.1A-B). Both metabolic based approaches gave 
significantly higher viabilities than the nuclei counting approach for all three vorinostat 









Figure	  3.1	  Comparison	  of	  endpoint	  viability	  assays	  
A	   comparison	   of	   three	   different	   endpoint	   assays	   (resazurin	   reduction,	   CellTiter-­‐Glo,	   and	   Hoechst	   stained	  
nuclei	   counting)	   based	   on	   their	   cell	   viability	   measurements	   normalised	   to	   their	   respective	   DMSO-­‐treated	  
controls	   in	   (A)	  MCF10A	   and	   (B)	  MCF10A	  CDH1-­‐/-­‐	   cells.	   Data	   represents	   averaged	   values	   of	   three	   biological	  



































































Figure 3.1: Comparison of endpoint viability assays. 
A comparison of three different endpoint assays (resazurin reduction, CellTiter-Glo, and Hoechst 
stained nuclei counting) based on their cell viability measurements normalised to their respective 
DMSO-treated controls in (A) MCF10A and (B) MCF10A CDH1-/- cells. Data represents averaged 
values of three biological replicates with standard error shown. P-values calculated using Student’s 


















3.2.2 Real-Time Assays 
To complement the endpoint assays, real-time IncuCyte and xCELLigence assays were 
performed on MCF10A and MCF10A CDH1-/- cell lines treated with vorinostat over 48 hours 
(Figure 3.2A-B). The IncuCyte uses automated imaging to determine cellular confluence at 
designated intervals over the time course of an experiment as a measure of viability. The 
xCELLigence uses gold-plated plates to measure cell surface area coverage and adhesion 
strength via electrical impedance, combining these factors as a measurement of cell viability.  
 
From the IncuCyte and xCELLigence platforms, both cell lines showed a dose-dependent 
inhibitory response to vorinostat, although this effect was more pronounced in MCF10A  
CDH1-/- cells (Figure 3.2A-B). In order to compare the two real-time systems, we determined 
the proliferation rate at logarithmic growth phase (taken from 12 to 36 hours post drugging in 
Figure 3.2C) between control and drug treatment within the respective MCF10A and MCF10A 
CDH1-/- cells. In both systems, the proliferation rates of vorinostat treated MCF10A cells were 
quite comparable and differed by no more than 10% across each tested concentration.  MCF10A 
CDH1-/- cells showed slower proliferation rates in the xCELLigence than the IncuCyte. From 









Figure	  3.2	  Comparison	  of	  real-­‐time	  viability	  assays	  
A	  comparison	  of	  real-­‐time	  viability	  measurements	  in	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  as	  determined	  using	  
(A)	  the	  IncuCyte	  system,	  which	  uses	  cell	  surface	  confluence,	  and	  (B)	  the	  xCELLigence	  system,	  which	  measures	  
cellular	   surface	  area	   coverage	  and	  adherence	   strength.	  (C)	  A	   comparison	  of	  proliferation	   rates	  between	   the	  
two	  real-­‐time	  systems	  as	  determined	  by	   logarithmic	  growth	  phase	   (between	  12	   to	  36	  hours	  post	   treatment	  
from	  (B)	  and	  (C).	  The	  depicted	  proliferation	  rates	  are	  normalised	  to	  DMSO-­‐treated	  controls.	  A	  representative	  
experiment	  of	  each	  real-­‐time	  assay	  is	  shown.	  
Figure 3.2: Comparison of real-time viability assays. 
A comparison of real-t me viability measurements in MCF10A and MCF10A CDH1-/- cells a  
determined using (A) the IncuCyte system, which uses cell surface confluence, and (B) the 
xCELLigence system, which measures cellular surface area coverage and adherence strength. (C) 
A comparison of proliferation rates between the two real-time systems as determined by 
logarithmic growth phase (between 12 to 36 hours post treatment from B and C). The depicted 
proliferation rates are normalised to DMSO-treated controls. A representative experiment of each 












































































































































DMSO 0.63 1.25 
IncuCyte
xCELLigence
Time (h) Time (h)
Time (h)Time (h)
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At the conclusion of each assay, both real-time platforms showed that vorinostat treated 
MCF10A cells had achieved viability values very similar to DMSO-treated controls (Figure 
3.2A-B). This was contrary to data from the endpoint methods (Figure 3.1A), which had shown 
that each vorinostat concentration had produced lower viabilities than control treated cells, 
particularly in the nuclei counting assay. A closer inspection of representative phase-contrast 
and fluorescent images from the IncuCyte revealed an observable difference in cell density 
between control and vorinostat treated MCF10A cells (Figure 3.3A and 3.3C). Even though 
both control and vorinostat (1.25 μM) treated MCF10A cells showed full growth confluence 
covering the entire surface area of each respective well (Figure 3.3B), subsequent nuclei 
counting confirmed significant differences in cell numbers, whereby 39% fewer cells were 




Figure	  3.3	  Cellular	  confluence	  measurements	  do	  not	  reflect	  cell	  densities	  at	  full	  surface	  area	  coverage	  
(A)	   Phase-­‐contrast	   images	   of	   MCF10A	   cells	   at	   48	   h	   post	   DMSO	   and	   1.25	   μM	   vorinostat	   treatment	   (4X	  
magnification;	   scale	   bars	   =	   400	   μm	   in	   length).	   A	   more	   distinct	   difference	   in	   cell	   density	   was	   observed	   in	  
SYTOX-­‐stained	  cell	  nuclei	   compared	   to	   the	  phase-­‐contrast	   from	  the	  same	   field	   (fluorescent	   images	  captured	  
using	  IncuCyte	  under	  4X	  magnification).	  (B)	  Negligible	  cell	  viability	  difference	  observed	  between	  DMSO-­‐	  and	  
vorinostat-­‐treated	   MCF10A	   cells	   as	   determined	   using	   IncuCyte’s	   cell	   surface	   confluence	   measurements	   of	  
phase-­‐contrast	   images	   in	  A.	  (C)	  Differential	  cell	  densities	  quantified	   from	  nuclei	  enumeration	  of	  control	  and	  












































Figure 3.3: Cellular confluence measurements do not reflect cell densities at full surface area 
coverage. 
(A) Phase-contrast images of MCF10A cells at 48 h post DMSO a d 1.25 µM vorinostat treatment 
(4X magnification; scale bars = 400 µm in length). A more distinct difference in cell density was 
observed in SYTOX-stained cell nuclei compared to the phase-contrast from the same field 
(fluorescent images captured using IncuCyte under 4X magnification). (B) Negligible cell viability 
difference observed between DMSO- and vorinostat-treated MCF10A cells as determined using 
IncuCyte’s cell surface confluence measurements of phase-contrast images in A. (C) A significant 
difference in cell density as quantified from nuclei enumeration of control and drug-treated 
MCF10A cells shown in A. 
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3.2.3 Real-time Assay and Endpoint Assay Multiplexing 
To mitigate the shortfalls observed in the endpoint and real-time assays, we combined the 
IncuCyte real-time assay with both the resazurin reduction and nuclei counting assays. The 
resazurin reduction and nuclei counting methods were selected as endpoint assays as they have 
been reported to multiplex together effectively (Wu et al., 2009). This multiplexed approach 
also allowed for more data to be gathered from one drug-treated experiment. We also wanted to 
investigate if the combined approach was capable of evaluating synthetic lethal properties of 
two different drugs, where assay sensitivity is essential to distinguish preferential targeting of 
one cell type over another. In this case, a synthetic lethal effect would involve the selective 
growth inhibition of MCF10A CDH1-/- cells but not MCF10A cells. To test this, MCF10A and 
MCF10A CDH1-/- cells were subjected to either vorinostat or taxol treatment over 48 hours, 
with cellular growth being tracked in the IncuCyte, followed by resazurin reduction and nuclei 
counting at the conclusion of the real-time analysis.  
 
At 48 hours following vorinostat treatment (0.63, 1.25, 2.5 μM), the confluence measurements 
from the IncuCyte showed that MCF10A cells were marginally inhibited and proliferated 
similarly to control treated cells (Figure 3.4A). However, in MCF10A CDH1-/- cells, a 
significant dose-dependent inhibitory response was observed in which drug treated cells did not 
reach the confluency of control treated cells (Figure 3.4B). Following the IncuCyte assay, the 
same plate was then subjected to the resazurin reduction assay. Increasing vorinostat treatment 
caused a more marked reduction in MCF10A CDH1-/- cell viabilities (93%, 71%, and 43%; 
Figure 3.4C) compared to the corresponding MCF10A treated cells (98%, 83%, 55%; Figure 
3.4C). Similarly, the nuclei counting analysis, performed immediately after the resazurin 
reduction assay, also showed increasing vorinostat treatment causing a more marked effect on 
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MCF10A    CDH1-/- cell viabilities (77%, 47%, and 26%; Figure 3.4D) compared to MCF10A 
cells (79%, 57%, and 37%; Figure 3.4D). 
 
As another measure of synthetic lethality, the viability ratio of MCF10A CDH1-/- cells to 
MCF10A cells was calculated, whereby a ratio of less than 1 indicated an increased 
susceptibility of MCF10A CDH1-/- cells to drug treatment, concordant with a drug-induced 
synthetic lethal phenotype. Both the resazurin reduction and nuclei counting assays produced 
comparable viability ratios for 0.63, 1.25, and 2.5 μM vorinostat treatment between the isogenic 
cell lines (resazurin reduction: 0.95, 0.85, 0.78; nuclei counting: 0.97, 0.82, 0.70). The synthetic 
lethal effect seen in the endpoint assays was apparent in the IncuCyte confluence analysis, 
although the extent of this differential was more marked in real-time. Overall, the combined 
assays demonstrated an increased susceptibility of MCF10A CDH1-/- cells compared to 





Figure	   3.4	   Combined	   real-­‐time	   and	   endpoint	   assays	   facilitate	   the	   evaluation	   of	   drugs	   for	   synthetic	  
lethal	  properties	  in	  MCF10A	  isogenic	  cells	  
(A-­‐B)	   IncuCyte	   real-­‐time	   confluence	   measurements	   demonstrating	   a	   selective	   proliferation	   inhibition	   by	  
vorinostat	   in	  MCF10A	  CDH1-­‐/-­‐	   cells	   compared	   to	  MCF10A	   cells	   across	   a	   range	   of	   concentrations	   over	   48	   h.	  
Endpoint	   resazurin	  reduction	  (C)	   and	  Hoechst	  stained	  nuclei-­‐counting	  (D)	  performed	   immediately	  after	   the	  
real-­‐time	   assay	   (A-­‐B),	   showed	   a	   greater	   and	   selective	   inhibition	   of	   MCF10A	   CDH1-­‐/-­‐	   cells	   across	   three	  
concentrations	  of	  vorinostat.	  Endpoint	  assays	  show	  viabilities	  normalised	  to	  respective	  controls,	  representing	  
the	   averaged	   values	   of	   three	   biological	   replicates	   with	   standard	   error	   shown.	   P-­‐values	   calculated	   using	  



























































































Figure 3.4: Combined real-time and endpoint assays facilitate the evaluation of drugs for 
synthetic lethal properties in MCF10A isogenic cells. 
(A-B) IncuCyte real-time conflu ce measurements demonstrating a selective proliferation 
inhibition by vorinostat in MCF10A CDH1-/- cells compared to MCF10A cells across a range of 
concentrations over 48 h. Endpoint resazurin reduction (C) and Hoechst stained nuclei-counting 
(D) performed immediately after the real-time assay (A-B), showed a greater and selective 
inhibition of MCF10A CDH1-/- cells across three concentrations of vorinostat. Endpoint assays 
show viabilities normali ed to respective controls, representing the av raged values of three 
biological replicates with standard error shown. P-values calculated using Student’s t-test; ** P < 
0.01.   







We next used the combined endpoint and real-time assay approach to examine a drug that does 
not induce synthetic lethal effects in the MCF10A isogenic pair. The microtubule-targeting 
agent taxol was selected from the high-throughput drug screen for this purpose (Telford et al., 
2015). IncuCyte analysis showed MCF10A cells treated with 1 and 2 nM taxol exhibited 
negligible inhibition (Figure 3.5A). When treated with 4 nM taxol, MCF10A cell viability was 
affected within the first 36 hours but eventually attained confluence measurements similar to 
controls at the conclusion of the real-time assay (Figure 3.5A). A similar effect was seen in 
taxol treated MCF10A CDH1-/- cells, although the highest concentration (4 nM) gave rise to 
growth inhibition that prevented full confluency observed in control treatment (Figure 3.5B). 
The resazurin reduction and nuclei counting assays showed that taxol treatment also produced a 
dose-dependent effect in both MCF10A and MCF10A CDH1-/- cells, without showing 
preferential inhibition in either cell type at the tested concentration range (Figure 3.5C-D). 
Furthermore, the viability ratios determined from both the resazurin reduction and nuclei 
counting assays were not less than 1 (resazurin reduction: 1.00, 1.02, and 1.05; nuclei counting: 
1.02, 1.03, and 1.03), indicating no synthetic lethality. Taxol treatment at higher concentrations 
(up to 32 nM) yielded a dose-dependent effect in both isogenic cell lines although no synthetic 
lethal phenotype was observed at these concentrations (Appendix D.1).  
 
To summarise, the IncuCyte in combination with both resazurin reduction and nuclei counting 
assays successfully provided a comprehensive analysis of vorinostat- and taxol-induced 






Figure	   3.5	   Combined	   real-­‐time	   and	   endpoint	   assays	   facilitate	   the	   evaluation	   of	   drugs	   for	   synthetic	  
lethal	  properties	  in	  MCF10A	  isogenic	  cells	  
(A-­‐B)	   IncuCyte	   real-­‐time	   confluence	  measurements	   demonstrating	  modest	   selective	   proliferation	   inhibition	  
by	   taxol	   in	   MCF10A	   CDH1-­‐/-­‐	   cells	   compared	   to	   MCF10A	   cells	   across	   a	   range	   of	   concentrations	   over	   48	   h.	  
Endpoint	   resazurin	  reduction	  (C)	   and	  Hoechst	  stained	  nuclei-­‐counting	  (D)	  performed	   immediately	  after	   the	  
real-­‐time	  assay	  (A-­‐B),	  did	  not	  show	  selective	  inhibition	  of	  MCF10A	  CDH1-­‐/-­‐	  cells	  across	  three	  concentrations	  of	  
taxol.	  Endpoint	  assays	  show	  viabilities	  normalised	  to	  respective	  controls,	  representing	  the	  averaged	  values	  of	  






























































































Figure 3.5: Combined real-time and endpoint assays facilitate the evaluation of drugs for 
synthetic lethal properties in MCF10A isogenic cells. 
(A-B) IncuCyte real-time confluence measurements demonstrating modest selective proliferation 
inhibition by taxol in MCF10A CDH1-/- cells compared to MCF10A cells across a range of 
concentrations over 48 h. Endpoint resazurin reduction (C) and Hoechst stained nuclei-counting 
(D) performed immediately after the real-time assay (A-B), did not show selective inhibition of 
MCF10A CDH1-/- cells across three concentrations of taxol. Endpoint assays show viabilities 
normalised to respective controls, representing the averaged values of three biological replicates 




In this chapter, we have shown that both metabolic-based endpoint assays examined gave 
significantly higher viabilities than the nuclei-counting approach, suggesting that resazurin 
reduction and CellTiter-Glo over-represent cell viability. In addition, viability as measured by 
nuclei counting was more comparable to that measured using resazurin reduction, suggesting 
CellTiter-Glo is less sensitive than other endpoint methodologies, at least for cells treated with 
vorinostat. This is contrary to previous literature reports, which indicate that CellTiter-Glo can 
provide higher sensitivity than resazurin-based assays (Peternel et al., 2009; Riss et al., 2004).  
 
In addition to reduced sensitivity, the two metabolic assays also have other potential limitations. 
For example, the resazurin reduction assay requires a 37 °C incubation step of several hours 
which has been reported to cause morphological changes in cells (Riss et al., 2004). However, 
we did not observe resazurin-induced morphology changes in our cell lines (data not shown). 
On the other hand, CellTiter-Glo, which has a shorter incubation phase to permeabilise cells and 
release their ATP for measurement, has a considerably greater cost, which can be a drawback in 
high-throughput screening. Furthermore, it is possible that drugs affecting cellular metabolic 
processes could interfere with the performance of both the resazurin reduction and CellTiter-
Glo assays, giving rise to inaccurate viability measurements (Kepp et al., 2011). 
 
Overall, the nuclei counting method is still considered to be the most accurate measure of cell 
viability (Chan et al., 2013). A drawback to this approach is the application to high-throughput 
screening, requiring efficient automated imaging systems with built-in enumeration software, 
which can be cost prohibitive. Fortunately, more affordable entry-level systems, such as the 
Cytell (General Electric), Cytation 5 (BioTek), and EVOS (Thermo), are available to provide 
such technologies at a reduced cost. Alternatively, more standard imaging systems without 
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accompanying enumeration software can be used with free open sourced applications such as 
ImageJ (Schneider et al., 2012) or CellProfiler (Lamprecht et al., 2007). 
 
The IncuCyte and xCELLigence platforms each produced comparable proliferation rates for 
vorinostat-treated MCF10A cells. When using MCF10A CDH1-/- cells, however, discrepancies 
in recorded proliferation rates from the two systems became apparent, with the xCELLigence 
producing slower rates than those seen using the IncuCyte. It is possible that this difference 
could be attributed to the compromised adhesion previously characterised in MCF10A CDH1-/- 
cells (Chen et al., 2014a), which may have been further exacerbated by vorinostat treatment. As 
a result, the xCELLigence, which measures adhesion impedance, would have registered a 
greater reduction in MCF10A CDH1-/- cell viability compared to the IncuCyte, which is 
incapable of detecting adhesion strength. MCF10A cells showed no marked difference between 
the two systems, presumably since this cell line does not exhibit compromised cellular adhesion 
(Chen et al., 2014a).  
 
The gold-plated xCELLigence plates used in this study unfortunately lacked clear bottoms 
which prevented imaging analysis. Newer E-plates with partial clear bottom sections for cell 
visualisation are now available; however, these were not released prior to our investigation. 
Conversely, the IncuCyte system was able to provide images which showed no substantial 
morphological changes over the time course of vorinostat treatment in both cell types (Figure 
3.3A). Overall, both real-time platforms showed comparable performance, except for measuring 
MCF10A CDH1-/- cells treated with 0.63 μM vorinostat. 
 
A noteworthy observation was the IncuCyte’s inability to discriminate between differing 
cellular densities when cells had covered the entire surface area of their respective wells. As 
such, caution should be taken when analysing data at full cellular confluence as further 
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validation is required from direct cell counting. Nevertheless, the IncuCyte still produced 
valuable data during sub-confluent growth phases, which was comparable to nuclei counting 
data (data not shown). These results demonstrate that a combination of distinct methodologies 
provides a more comprehensive and accurate assessment of drug efficacy than singular assays.   
 
In conclusion, this chapter has shown that the IncuCyte system is well suited for tracking sub-
confluent cell growth phases, which can be followed up by nuclei counting to assess drug 
efficacy when cells are at full confluence. In the absence of a real-time system like the 
IncuCyte, nuclei counting should be performed as it provided the most accurate measurement of 
viable cells in this analysis. Overall, we have demonstrated the utility and strengths of five 
viability assays and have adapted a robust real-time and endpoint multiplexed method for the 







































4. SYNERGISTIC SYNTHETIC 
LETHAL DRUG SCREENING 
4.1 INTRODUCTION 
We have previously identified drugs that are synthetic lethal in a non-malignant breast cell line 
lacking E-cadherin expression, MCF10A CDH1-/-, relative to wild-type MCF10A (Single et al., 
2015; Telford et al., 2015). However, these synthetic lethal effects were relatively modest. This 
led to our goal of discovering synergistic drug combinations capable of accentuating our initial 
synthetic lethal vulnerabilities. Clinically, this approach would allow for maximal therapeutic 
outcomes to be achieved for HDGC and ILBC patients with lower risks of drug toxicity. 
 
4.1.1 Drug Combination Testing 
The recommended approach for identifying synergistic drug-drug interactions involves the 
application of Chou-Talalay’s median-effect analysis to cell viability data obtained using a 
constant-ratio experimental design (Chou, 2010; Chou and Martin, 2007; Chou and Talalay, 
1984).  
 
The constant-ratio experimental design determines a drug’s potency in a particular cell line 
when given as both a single-agent and combined treatment with another drug. This is important 
as it allows for the kill-curve, or ‘shape’, of each drug to be determined prior to assessment of 
its behaviour in combination. The basis of the constant-ratio experimental design involves 
treating a particular cell line with a titrated range of two or more single-agent drugs alongside a 
titrated range of these drugs in combination. This combination treatment must be provided to 
the cell line with each titration point consisting of a constant-ratio of drug 1 and drug 2. 
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Following conclusion of the experiment, cell viability data gathered from each single-agent and 
combination treatment is inputted into Chou-Talalay’s equation for determining the combined 
drug interaction. As previously mentioned, the output of this equation denotes a ‘combination 
index’ (CI) whereby: CI < 0.9 indicates a synergistic drug interaction; CI = 0.9-1.1 indicates an 
additive drug interaction; CI > 1.1 indicates an antagonistic drug interaction (Chou, 2010). It is 
this Chou-Talalay method and combination index interpretation that has formed the basis of 
drug combination screening in this chapter. 
 
4.1.2 Synergistic Combinations with HDACi 
Multiple reports of drug combinations involving HDACi are evident in the literature. These 
include descriptions of HDACi in combination with drugs such as microtubule stabilising 
agents, poly (ADP-ribose) polymerase (PARP) inhibitors, multikinase inhibitors, and inhibitors 
of the mevalonate pathway. Synergy between HDACi and the microtubule stabilising agent 
taxol has been observed across numerous cancer cell lines (Cooper et al., 2007; Dietrich et al., 
2010; Dowdy et al., 2006; Owonikoko et al., 2010; Shi et al., 2010; Zuco et al., 2011), 
including the wild-type MCF10A line (Shi et al., 2010). We have previously reported that 
MCF10A CDH1-/- cells have grossly disrupted microtubule organisation (Chen et al., 2014a; 
Telford et al., 2015). This suggests that taxol has the potential to act synergistically with 
HDACi, such as vorinostat, in MCF10A CDH1-/- cells through the simultaneous targeting of 
microtubules. One target of vorinostat, a pan-HDACi, is HDAC6. Cytoplasmic HDAC6 
mediates the removal of acetylation tags on alpha-tubulin lysine residues, leading to a relaxed 
microtubule state (Glozak et al., 2005; Zhang et al., 2003). The inhibition of HDAC6 with 
vorinostat therefore results in acetylated, stabilised microtubules (Zilberman et al., 2009). 
Simultaneous treatment of HDACi in conjunction with a microtubule stabilising agent such as 
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taxol, would be predicted to exacerbate this stabilised tubulin state, leading to dysfunction in 
cell motility, trafficking, and mitotic processes.  
 
In addition to cytoskeleton modifying effects, HDACi have been reported to modulate 
homologous DNA repair mechanisms (Chao and Goodman, 2014). This is achieved by HDACi-
induced downregulation of double stranded break (DSB) repair, a process known to involve the 
PARP proteins (Chao and Goodman, 2014). It is therefore thought that combined treatment of 
HDACi with PARP inhibitors (PARPi) may exert a critical decrease in the rate of DNA repair 
and thus produce a marked cellular apoptotic response. Indeed, current in vitro studies across a 
range of cell lines provide evidence supporting a synergistic interaction between vorinostat and 
the PARPi, olaparib (Chao and Goodman, 2014; Hegde et al., 2016; Konstantinopoulos et al., 
2014; Rasmussen et al., 2016; Zhang et al., 2012). It is unlikely that E-cadherin loss will 
sensitise our normalised MCF10A cell line to DNA repair inhibition, however, HDACi and 
PARPi combinations will be tested for potential synergistic interactions. 
 
In vitro data have shown combined sorafenib and HDACi treatment induces a synergistic 
apoptotic response in cell lines derived from tissues including CNS, renal carcinoma, and the 
liver (Chen et al., 2014b; Kim et al., 2012; Lachenmayer et al., 2012; Tang et al., 2012). 
Sorafenib is a multikinase inhibitor known to inhibit multiple cellular signalling pathways, 
including Raf kinases, VEGF, and platelet-derived growth factor receptors (Chen et al., 2014b). 
Additionally, sorafenib has been shown to prevent the cellular antiapoptotic response by 
translationally downregulating Bcl-2 family proteins (Rahmani et al., 2005; Yu et al., 2005). 
Sorafenib currently serves as the only FDA-approved drug for patients with advanced 
hepatocellular carcinoma (HCC), however, recent preclinical studies have shown great promise 
for the treatment of other malignancies such as melanoma, non-small cell lung cancer, 
colorectal cancer, and breast cancer (Wilhelm et al., 2008 and references therein). Due to the 
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broad-spectrum nature of multikinase and HDAC inhibition, the synergistic mechanism for this 
response is yet to be fully understood, however, some reports suggest the ERK signalling 
pathway may play a key role (Chen et al., 2014b). Both epithelial (E-cadherin-expressing) and 
mesenchymal (E-cadherin-deficient) MCF10A cells require ERK signalling for cell cycle 
progression (Klein et al., 2008), suggesting ERK inhibition alone may not be an exploitable 
synthetic lethal vulnerability in our isogenic system.  
 
Simultaneous PI3K inhibitor (PI3Ki) and HDACi treatment has been shown to exert synergistic 
antiproliferative effects both in vitro and in vivo (Bodo et al., 2013; Erlich et al., 2012; Pei et 
al., 2016; Piao et al., 2016; Wozniak et al., 2010; Yamada et al., 2013; Yoshioka et al., 2013). 
Interestingly, these studies have spurred development of PI3Ki-HDACi hybrid compounds. 
CUDC-907 is an example of one such compound containing both HDAC and PI3K inhibition 
moieties that is currently undergoing phase II clinical trials for non-Hodgkin’s lymphoma and 
multiple myeloma (Rana et al., 2015). 
 
The PI3K pathway is regulated, at least in part, by E-cadherin mediated cell-to-cell adhesion 
dynamics (Fukata and Kaibuchi, 2001; Kovacs et al., 2002). Consistent with this, activating 
PI3K mutations are frequently identified in tumours devoid of E-cadherin expression – 
particularly in the case of ILBC (Christgen and Derksen, 2015; Christgen et al., 2013; Christgen 
et al., 2016). Although the MCF10A cell model used in this study does not harbour an 
activating PI3K mutation (Isakoff et al., 2005; Zhang et al., 2008), we hypothesise that 
inhibition of the PI3K signalling cascade in a drug combination context may be capable of 
exploiting an underlying vulnerability following E-cadherin loss. 
 
Synergistic combinations between HDACi and mevalonate pathway inhibitors have been 
described in a range of malignant cell lines (Gan et al., 2008; Lin et al., 2017; Sonnemann et al., 
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2007). These studies support investigation of the mevalonate signalling cascade in our E-
cadherin-deficient synthetic lethal model. The mevalonate pathway is responsible for the 
production of cellular steroids, post-translational prenylation modifications, and intracellular 
cholesterol (Mullen et al., 2016). The rate-limiting step of these processes involves conversion 
of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid via the enzyme HMG-CoA 
reductase (HMGCR). The best-known HMGCR inhibitors are statins, which are widely used as 
lipid-lowering medications (Mullen et al., 2016).  
 
Recent studies have highlighted the mevalonate pathway’s involvement in cell proliferation, 
motility, and invasion (Al-Haidari et al., 2014; Sanchez et al., 2008; Wong et al., 2002; Yu et 
al., 2013). Specifically in breast cancer cell lines, the inhibition of multiple mevalonate pathway 
steps has been shown to induce drastic morphological changes by altering levels of key 
cytoskeletal regulators such as Rac, Rho, and Cdc42 (Gobel et al., 2016). Activation of these 
cytoskeletal-associated proteins is governed by the mevalonate pathway’s addition of post-
translational prenylation motifs (Sahai and Marshall, 2002). Prenylation facilitates protein 
anchoring to the lipid membrane via addition of a 15-carbon or 20-carbon tag to cysteine 
residues, processes termed farnesylation and geranylgeranylation, respectively (Thurnher et al., 
2012; Wang and Casey, 2016). Interestingly, statin-mediated mevalonate pathway inhibition 
reduced proliferation in the E-cadherin devoid MDA-MB-231 cell line whilst minimally 
affecting an E-cadherin expressing MDA-MB-231 line (Warita et al., 2014). Although the 
underlying mechanism of this susceptibility is not understood, the application of statins to the 
MCF10A and MCF10A CDH1-/- cell lines is an exciting prospect.  
 
In this chapter, candidate HDACi, cytoskeleton-targeting, and statin drug combinations have 
been tested in an isogenic MCF10A cell line pair to identify synergistic synthetic lethal 
combinations in E-cadherin-deficient cells, MCF10A CDH1-/-.   
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4.2 RESULTS 
4.2.1 Histone Deacetylase Inhibitor (HDACi) Combinations 
4.2.1.1 HDACi and the SRC Inhibitor Saracatinib 
To identify a drug combination that causes a synergistic synthetic lethal effect in E-cadherin-
deficient cells, we first tested the combination of our previously identified lead drugs, histone 
deacetylase inhibitors (HDACi; entinostat and vorinostat; Figure 4.1A-B) and the SRC 
inhibitor, saracatinib (Figure 4.1C). 24 hours after seeding, MCF10A and MCF10A CDH1-/- 
cells were treated with a range of concentrations of HDACi (entinostat or vorinostat), 
saracatinib, and a combination of HDACi and saracatinib, and cultured for an additional 48 
hours. Cellular viability was then assessed using nuclei counting and potential synergistic drug 
interactions identified using an isobologram analysis via CompuSyn software. This analysis 
showed that both entinostat/saracatinib and vorinostat/saracatinib produced marked synthetic 
lethal effects in MCF10A CDH1-/- cells (Figure 4.2A, 4.3A). This was evident by comparing 
IC50 values between the isogenic cell lines, with higher IC50 values seen in MCF10A cells than 
MCF10A CDH1-/- cells (Table 4.1). The isobologram analysis, plotted as Combination Index 
(CI) against cellular viability loss from combination treatment (fraction of cells affected, Fa) 
showed an antagonistic interaction for both tested HDACi and saracatinib combinations (CI > 
1.1; Figure 4.2B-C, 4.3B-C; Table 4.1). In summary, both entinostat and saracatinib or 
vorinostat and saracatinib produced a significant synthetic lethal effect in E-cadherin-deficient 
MCF10A cells but did not show evidence of a synergistic drug interaction. 
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Figure	  4.1	  Validation	  of	  previously	  identified	  synthetic	  lethal	  drugs	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  either	  (A)	  vorinostat,	  (B)	  entinostat,	  
or	  (C)	   saracatinib	  over	  a	  range	  of	  concentrations.	  At	  48	  h	  post-­‐treatment,	  cell	  viability	  was	  assessed	  using	  a	  
Hoechst-­‐stained	   nuclei	   counting	   assay.	   MCF10A	   CDH1-­‐/-­‐	   cells	   showed	   greater	   sensitivity	   to	   each	   drug	  
treatment	  than	  MCF10A	  cells,	  concordant	  with	  a	  synthetic	  lethal	  phenotype.	  Data	  represents	  averaged	  values	  
of	  two	  biological	  replicates	  with	  standard	  error	  shown.	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  0.05;	  **	  
P	  <	  0.01.	  
Figure 4.1: Validation of previously identified synthetic lethal drugs in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- c lls were g own for 24 h and treat d with either (A) vorinostat, (B) 
entinostat, or (C) sarac tinib over a range of concentrations. At 48 h post-treatment, cell viability was 
assessed using a Hoechst-stained nuclei counting assay. MCF10A CDH1-/- cells showed greater 
sensitivity to each drug treatment than MCF10A cells, concordant with a synthetic lethal phenotype. 
Data represents averaged values of two biological replicates with standard error shown. P-values 


































































































Figure	   4.2	   Entinostat	   and	   saracatinib	   Treatment	   is	   synthetic	   lethal	   but	   not	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   entinostat	   or	  
saracatinib,	  or	  combined	  entinostat	  and	  saracatinib	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐
stained	   nuclei	   counting	   assay	   (A)	   and	   used	   to	   assess	   drug	   synergy	   at	   ED50,	   ED75,	   and	   ED90	   doses	   via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	   greater	   sensitivity	   to	   entinostat	   and	   saracatinib	   treatment	   than	   MCF10A	   cells,	   concordant	   with	   a	  
synthetic	  lethal	  phenotype.	  Entinostat	  and	  saracatinib	  treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  
cell	  lines	  (CI	  >	  0.9).	  (A)	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  
representative	  experiment	  is	  shown	  for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  0.05;	  **	  P	  
<	  0.01.	  
i  4.2: Entinostat + saracatinib treatment is synthetic lethal but not synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent entinostat or saracatinib, or 
combined entinostat + saracatinib for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, C). 
Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivity to entinostat + 
saracatinib treatment than MCF10A cells, concordant with a synthetic lethal phenotype. Entinostat + saracatinib 
treatment was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged values of two 
bi logical plicates with standard error shown; a rep esentative experiment is shown for (B) and (C). P-values 
























































































Figure	   4.3	   Vorinostat	   and	   saracatinib	   treatment	   is	   synthetic	   lethal	   but	   not	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   vorinostat	   or	  
saracatinib,	  or	  combined	  vorinostat	  and	  saracatinib	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐
stained	   nuclei	   counting	   assay	   (A)	   and	   used	   to	   assess	   drug	   synergy	   at	   ED50,	   ED75,	   and	   ED90	   doses	   via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	   greater	   sensitivity	   to	   vorinostat	   and	   saracatinib	   treatment	   than	   MCF10A	   cells,	   concordant	   with	   a	  
synthetic	  lethal	  phenotype.	  Vorinostat	  and	  saracatinib	  treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  
cell	  lines	  (CI	  >	  0.9).	  (A)	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  
representative	  experiment	  is	  shown	  for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  **	  P	  <	  0.01.	  
Figure 4.3: Vorinostat + saracatinib treatment is synthetic lethal but not synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent vorinostat or saracatinib, or 
combined vorinostat + saracatinib for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, C). 
Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivity to vorinostat + 
saracatinib treatment than MCF10A cells, concordant with a synthetic lethal phenotype. Vorinostat + saracatinib 
treatment was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged values of two 
biological replicates with standard error shown; a representative experiment is shown for (B) and (C). P-values 






























































































Table	  4.1	  HDACi	  (entinostat	  and	  vorinostat)	  and	  saracatinib	  combination	  IC50	  values	  and	  ED50	  



















MCF10A 3.07/1.54 1.69 




MCF10A 1.87/1.87 1.37 
MCF10A CDH1-/- 1.14/1.14 2.41 
 66 
4.2.1.2 HDACi and the Microtubule Stabilising Drug Taxol  
We next investigated HDACi in combination with the microtubule stabilising agent taxol in the 
MCF10A isogenic pair. MCF10A and MCF10A CDH1-/- cells were grown for 24 hours, then 
treated with single-agent vorinostat or taxol, or both drugs in combination for an additional 48 
hours. Cell viability was then assessed using nuclei counting and drug synergy quantified using 
an isobologram analysis via CompuSyn. The nuclei counting analysis showed single-agent taxol 
treatment did not induce a synthetic lethal phenotype in MCF10A CDH1-/- cells (Appendix 
D.1). Combined vorinostat and taxol treatment also exerted a dose-dependent effect in both 
MCF10A isogenic cell lines without inducing a synthetic lethal effect in the MCF10A CDH1-/- 
cell line (Figure 4.4A). The lack of synthetic lethality was reflected by similar IC50 values in 
each isogenic cell line following treatment (Table 4.2). In addition, the isobologram analysis 
showed an antagonistic effect for combined vorinostat and taxol treatment in both MCF10A 
isogenic cell lines, producing ED50 combination indices of 1.20 and 1.27 for MCF10A and 
MCF10A CDH1-/- cells, respectively (CI > 1.1; Figure 4.4B-C; Table 4.2). To summarise, 
combined treatment of an HDACi (vorinostat) and microtubule stabilising drug (taxol) failed to 
increase the synthetic lethal effect of vorinostat-only treatment in MCF10A CDH1-/- cells and, 







Figure	  4.4	  Vorinostat	  and	  taxol	  treatment	  is	  neither	  synthetic	  lethal	  nor	  synergistic	  in	  MCF10A	  CDH1-­‐/-­‐	  
cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  vorinostat	  or	  taxol,	  or	  
combined	   vorinostat	   and	   taxol	   for	   48	   h.	   Cell	   viabilities	   were	   determined	   using	   a	   Hoechst-­‐stained	   nuclei	  
counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  
analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  
CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  antagonism.	  MCF10A	  CDH1-­‐/-­‐	  cells	  did	  not	  show	  significant	  
increased	  sensitivity	  to	  vorinostat	  and	  taxol	  treatment	  when	  compared	  to	  MCF10A	  cells.	  Vorinostat	  and	  taxol	  
treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  cell	  lines	  (CI	  >	  0.9).	  (A)	  represents	  averaged	  values	  of	  
two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  representative	  experiment	  is	  shown	  for	  (B)	  and	  (C).	  
Figure 4.4: Vorinostat + taxol treatment is neither synthetic lethal nor synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent vorinostat or taxol, or 
combined vorinostat + taxol for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, 
C). Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells did not show significant increased 
sensitivity to vorinostat + taxol treatment when compared to MCF10A cells. Vorinostat + taxol treatment was not 
synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged values of two biological 



























































































Table	  4.2	  Vorinostat	  and	  taxol	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 1.31/4.20 1.20 














4.2.1.3 HDACi and the PARPi Olaparib  
To investigate combined HDACi and PARPi treatment in the MCF10A isogenic pair, MCF10A 
and MCF10A CDH1-/- cells were grown for 24 hours then treated for an additional 48 hours 
with a range of either single-agent vorinostat or olaparib, or combined vorinostat and olaparib. 
Cell viability was then assessed using nuclei counting and potential drug synergy analysed 
using an isobologram analysis via CompuSyn. From the nuclei counting assay, single-agent 
olaparib treatment did not induce a synthetic lethal effect in the MCF10A CDH1-/- cell line 
(Appendix D.2). Additionally, synthetic lethality was not observed in the isogenic pair across 
each concentration of the vorinostat and olaparib combination (Figure 4.5A). This was 
supported by similar IC50 values for combined HDACi and PARPi treatment in the MCF10A 
isogenic cell lines (Table 4.3). Furthermore, combined vorinostat and olaparib treatment showed 
no evidence of synergy in MCF10A CDH1-/- cells, producing an ED50 combination index of 
1.01 (CI > 0.9; Figure 4.5B-C; Table 4.3). The MCF10A cell line, however, showed a mild 
synergistic effect for this combination, with an ED50 combination index of 0.80 produced from 
the isobologram analysis (CI < 0.9; Figure 4.5B-C; Table 4.3). Together, these data show that 
combined HDACi and PARPi treatment showed no evidence of synthetic lethality or drug 




Figure	   4.5	   Vorinostat	   and	   olaparib	   treatment	   is	   neither	   synthetic	   lethal	   nor	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  vorinostat	  or	  olaparib,	  
or	  combined	  vorinostat	  and	  olaparib	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐stained	  nuclei	  
counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  
analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  
CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  antagonism.	  MCF10A	  CDH1-­‐/-­‐	  cells	  did	  not	  show	  significant	  
increased	   sensitivity	   to	   vorinostat	   and	  olaparib	   treatment	  when	   compared	   to	  MCF10A	   cells.	   Vorinostat	   and	  
olaparib	  treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  cell	  lines	  (CI	  >	  0.9).	  (A)	  represents	  averaged	  

















































































Figure 4.5: Vorinostat + olaparib treatment is neither synthetic lethal nor synergistic in MCF10A CDH1-/- 
cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent vorinostat or olaparib, or 
combined vorinostat + olaparib for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, 
C). Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells did not show significant increased 
sensitivity to vorinostat + olaparib treatment when compared to MCF10A cells. Vorinostat + olaparib treatment 
was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged values of two 












Table	  4.3	  Vorinostat	  and	  olaparib	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 0.59/4.69 0.80 












4.2.1.4 HDACi and the Multikinase Inhibitor Sorafenib 
We next tested vorinostat in combination with the multikinase inhibitor sorafenib. Akin to 
previous HDACi combination testing, MCF10A and MCF10A CDH1-/- cells were grown for 24 
hours and treated for an additional 48 hours with a range of single-agent vorinostat or sorafenib, 
or each drug in combination. Cell viability was then assessed using nuclei counting and drug 
synergy investigated using an isobologram analysis via CompuSyn. The nuclei counting assay 
showed single-agent sorafenib treatment did not induce a synthetic lethal effect in the MCF10A 
CDH1-/- cell line (Appendix D.3). However, modest synthetic lethality was observed in the 
isogenic pair following combined vorinostat and sorafenib treatment at two of the five tested 
drug concentrations (Figure 4.6A). This was reflected by higher IC50 values in MCF10A cells 
than MCF10A CDH1-/- cells (Table 4.4). Although slightly synthetic lethal, the vorinostat and 
sorafenib combination showed evidence for an antagonistic interaction in both isogenic cell 
lines, with the isobologram analysis producing ED50 combination indices of 2.04 and 1.56 for 
MCF10A and MCF10A     CDH1-/- cells, respectively (CI > 1.1; Figure 4.6B-C; Table 4.4). To 
summarise, combined vorinostat and sorafenib treatment produced a slight synthetic lethal 
effect in the MCF10A pair; however, an antagonistic combination index for these drugs 




Figure	   4.6	   Vorinostat	   and	   sorafenib	   treatment	   is	   modestly	   synthetic	   lethal	   but	   not	   synergistic	   in	  
MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  vorinostat	  or	  sorafenib,	  
or	  combined	  vorinostat	  and	  sorafenib	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐stained	  nuclei	  
counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  
analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  
CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	   MCF10A	   CDH1-­‐/-­‐	   cells	   showed	   modest	  
sensitivity	   to	   vorinostat	   and	   sorafenib	   treatment	   when	   compared	   to	   MCF10A	   cells,	   concordant	   with	   a	  
synthetic	   lethal	  phenotype.	  Vorinostat	  and	  sorafenib	  treatment	  was	  not	  synergistic	   in	  both	  MCF10A	  isogenic	  
cell	  lines	  (CI	  >	  0.9).	  (A)	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  



















































































Figure 4.6: Vorinostat + sorafenib treatment is modestly synthetic lethal but not synergistic in MCF10A 
CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent vorinostat or sorafenib, or 
combined vorinostat + sorafenib for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, C). 
Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed modest sensitivity to vorinostat 
+ sorafenib treatment when compared to MCF10A cells, concordant with a synthetic lethal phenotype. Vorinostat + 
sorafenib treatment was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged 
values of two biological replicates with standard error shown; a representative experiment is shown for (B) and (C). 












Table	  4.4	  Vorinostat	  and	  sorafenib	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 1.42/11.37 2.04 











4.2.1.5 HDACi and Phosphoinositide 3-kinase (PI3K) Inhibition  
To investigate potential synergy between HDACi and PI3K signalling, we first tested the PI3K 
signalling cascade as a potential vulnerability in E-cadherin-deficient cells. MCF10A and 
MCF10A CDH1-/- cells were grown for 24 hours, then incubated for an additional 48 hours with 
a titration of a PI3K inhibitor; PI-103, PIK-75, HS-173, or LY294002, with cell viability 
assessed using nuclei counting (Figure 4.7). From the viability analysis, PIK-75, HS-173 and 
LY294002 treatment each showed a dose-dependent viability reduction in both MCF10A 
isogenic cell lines without producing a significant synthetic lethal phenotype (Figure 4.7B-D). 
PI-103 treatment, however, yielded a modest synthetic lethal effect in the MCF10A CDH1-/- cell 
line, producing IC50 values of 0.71 and 0.64 μM for MCF10A and MCF10A CDH1-/- cells, 
respectively (Figure 4.7A). PI-103 was therefore selected as the lead PI3K inhibitor for 









































Figure	  4.7	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cell	  viability	  following	  PI3K	  inhibitor	  (PI3Ki)	  treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   a	   PI3Ki	   over	   a	   range	   of	  
concentrations;	   either	   (A)	   PI-­‐103,	   (B)	   PIK-­‐75,	   (C)	   HS-­‐173,	   or	   (D)	   LY294002.	   At	   48	   h	   post-­‐treatment,	   cell	  
viability	  was	  assessed	  using	  a	  Hoechst-­‐stained	  nuclei	  counting	  assay.	  A	  modest	  synthetic	  lethal	  phenotype	  was	  
seen	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  following	  (A)	  PI-­‐103	  treatment.	  No	  significant	  difference	  between	  MCF10A	  and	  
MCF10A	   CDH1-­‐/-­‐	   cell	   viability	   was	   observed	   following	   PIK-­‐75,	   HS-­‐173,	   or	   LY294002	   treatment	   (B-­‐D).	   Data	  
represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown.	  P-­‐values	  calculated	  using	  














































Figure 4.7: MCF10A and MCF10A CDH1-/- cell viability following PI3K inhibitor (PI3Ki) treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with a PI3 i over a range of 
concentrations; either (A) PI-103, (B) PIK-75, (C) HS-173, or (D) LY294002. At 48 h post-treatment, cell 
viability was assessed using a Hoechst-stained nuclei counting assay. A modest synthetic lethal phenotype was 
seen in MCF10A CDH1-/- cells following (A) PI-103 treatment. No significant difference between MCF10A 
and MCF10A CDH1-/- cell viability was observed following PIK-75, HS-173, or LY294002 treatment (B-D). 
Data repr sents averaged values of two biological replicates with standard error shown. P-values calculated 






































































Next, MCF10A and MCF10A CDH1-/- cell lines were grown for 24 hours and treated with a 
range of concentrations of entinostat, PI-103, and a combination of entinostat and PI-103, for an 
additional 48 hours. Entinostat was selected as a representative HDACi due to a lack of 
availability of vorinostat at the time of testing. Cell viability was then assessed using nuclei 
counting and potential synergistic effects evaluated using an isobologram analysis via 
CompuSyn. This analysis showed that combined entinostat and PI-103 marginally maintained 
the synthetic lethal effect of each individual drug at two of the seven tested combination 
concentrations (Figure 4.8A). A mild synthetic lethal effect was also evident in the IC50 values 
for each isogenic cell line (Table 4.5). The isobologram analysis, however, showed an 
antagonistic effect for the entinostat and PI-103 combination in both isogenic cell lines, 
producing ED50 combination indices of 1.33 and 1.35 for MCF10A and MCF10A CDH1-/- 
cells, respectively (CI > 1.1; Figure 4.8B-C; Table 4.5). In summary, combined entinostat and 
PI-103 treatment produced a mild synthetic lethal effect in MCF10A CDH1-/- cells; however, an 
antagonistic combination index for these drugs suggests the combination is no more effective 





Figure	  4.8	  Entinostat	  and	  PI-­‐103	  treatment	  is	  modestly	  synthetic	  lethal	  but	  not	  synergistic	  in	  MCF10A	  
CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  PI-­‐103	  or	  entinostat,	  or	  
combined	   PI-­‐103	   and	   entinostat	   for	   48	   h.	   Cell	   viabilities	   were	   determined	   using	   a	   Hoechst-­‐stained	   nuclei	  
counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  
analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  
CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	   MCF10A	   CDH1-­‐/-­‐	   cells	   showed	   modest	  
sensitivity	  to	  PI-­‐103	  and	  entinostat	  treatment	  when	  compared	  to	  MCF10A	  cells,	  concordant	  with	  a	  synthetic	  
lethal	  phenotype.	  PI-­‐103	  and	  entinostat	  treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  cell	  lines	  (CI	  >	  
0.9).	  (A)	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  representative	  
experiment	  is	  shown	  for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  0.05.	  
Figure 4.8: Entinostat + PI-103 treatment is modestly synthetic lethal but not synergistic in MCF10A CDH1-/- 
cells. 
CF10A and CF10A CDH1-/- cells were grown for 24 h and treated with single-agent entinostat or PI-103, or 
combined entinostat + PI-103 for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, C). 
Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed modest sensitivity to PI-103 + 
entinostat treatment when compared to MCF10A cells, concordant with a synthetic lethal phenotype. PI-103 + 
entinostat treatment was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged 
values of two biological replicates with standard error shown; a representative experiment is shown for (B) and (C). 





























































































Table	  4.5	  Entinostat	  and	  PI-­‐103	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 1.62/0.10 1.33 











4.2.2 Focal Adhesion Signalling Inhibition  
4.2.2.1 Saracatinib and PI-103 
We next tested focal adhesion signalling inhibition for synergistic synthetic lethal effects in the 
isogenic MCF10A cell lines. As SRC and PI3K are both involved in the focal adhesion 
signalling cascade (Zhao and Guan, 2011), the SRC inhibitor saracatinib and PI3K inhibitor PI-
103 were tested in combination in the MCF10A isogenic pair. Similarly to combined HDACi 
and PI3K inhibitor, MCF10A and MCF10A CDH1-/- cells were grown for 24 hours and treated 
for an additional 48 hours with either single-agent saracatinib, PI-103, or both drugs in 
combination. Cell viability and potential synergy were determined as before. This analysis 
showed that combined saracatinib and PI-103 treatment produced a marked synthetic lethal 
effect in the MCF10A pair across a range of concentrations (Figure 4.9A). This was reflected by 
higher IC50 values in MCF10A cells than MCF10A CDH1-/- cells (Table 4.6). The isobologram 
analysis, however, showed a lack of synergy for combined saracatinib and PI-103 treatment, 
producing ED50 combination indices of 0.98 and 1.12 in MCF10A and MCF10A CDH1-/- cell 
lines, respectively (CI > 0.9; Figure 4.9B-C; Table 4.6). Altogether, SRC inhibition in 
combination with PI3K inhibition failed to produce a synergistic drug response and did not 




Figure	   4.9	   Saracatinib	   and	   PI-­‐103	   treatment	   is	   synthetic	   lethal	   but	   not	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  PI-­‐103	  or	  saracatinib,	  or	  
combined	   PI-­‐103	   and	   saracatinib	   for	   48	   h.	   Cell	   viabilities	   were	   determined	   using	   a	   Hoechst-­‐stained	   nuclei	  
counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  
analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  
CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	   MCF10A	   CDH1-­‐/-­‐	   cells	   showed	   greater	  
sensitivity	   to	   PI-­‐103	   and	   saracatinib	   treatment	   than	   MCF10A	   cells,	   concordant	   with	   a	   synthetic	   lethal	  
phenotype.	  PI-­‐103	  and	  saracatinib	  treatment	  was	  not	  synergistic	  in	  both	  MCF10A	  isogenic	  cell	  lines	  (CI	  >	  0.9).	  
(A)	   represents	   averaged	   values	   of	   two	   biological	   replicates	   with	   standard	   error	   shown;	   a	   representative	  
experiment	  is	  shown	  for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  0.05;	  **	  P	  <	  0.01.	  
Figure 4.9: Saracatinib + PI-103 treatment is synthetic lethal but not synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent saracatinib or PI-103, or 
combined saracatinib + PI-103 for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting 
assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software analysis (B, C). 
Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 
indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivity to PI-103 + 
saracatinib treatment than MCF10A cells, concordant with a synthetic lethal phenotype. PI-103 + saracatinib 
treatment was not synergistic in both MCF10A isogenic cell lines (CI > 0.9). (A) represents averaged values of two 
biological replicates with standard error shown; a representative experiment is shown for (B) and (C). P-values 
































































































Table	  4.6	  Saracatinib	  and	  PI-­‐103	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 2.24/0.28 0.98 











4.2.2.2 Focal Adhesion Kinase Inhibitors (FAKi) 
The focal adhesion kinase, FAK, is central to focal adhesion signalling and considered a 
potential synthetic lethal target that may be synergistic with one or more of our other synthetic 
lethal drugs. To test this, MCF10A and MCF10A CDH1-/- cells were first grown for 24 hours 
and treated with a range of FAK inhibitors (FAKi), TAE226 or PF-573228, for an additional 48 
hours. Cell viability was then assessed using nuclei counting. From this analysis, the MCF10A 
isogenic cell lines showed a dose-dependent effect in response to FAKi treatment (Figure 4.10). 
However, neither TAE226 nor PF-573228 treatment induced synthetic lethal effects in the 
isogenic cells (Figure 4.10A-B). This was reflected by similar IC50 values seen in each 
MCF10A cell line following FAKi treatment (Table 4.7). These data therefore suggest that 
drug-based FAK inhibition is not a synthetic lethal vulnerability in E-cadherin-deficient 
MCF10A cells. For this reason, FAKi did not progress to drug combination studies in this 

















Figure	  4.10	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cell	  viability	  following	  focal	  adhesion	  kinase	  inhibitor	  (FAKi)	  
treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   a	   FAKi	   over	   a	   range	   of	  
concentrations;	  either	  (A)	  TAE226	  or	  (B)	  PF-­‐573228.	  At	  48	  h	  post-­‐treatment,	  cell	  viability	  was	  assessed	  using	  
a	  Hoechst-­‐stained	  nuclei	  counting	  assay.	  No	  marked	  synthetic	  lethal	  phenotype	  was	  seen	  in	  MCF10A	  CDH1-­‐/-­‐	  
cells	  following	  treatment	  with	  either	  FAKi.	  Data	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  











































Figure 4.10: MCF10A and MCF10A CDH1-/- cell viability following focal adhesion kinase inhibitor 
( AKi) treatment.  
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with a FAKi over a range of 
concentrations; either (A) TAE226 or (B) PF-573228. At 48 h post-treatment, cell viability was assessed 
using a Hoechst-stained nuclei counting assay. No marked ynthetic lethal phenotype wa  een in 
MCF10A CDH1-/- cells follow  tre tment with either FAKi. Data r presents veraged values of two 


































Table	  4.7	  FAKi	  (TAE226	  and	  PF-­‐573228)	  IC50	  values	  in	  MCF10A	  and	  
MCF10A	  CDH1-­‐/-­‐	  cells	  
  IC50 (μM) 
TAE226 
MCF10A 0.56 
MCF10A CDH1-/- 0.78 
PF-573228 
MCF10A 4.39 













A recent report demonstrating that E-cadherin-expressing MDA-MB-231 cells possessed 
greater resistance to statin treatment than an E-cadherin-deficient counterpart prompted 
investigation of statins as potential synthetic lethal drugs in the MCF10A isogenic pair (Warita 
et al., 2014). To test this, MCF10A and MCF10A CDH1-/- cells were grown for 24 hours, 
followed by treatment with a concentration range of atorvastatin, lovastatin, or simvastatin over 
an additional 48 hours, with cell viability assessed using nuclei counting (Figure 4.11). Each 
tested statin produced a negligible loss of viability in MCF10A cells and a mild viability loss in 
MCF10A CDH1-/- cells, approximately 20% reduced viability relative to controls.  This 
synthetic lethal effect was apparent across a wide concentration range (atorvastatin ≤ 10 μM; 
lovastatin ≤ 5 μM; simvastatin ≤ 5 μM), with both cell lines exhibiting reduced proliferation and 
a lack of synthetic lethality when concentrations exceeded this range. Following this 
observation, atorvastatin was selected as a representative statin for subsequent drug combination 










Figure	  4.11	  Statins	  induce	  a	  synthetic	  lethal	  phenotype	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   either	   (A)	   atorvastatin,	   (B)	  
lovastatin,	   or	   (C)	   simvastatin	   over	   a	   range	   of	   concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	   was	  
assessed	  using	   a	  Hoechst-­‐stained	  nuclei	   counting	   assay.	  MCF10A	  CDH1-­‐/-­‐	   cells	   showed	  greater	   sensitivity	   to	  
statin	  treatment	  than	  MCF10A	  cells,	  concordant	  with	  a	  synthetic	  lethal	  phenotype.	  Data	  represents	  averaged	  
values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown.	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  
































































Figure 4.11: Statins induce a synthetic lethal phenotype in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24  and treated with either (A) atorvastatin, (B) 
lovastatin, or (C) simvastatin over a range  concentrations. At 48 h post-treatment, c ll viability was 
assessed using a Hoechst-stained nuclei counting assay. MCF10A CDH1-/- cells showed greater 
sensitivity to statin treatment than MCF10A cells, concordant with  synthetic lethal phenotype. Dat  
represents averaged va ues of two biological r plicates with standard error shown. P-values calculated 























** ** ** ** **
** ** ** ** *
** ** ** ** **
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4.2.3.1 Atorvastatin and HDACi  
To assess atorvastatin in combination with HDACi, MCF10A and MCF10A CDH1-/- cells were 
grown for 24 hours and treated with a range of concentrations of atorvastatin, HDACi 
(entinostat and vorinostat), and a combination of atorvastatin and HDACi. Cell viability and 
potential synergistic interactions were identified as before. This analysis showed that 
atorvastatin/entinostat and atorvastatin/vorinostat produced marked synthetic lethal effects in 
MCF10A CDH1-/- cells (Figure 4.12A, 4.13A). This was supported by lower IC50 values in 
combination-treated MCF10A CDH1-/- cells than MCF10A cells (Table 4.8). The isobologram 
analysis showed evidence for a synergistic interaction for each atorvastatin and HDACi drug 
combination, with ED50 combination indices below 0.9 in each MCF10A cell line (CI < 0.9; 
Figure 4.12B-C; Table 4.8). Interestingly, the increased toxicity and synergistic effects of each 
statin and HDACi combination failed to preserve the wide synthetic lethal concentration range 
observed following statin-only treatment (Figure 4.11). In summary, combined 
atorvastatin/entinostat and atorvastatin/vorinostat treatment produced synergistic synthetic lethal 







Figure	   4.12	   Atorvastatin	   and	   entinostat	   treatment	   is	   synthetic	   lethal	   and	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   atorvastatin	   or	  
entinostat,	  or	  combined	  atorvastatin	  and	  entinostat	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐
stained	   nuclei	   counting	   assay	   (A)	   and	   used	   to	   assess	   drug	   synergy	   at	   ED50,	   ED75,	   and	   ED90	   doses	   via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	   greater	   sensitivity	   to	   atorvastatin	   and	   entinostat	   treatment	   than	  MCF10A	   cells,	   concordant	   with	   a	  
synthetic	   lethal	   phenotype.	   Atorvastatin	   and	   entinostat	   treatment	  was	   synergistic	   in	   both	  MCF10A	   isogenic	  
cell	   lines	   (CI	   <	   0.9),	   with	   a	   stronger	   synergistic	   effect	   observed	   in	   MCF10A	   CDH1-­‐/-­‐	   cells.	   (A)	   represents	  
averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  representative	  experiment	  is	  shown	  











































































Figure 4.12: Atorvastatin + entinostat treatment is synthetic lethal and synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent atorvastatin or entinostat, 
or combined atorvastatin + entinostat for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei 
counting assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software 
analysis (B, C). Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 
0.9-1.1 indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivity to 
atorvastatin + entinostat treatment than MCF10A cells, concordant with a synthetic lethal phenotype. torvastatin + 
entinostat treatment was synergistic in both MCF10A isogenic cell lines (CI < 0.9), with a stronger synergistic effect 
observed in MCF10A CDH1-/- cells. (A) represents averaged values of t o biological replicates with standard error 












Figure	   4.13	   Atorvastatin	   and	   vorinostat	   treatment	   is	   synthetic	   lethal	   and	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells 
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   atorvastatin	   or	  
vorinostat,	  or	  combined	  atorvastatin	  and	  vorinostat	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐
stained	   nuclei	   counting	   assay	   (A)	   and	   used	   to	   assess	   drug	   synergy	   at	   ED50,	   ED75,	   and	   ED90	   doses	   via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	   greater	   sensitivity	   to	   atorvastatin	   and	   vorinostat	   treatment	   than	  MCF10A	   cells,	   concordant	   with	   a	  
synthetic	   lethal	   phenotype.	  Atorvastatin	   and	   vorinostat	   treatment	  was	   synergistic	   in	   both	  MCF10A	   isogenic	  
cell	  lines	  (CI	  <	  0.9),	  with	  a	  stronger	  synergistic	  effect	  observed	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  at	  the	  ED50	  dose.	  (A)	  
represents	   averaged	   values	   of	   two	   biological	   replicates	   with	   standard	   error	   shown;	   a	   representative	  
experiment	  is	  shown	  for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  **	  P	  <	  0.01.	  
Figure 4.13: Atorvastatin + vorinostat treatment is synthetic lethal and synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent atorvastatin or vorinostat, 
or combine  atorvastatin + vorinostat for 48 h. Cell viabilities were determined using a Ho chst-stained nuclei 
cou ting assay (A) an  used to ssess drug synergy at ED50, ED75, and ED90 doses via CompuSyn software 
analysis (B, C). Drug synergy is evalu te  sing a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 
0.9-1.1 indicates additivit ; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivity to 
atorvastatin + vorinostat treatment tha  MCF10A cells, concordant w th a synthetic lethal phenotype. Atorvastatin + 
v rinostat treatment was synergis ic in both MCF10A isogenic cell lines (CI < 0.9), with a stronger synergistic effect 
observed in MCF10A CDH1-/- cells at he ED50 dose. (A) represents averaged values of tw  biological replicates 
with standard error shown; a representative experiment is show  for (B) and (C). P-values calculated using 































































































Table	  4.8	  Atorvastatin	  and	  HDACi	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells.	  




MCF10A 5.80/1.50 0.64 




MCF10A 3.09/0.77 0.67 










4.2.3.2 Atorvastatin and Saracatinib 
We next tested atorvastatin in combination with saracatinib in the MCF10A isogenic pair. 
Similarly to statin and HDACi testing, MCF10A and MCF10A CDH1-/- cells were grown for 24 
hours and treated for an additional 48 hours with a concentration range of single-agent 
atorvastatin, saracatinib, or both drugs in combination. Cell viability and potential drug synergy 
were tested as before. From the viability analysis, combined atorvastatin and saracatinib 
treatment produced a marked synthetic lethal effect in MCF10A CDH1-/- cells across a wide 
concentration range (Figure 4.14A). This was supported by lower IC50 values in MCF10A 
CDH1-/ than MCF10A following combined atorvastatin/saracatinib treatment (Table 4.9). The 
isobologram analysis showed a synergistic interaction for combined atorvastatin and saracatinib 
treatment in both MCF10A isogenic cell lines, yielding ED50 combination indices of 0.73 and 
0.47 in MCF10A and MCF10A CDH1-/- cell lines, respectively (CI < 0.9; Figure 4.14B-C; 
Table 4.9). Although synergistic, combined atorvastatin and saracatinib treatment reduced wild-
type MCF10A cell viability across the synthetic lethal concentration range, and thus failed to 
maintain the synthetic lethal effect produced by atorvastatin treatment alone (Figure 4.11). In 
summary, the combination of atorvastatin and saracatinib mirrored the effects of combined 
statin and HDACi treatment, whereby drug toxicity was enhanced in the MCF10A and 
MCF10A CDH1-/- cell lines without enhancing the synthetic lethal effects produced by single-
agent statin treatment.  
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Figure	   4.14	   Atorvastatin	   and	   saracatinib	   treatment	   is	   synthetic	   lethal	   and	   synergistic	   in	   MCF10A	  	  	  	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   atorvastatin	   or	  
saracatinib,	   or	   combined	   atorvastatin	   and	   saracatinib	   for	   48	   h.	   Cell	   viabilities	   were	   determined	   using	   a	  
Hoechst-­‐stained	  nuclei	  counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	   greater	   sensitivity	   to	   atorvastatin	   and	   saracatinib	   treatment	   than	  MCF10A	   cells,	   concordant	  with	   a	  
synthetic	   lethal	  phenotype.	  Atorvastatin	  and	  saracatinib	   treatment	  was	  synergistic	   in	  both	  MCF10A	   isogenic	  
cell	   lines	   (CI	   <	   0.9),	   with	   a	   stronger	   synergistic	   effect	   observed	   in	   MCF10A	   CDH1-­‐/-­‐	   cells.	   (A)	   represents	  
averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  representative	  experiment	  is	  shown	  
for	  (B)	  and	  (C).	  P-­‐values	  calculated	  using	  Student’s	  t-­‐test;	  *	  P	  <	  0.05;	  **	  P	  <	  0.01.	  
Figure 4.14: Atorvastatin + saracatinib treatment is synthetic lethal and synergistic in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent atorvastatin or saracatinib, 
or combined atorvastatin + saracatinib for 48 h. Cell viabilities were d termined using a Hoechst-stained nuclei 
counting assay (A) and used t  as ess drug synergy at ED50, ED75, and ED90 do es via CompuSyn software 
analysis (B, C). Drug synergy is ev luated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 
0.9-1.1 indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater sensitivit  to 
atorvastatin + saracatinib treatment than MCF10A cells, concordant with a synthetic lethal phenotype. torvastatin + 
saracatinib treatment was synergistic in both MCF10A isogenic cell lines (CI < 0.9), with a stronger synergistic 
effect observed in MCF10A CDH1-/- cells. (A) represents averaged values of two biological replicates with standard 
error shown; a representative experiment is shown for (B) and (C). P-values calculated using Student’s t-test; * P < 
































































































Table	  4.9	  Atorvastatin	  and	  saracatinib	  combination	  IC50	  values	  and	  ED50	  combination	  indices	  (CI)	  in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  




MCF10A 5.43/1.36 0.73 











4.2.3.3 Atorvastatin and Mifepristone 
In an attempt to identify other potential drugs that would be synergistic and synthetic lethal in 
MCF10A CDH1-/- cells, we searched our previously published drug screen data to find hits 
displaying a synthetic lethal effect similar to that seen with statins. Specifically, drugs that were 
synthetic lethal over a wide concentration range without reducing wild-type MCF10A viability. 
From this search, the progesterone receptor and glucocorticoid receptor antagonist mifepristone 
was identified and its synthetic lethal effect validated by A. Chen (Figure 4.15). This validation 
showed that mifepristone treatment yielded a synthetic lethal effect in the MCF10A isogenic 
pair over a wide concentration range, with both cell lines losing viability and the synthetic lethal 
























Figure	  4.15	  Mifepristone	  induces	  a	  synthetic	  lethal	  phenotype	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   mifepristone	   over	   a	   range	   of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	  was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	  
assay.	   MCF10A	   CDH1-­‐/-­‐	   cells	   showed	   greater	   sensitivity	   to	   mifepristone	   treatment	   than	   MCF10A	   cells,	  
concordant	  with	   a	   synthetic	   lethal	   phenotype.	   Data	   represents	   averaged	   values	   of	   two	   biological	   replicates	  
with	  standard	  error	  shown	  and	  is	  a	  validation	  of	  initial	  work	  by	  A.Chen.	  P-­‐values	  calculated	  using	  Student’s	  t-­‐







Figure 4.15: Mifepristone induces a synthetic lethal phenotype in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cell  wer  grown for 24 h and treated with mifepristone over a range of 
concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained nuclei counting 
assay. MCF10A CDH1-/- cells showed greater sensitivity to mifepristone treatment than MCF10A cells, 
concordant with a synthetic lethal phenotype. Data represents averaged values of two biological replicates 
with standard error shown and is a validation of initial work by A. Chen. P-values calculated using 
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To assess potential synergy between atorvastatin and mifepristone, MCF10A and MCF10A 
CDH1-/- cells were grown for 24 hours and treated with a concentration range of single-agent 
atorvastatin, mifepristone, or both drugs in combination. Following a 48 hour incubation, 
cellular viability was analysed using nuclei counting and drug synergy assessed using an 
isobologram analysis via CompuSyn. From this analysis, combined atorvastatin and 
mifepristone treatment produced a marked synthetic lethal effect in the MCF10A CDH1-/- cell 
line (Figure 4.16A). This was reflected by IC50 values for the combination, with MCF10A cells 
producing an IC50 over ten-fold higher than MCF10A CDH1-/- cells (Table 4.10). Additionally, 
combined atorvastatin/mifepristone treatment produced a synthetic lethal effect across a wide 
concentration range with minimal impact on MCF10A cell viability, akin to single-agent 
atorvastatin and mifepristone treatment. This effect was apparent up to a maximum 
concentration of 5/5 μM ([atorvastatin]/[mifepristone]). The isobologram analysis revealed a 
strong synergistic interaction for the combination in the MCF10A isogenic pair, producing 
ED50 combination indices of 0.49 and 0.08 in MCF10A and MCF10A CDH1-/- cells, 
respectively (CI < 0.9; Figure 4.16B-C; Table 4.10). Altogether, these data identified combined 
atorvastatin and mifepristone treatment as the strongest synthetic lethal and synergistic drug 





Figure	   4.16	   Atorvastatin	   and	   mifepristone	   treatment	   is	   synthetic	   lethal	   and	   synergistic	   in	   MCF10A	  	  	  	  
CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   atorvastatin	   or	  
mifepristone,	   or	   combined	   atorvastatin	   and	  mifepristone	   for	   48	   h.	   Cell	   viabilities	  were	   determined	   using	   a	  
Hoechst-­‐stained	  nuclei	  counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  doses	  via	  
CompuSyn	  software	  analysis	  (B,	  C).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  index	  (CI),	  whereby	  CI	  <	  
0.9	   indicates	   synergy;	   CI	   =	   0.9-­‐1.1	   indicates	   additivity;	   CI	   >	   1.1	   indicates	   antagonism.	  MCF10A	  CDH1-­‐/-­‐	   cells	  
showed	  greater	  sensitivity	  to	  atorvastatin	  and	  mifepristone	  treatment	  than	  MCF10A	  cells,	  concordant	  with	  a	  
synthetic	  lethal	  phenotype.	  Atorvastatin	  and	  mifepristone	  treatment	  was	  synergistic	  in	  both	  MCF10A	  isogenic	  
cell	   lines	   (CI	   <	   0.9),	  with	   a	   stronger	   synergistic	   effect	   observed	   in	  MCF10A	  CDH1-­‐/-­‐	   cells	   at	   ED50	   and	  ED75	  
doses.	  (A)	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown;	  a	  representative	  



















































































i e 4.16: Atorvastatin + mifepristone treatment is sy hetic le al and synergistic i  MCF10A CDH1-/- 
cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent atorvastatin or 
mifepristone, or combined atorvastatin + mifepristone for 48 h. Cell viabilities were determined using a Hoechst-
stained nuclei counting assay (A) and used to assess drug synergy at ED50, ED75, and ED90 doses via CompuSyn 
software analysis (B, C). Drug synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates 
synergy; CI = 0.9-1.1 indicates additivity; CI > 1.1 indicates antagonism. MCF10A CDH1-/- cells showed greater 
sensitivity to atorvastatin + mifepristone treatment than MCF10A cells, concordant with a synthetic lethal 
phenotype. Atorvastatin + mifepristone treatment was synergistic in both MCF10A isogenic cell lines (CI < 0.9), 
with a stronger synergistic effect observed in MCF10A CDH1-/- cells at ED50 and ED75 doses. (A) represents 
averaged values of two biological replicates with standard error shown; a representative experiment is shown for (B) 













Table	   4.10	   Atorvastatin	   and	   mifepristone	   combination	   IC50	   values	   and	   ED50	   combination	   indices	   (CI)	   in	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  




MCF10A 6.06/6.06 0.49 










In this chapter, a range of synthetic lethal drug leads and potentially synergistic combinations 
were applied to MCF10A and MCF10A CDH1-/- cell lines. Interestingly, combinations 
involving our previously identified synthetic lethal drugs, HDACi and saracatinib, did not 
feature as the strongest synthetic lethal synergistic hits in this study. In addition, drug classes 
including FAKi and PI3K inhibitors also failed to produce marked antiproliferative effects 
exclusively in the E-cadherin-deficient cell line. Instead, it was found that statins, alone and in 
combination, were highly synthetic lethal and synergistic in this pair of isogenic MCF10A cell 
lines.  
 
We hypothesise that vorinostat, a pan-HDACi, may be exerting its synthetic lethal effect 
through HDAC6 inhibition and subsequent microtubule stabilisation (Glozak et al., 2005; 
Zhang et al., 2003). Combined treatment with taxol would therefore be predicted to exacerbate 
this effect and enhance the synthetic lethality of vorinostat alone. Interestingly, co-treatment of 
vorinostat and taxol caused the reverse effect, nullifying the synthetic lethal differential 
provided by the HDACi (Figure 4.4).  
 
The targeting of DNA repair mechanisms using co-treatment of vorinostat and olaparib  
(HDACi and PARPi) also failed to induce a synthetic lethal synergistic response in MCF10A 
CDH1-/- cells (Figure 4.5). The apparent lack of synergy between these inhibitors is in contrast 
to previously published data, although these studies were not performed using the MCF10A line 
(Chao and Goodman, 2014; Hegde et al., 2016; Konstantinopoulos et al., 2014; Rasmussen et 
al., 2016; Zhang et al., 2012). It seemed unlikely that E-cadherin loss would play a significant 
role in homologous DNA repair. Therefore, the observed lack of synthetic lethality is perhaps 
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not surprising, as functional DSB machinery would also be required for maintaining the genetic 
integrity of wild-type MCF10A cells. 
 
Sorafenib treatment showed that multikinase inhibition is not an exploitable synthetic lethal 
approach in this study (Appendix D.3). Additionally, a synergistic response was not seen 
following combined sorafenib and vorinostat treatment in either MCF10A or MCF10A CDH1-/- 
cells (Figure 4.6). It is probable that multiple cell survival pathways are inhibited by sorafenib 
treatment, blunting any differential dependent on E-cadherin loss. Notably, inhibition of the 
MEK/ERK signalling cascade was shown to exert a growth advantage to MCF10A CDH1-/- 
cells over MCF10A cells (Appendix D.4), an effect we have termed ‘reverse-synthetic 
lethality’. As the ERK pathway is a known target of sorafenib (Chen et al., 2014b), this may 
explain a lack of synthetic lethality for this combination in the MCF10A isogenic pair.  
 
The majority of the PI3K inhibitors we tested were unsuccessful in exclusively reducing 
MCF10A CDH1-/- cell proliferation (Figure 4.7). Furthermore, combined PI3K inhibitor 
treatment with our lead synthetic lethal drugs, HDACi and saracatinib, failed to produce a 
synergistic response and increase the synthetic lethal viability differential provided by single-
agent treatment in the MCF10A isogenic pair (Figure 4.8-9). Activating PIK3CA mutations are 
known to drive metastasis in ILBC (Christgen and Derksen, 2015; Christgen et al., 2013; 
Christgen et al., 2016). The MCF10A CDH1-/- cell line may thus share closer resemblance to 
very early stage carcinoma, prior to additional mutation events.  PI3K inhibitors may therefore 
hold greater promise in cell lines derived from later stage carcinoma, such as the E-cadherin-
deficient, ILBC-derived IPH-926 (Christgen et al., 2009; Christgen and Derksen, 2015). 
 
Statin inhibition of HMGCR, the rate-limiting step of the mevalonate pathway, was synthetic 
lethal in the MCF10A CDH1-/- cell line (Figure 4.11) – an effect that was synergistically 
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enhanced following co-treatment with HDACi, saracatinib, and mifepristone (Figure 4.12-14, 
4.16). The exact mechanism underpinning this synthetic lethal effect will provide strong leads 
in our efforts to develop more powerful synthetic lethal combinations. 
 
E-cadherin is known to modulate lipid-associated signalling molecules such as small GTPases 
(Rho and Rac) and PI3K (Kovacs et al., 2002; Nakagawa et al., 2001; Pece and Gutkind, 2000; 
Ratheesh et al., 2012). Subsequently, current literature has hypothesised that alterations to the 
E-cadherin-localised lipid environment are likely to influence signalling of these pathways (Yap 
et al., 2015). It is therefore possible that cholesterol depletion following statin treatment may 
underpin the synthetic lethal phenotype in MCF10A CDH1-/- cells. Coincidentally, the statins 
investigated in this study (atorvastatin, simvastatin, and lovastatin) comprise three of the most 
lipophilic statin variants. As levels of free cholesterol have been shown to differ between 
lipophilic and hydrophilic statin treatment in vivo (Kirsch et al., 2003), it would be interesting to 
test if MCF10A CDH1-/- synthetic lethality is preserved following hydrophilic statin treatment. 
 
Recent literature has also identified inhibition of HDACs by statins (Lin et al., 2008). As both 
class-I specific (entinostat) and pan-HDACi (vorinostat) produce a synthetic lethal effect in 
MCF10A CDH1-/- cells, it therefore remains possible that HDAC inhibition may account for the 
observed statin-mediated synthetic lethality. 
 
Mevalonate pathway-mediated prenylation may also play a role in the observed synthetic 
lethality. Prenylation, both farnesylation and geranylgeranylation, are known to activate small 
GTPase proteins, such as Rac and Rho (Etienne-Manneville and Hall, 2002). Rac and Rho are 
involved in G-protein coupled receptor (GPCR) signal transduction. We have previously noted 
GPCR signalling as being a synthetic lethal vulnerability in MCF10A CDH1-/- cells (Telford et 
al., 2015), suggesting statin-mediated inactivation of GTPases may be active in this pathway.  
 103 
Mifepristone is a known progesterone receptor (PR) and glucocorticoid receptor (GR) 
antagonist currently used clinically as an abortifacient agent. It is noteworthy that the MCF10A 
cell line is devoid of PR expression (Coppock et al., 2007; Moran et al., 2000), meaning the 
observed mifepristone-induced synthetic lethal effects in MCF10A CDH1-/- cells are a likely 
result of GR inhibition. As future work, it would be worthwhile investigating the status of PR 
and GR expression in the isogenic cell lines pre and post mifepristone treatment. Nuclear 
shuttling of the GR via a chaperone-based interaction with cytoplasmic HDACs suggests 
another explanation for the observed synthetic lethality in MCF10A CDH1-/- cells following 
both mifepristone and HDACi treatment (Kovacs et al., 2005). 
 
Current literature has highlighted mifepristone’s ability to inhibit the focal adhesion signalling 
pathway (Yu et al., 2015). The focal adhesion pathway defines one mechanism by which cells 
interact with their external environment (Miranti and Brugge, 2002). Central to this process are 
integrins, transmembrane cell surface receptors that bridge the external and internal cellular 
environments via extracellular matrix (ECM) and cytoskeleton binding, respectively (Hynes, 
2002). The nodes where integrins adhere to the ECM are termed focal adhesions. Downstream 
of integrin receptors are tyrosine protein kinases that play a key role in conveying signals from 
external stimuli, with an important regulator of this process being the focal adhesion kinase, 
FAK (Parsons et al., 2008). We have previously identified compromised cell adhesion 
dynamics and abnormal cytoskeletal organisation following E-cadherin loss in MCF10A cells 
(Chen et al., 2014a; Telford et al., 2015). Additionally, a recent KEGG pathway analysis using 
our previously published siRNA screen data in the MCF10A isogenic pair identified focal 
adhesion signalling genes as highly significant synthetic lethal partners with E-cadherin (P. 
Guilford, unpublished data). In the current study, we have demonstrated that direct inhibition of 
FAK, using TAE-226 and PF-573228, failed to induce a synthetic lethal phenotype in the 
MCF10A CDH1-/- cell line (Figure 4.10). We therefore hypothesise that, in addition to GR 
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antagonism, mifepristone-mediated inhibition of the focal adhesion pathway may be occurring 
downstream of FAK, targeting a protein less crucial for wild-type MCF10A viability.  
 
To the best of our knowledge, the effects of combined statin and mifepristone treatment has not 
been reported in the current literature. The exact mechanism explaining the observed synergy 
between these two drugs is therefore undefined. Studies investigating metabolites of the 
mevalonate pathway have identified farnesyl pyrophosphate (FPP), produced downstream of 
HMGCR, serves as a natural ligand for the GR capable of invoking its translocation to the 
nucleus (Vukelic et al., 2010). More recently, the FPP-GR complex has been shown to mimic 
the effects of GR stimulation via glucocorticoids, meaning mevalonate pathway metabolites can 
alter the transcriptional regulation of pathways such as interferon, insulin growth factor, and 
epithelial adherens junction signalling (Pastar et al., 2016; Stojadinovic et al., 2007). This 
interplay between the mevalonate pathway, GR, and adherens junction signalling may explain 
our observed synergistic effect between atorvastatin and mifepristone as well as the synthetic 
lethal phenotype produced by these drugs in the E-cadherin-deficient MCF10A cell line. 
 
External to the mevalonate pathway, statin and mifepristone treatment have each been shown to 
alter activity of the Hippo pathway regulator Yes-associated protein, YAP (Sorrentino et al., 
2014; Sorrentino et al., 2017). A screen of 640 FDA-approved drugs in a triple negative breast 
cancer cell line (MDA-MB-231 cells) identified statins as the lead drug class capable of 
preventing YAP nuclear translocation, thus activating the Hippo pathway (Sorrentino et al., 
2014). A follow-up analysis found GR agonists such as dexamethasone and hydrocortisone 
were the top drug class inducing the reverse effect, deactivating the Hippo pathway by 
promoting YAP nuclear entry (Sorrentino et al., 2017). Treatment with the GR antagonist 
mifepristone prevented this effect (Sorrentino et al., 2017). As nuclear YAP is a hallmark of E-
cadherin deficiency in ILBC (Vlug et al., 2013), we hypothesise that statin and mifepristone 
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induced Hippo pathway activation may also explain both the synergistic and synthetic lethal 
effects of these drugs in the MCF10A isogenic pair.  
 
Regardless of the mechanism at play, we have identified a strongly synergistic and potent drug 
combination that may hold therapeutic utility in treating E-cadherin-deficient cancers, such as 
HDGC and ILBC.  It would therefore be of interest to investigate if the synergistic and synthetic 
lethal effects of atorvastatin and mifepristone are also observed in other cell lines devoid of E-
cadherin expression. If so, there is the clear opportunity to repurpose these drugs for the 











































In the previous chapter, we discovered a novel synergistic drug combination, comprising 
atorvastatin and mifepristone, which exclusively reduced the viability of E-cadherin-deficient 
MCF10A cells (MCF10A CDH1-/-) at concentrations up to 5/5 μM 
([atorvastatin]/[mifepristone]). The exact mechanisms underpinning both the synergistic 
relationship and synthetic lethal phenotype are currently unknown. Here, we have explored the 
effects of combined atorvastatin and mifepristone treatment in more detail by investigating the 
role of key cell signalling pathways, cell cycle arrest, co-treatment with taxol, and employing 
additional E-cadherin-deficient cell lines. 
 
Atorvastatin is an inhibitor of the rate-limiting enzyme of the mevalonate pathway, HMGCR. 
The mevalonate pathway is involved in a range of cell signalling pathways, including 
prenylation events, dolichol synthesis, and cholesterol production. Understanding the potential 
role of these pathways in our E-cadherin-negative and E-cadherin-expressing cell lines is 
necessary in order to define the mechanisms of synthetic lethality and synergy with 
mifepristone. 
 
Downstream of HMGCR in the mevalonate signalling cascade is farnesyl diphosphate synthase 
(FDPS; Figure 5.1). FDPS is crucial for the conversion of isopentenyl-5-pyrophosphate (IPP) to 
farnesyl pyrophosphate (FPP). FPP is a metabolite central to downstream functioning of the 
mevalonate pathway, used to initiate each of the prenylation, dolichol, and cholesterol 
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production events. In addition to the mevalonate pathway, FPP has been shown to directly 
stimulate the glucocorticoid receptor (Das et al., 2007; Pastar et al., 2016; Vukelic et al., 2010), 
a known target inhibited by mifepristone. FDPS is inhibited by bisphosphonates, a drug class 
predominately used for the treatment of osteoporosis due to their ability to prevent bone mineral 
density loss. Bisphosphonate treatment in the MCF10A isogenic pair will show potential 




























Figure	  5.1	  The	  mevalonate	  pathway	  	  
The	   mevalonate	   pathway	   showing	   key	   enzymes	   (blue)	   and	   inhibitors	   (orange).	   Downstream	   of	   HMG-­‐CoA	  
reductase	  (HMGCR),	  isopentenyl-­‐5-­‐pyrophosphate	  (IPP)	  is	  converted	  to	  farnesyl	  pyrophosphate	  (FPP)	  via	  the	  
enzyme	   farnesyl	   diphosphate	   synthase	   (FDPS).	   FPP	   is	   an	   isoprenoid	   metabolite	   central	   to	   farnesylation,	  

























FPP is a key metabolite used for the addition of prenylation post-translational modifications, 
farnesylation and geranylgeranylation (Wang and Casey, 2016). Functionally, prenylation 
provides membrane-based anchoring for small GTPase proteins. Farnesylation is performed by 
farnesyltransferase (FTase), which catalyses the transfer of a 15-carbon farnesyl group from 
FPP to Ras GTPases (Wang and Casey, 2016). Geranylgeranylation first requires conversion of 
FPP to geranylgeranyl diphosphate (GGDP) via geranylgeranyl diphosphate synthase (GGDPS). 
GGDPS is an intermediary isoprenoid used by geranylgeranyltransferase type 1 (GGTase-I) to 
transfer a 20-carbon geranylgeranyl group to Rac and Rho GTPases (Etienne-Manneville and 
Hall, 2002; Wang and Casey, 2016). Currently, no prenylation inhibitors have successfully 
attained FDA-approval status, however, the FTase inhibitors lonafarnib and tipifarnib are 
undergoing clinical trials for treating progeria and a range of cancer subtypes, including acute 
myeloid leukaemia, breast cancer, chronic myelogenous leukaemia, glioblastoma, non-small 
cell lung cancer, and advanced metastatic urothelial carcinoma (Head and Johnston, 2004; 
Wang et al., 2017). Inhibitors specific to FTase and GGTase-I will be used to test prenylation 
pathway function in our MCF10A isogenic cell lines. 
 
FPP is also implicated in the production of the polyprenol dolichol. Interestingly, 
dexamethasone-induced glucocorticoid receptor stimulation has been shown to increase 
dolichol levels in vitro (Dutta et al., 1989). Dolichol is a non-steroid isoprenoid used to form the 
activated monosaccharides Dol-P-Man and Dol-P-Glc, which are in turn used as substrates for 
glycosyltransferases. Glycosyltransferases catalyse N-glycosylation, O-mannosylation, C-
mannosylation, and glycosylphosphatidylinositol posttranslational modifications (Welti, 2013). 
E-cadherin is a known target of N-glycosylation, a process shown to alter its adhesive 
capabilities at the adherens junction (Liwosz et al., 2006; Zhao et al., 2008). The biological 
interplay of mevalonate pathway-mediated dolichol production, E-cadherin N-glycosylation, 
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and glucocorticoid receptor activation highlights this branch of the mevalonate pathway as a 
potential vulnerability in our E-cadherin-deficient cell model.   
 
FPP is also utilised in the production of cellular cholesterol. This process involves the NADPH-
dependent condensation of two FPP molecules to form squalene, a reaction catalysed by 
squalene synthase (SQS), an enzyme that performs the first committed step of cholesterol 
synthesis (Charlton-Menys and Durrington, 2007; Do et al., 2009; Tansey and Shechter, 2000). 
Drug-based inhibition of SQS can be achieved using zaragozic acids (Bergstrom et al., 1993), 
however, these compounds are not approved for clinical use.  
 
In addition to the mevalonate pathway, statin and mifepristone treatment have each been shown 
to induce Hippo pathway activation (Sorrentino et al., 2014; Sorrentino et al., 2017). When 
activated, the Hippo pathway effector Yes-associated protein (YAP) is phosphorylated at serine 
residue 127 by LATS kinases, a process that prevents YAP’s nuclear entry and subsequent 
association with growth-promoting TEAD transcription factors (Johnson and Halder, 2014). 
The YAP-TEAD nuclear interaction can be inhibited with verteporfin, the only FDA-approved 
YAP inhibitor, currently used in photodynamic therapy for treating age-related macular 
degeneration (Henney, 2000; Liu-Chittenden et al., 2012). Verteporfin has recently shown 
promise as a chemotherapeutic agent, however, its use in an E-cadherin-deficient isogenic cell 
line system is currently unknown.  
 
The E-cadherin-deficient triple-negative breast cancer (TNBC) cell line MDA-MB-231 has 
been shown to exhibit reduced viability following single-agent statin and mifepristone treatment 
(Brandhagen et al., 2013; Campbell et al., 2006; Shen et al., 2015; Warita et al., 2014). This 
effect involves both apoptotic and cell cycle arrest mechanisms, the latter occurring in response 
to low dose treatment (Brandhagen et al., 2013; Shen et al., 2015).  To the best of our 
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knowledge, combined statin and mifepristone treatment has not yet been described in the 
literature. Similarly, the use of statins and mifepristone in ILBC cell lines has not been reported, 
either individually or in combination. Accordingly, in this chapter we have also determined the 





5.2.1 Real-Time Proliferation Analysis 
Single-agent and combined atorvastatin and mifepristone treatment showed marked synthetic 
lethality in MCF10A CDH1-/- cells using nuclei counting endpoint assays (Figure 4.11A, 4.15, 
4.16A). We next wanted to assess each drug’s performance using a real-time assay platform. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 hours and treated with a range of 
single-agent atorvastatin and mifepristone concentrations, both alone and in combination. Cells 
were then incubated for an additional 48 hours, with cellular confluence tracked in real-time 
using an IncuCyte FLR. Firstly, atorvastatin-only treatment showed a modest effect on 
MCF10A cell proliferation, with drug- and control-treated cells attaining similar confluence 
readings at 48 hours (Figure 5.2A). Atorvastatin treated MCF10A CDH1-/- cells exhibited 
reduced proliferation over the time course of the assay and failed to achieve comparable 
confluence to control-treated cells (Figure 5.2B). At 48 hours, atorvastatin-treated MCF10A 
CDH1-/- cellular confluence was at least 18% lower than control-treated cells, consistent with 
previous endpoint assay testing (Figure 4.11A).  
 
Single-agent mifepristone treatment showed a minor inhibitory effect on MCF10A cell 
proliferation, however, cellular confluence measurements were comparable between drug-
treated and control-treated cells at the conclusion of the assay (Figure 5.2C). Mifepristone-
treated MCF10A CDH1-/- cells exhibited a marked reduction in cell proliferation over the time-
course of the assay, with drug-treated cells yielding confluence measurements at least 25% 
lower than control treatment at 48 hours (Figure 5.2D). This differential was similar to previous 
endpoint testing (Figure 4.15). 
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Similarly to single-agent treatment, combined atorvastatin and mifepristone induced minor 
growth inhibition in MCF10A cells (Figure 5.2E). At 48 hours, MCF10A cells treated with the 
highest tested drug concentration (10/10 μM) showed a 4% confluence reduction relative to 
control treatment. Combined atorvastatin and mifepristone treated MCF10A CDH1-/- cells 
showed a marked proliferation reduction over the assay time course (Figure 5.2F). A confluence 
differential of at least 31% was evident in drug treated MCF10A CDH1-/- cells relative to 
control treatment at 48 hours. Combined treatment at 10/10 μM induced a 44% confluence 
reduction in MCF10A CDH1-/- cells relative to control treatment at 48 hours, an inhibitory 
effect 11-fold higher than that seen in MCF10A cells. Overall, the real-time confluence analysis 
supported the synthetic lethal and synergistic phenotype seen in endpoint assays following 









Figure	   5.2	   Real-­‐time	   confluence	   assays	   show	   atorvastatin	   and	   mifepristone	   synthetic	   lethality	   and	  
synergy	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  single-­‐agent	  atorvastatin	  (A-­‐B)	  or	  
mifepristone	   (C-­‐D),	   or	   combined	   atorvastatin	   and	   mifepristone	   (Atorv+Mif;	   E-­‐F),	   with	   cellular	   confluence	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Figure 5.2: Real-time confluence assays show atorvastatin + mifepristone synthetic lethality and 
synergy in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent atorvastatin 
(A-B) or mifepristone (C-D), or combined atorvastatin + mif pristone (Atorv+Mif; E-F), with cellular 
confluence measured over 48 h post-treatment.  A representative experiment of each real-time assay is 
shown.    
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5.2.2 Cell Cycle Analysis 
Statins and mifepristone have been shown to prevent cell proliferation via cytostatic 
mechanisms, specifically via growth arrest in the G1 phase of the cell cycle (Brandhagen et al., 
2013; Shen et al., 2015). A lack of cytotoxicity was evident following single-agent and 
combined statin and mifepristone treatment in both endpoint and real-time viability assays, 
where MCF10A CDH1-/- cells exhibited reduced proliferation without a complete loss of 
viability (Figure 4.11A, 4.15, 4.16A, 5.2). Cell cycle analysis was therefore undertaken to 
characterise cytostatic effects in the drug-treated MCF10A isogenic cell lines. 
 
MCF10A and MCF10A CDH1-/- cells were grown for 24 hours and treated with either single-
agent atorvastatin and mifepristone, or both drugs in combination. Complete growth medium- 
and DMSO-treated cells were used as untreated and vehicle-treated controls, respectively. At 24 
hours post-treatment, cells were harvested and assessed for cell cycle staging via propidium 
iodide nuclear staining and flow cytometry. From this analysis, MCF10A cells showed a lack of 
cell cycle arrest in response to atorvastatin and mifepristone treatment, either as single-agents or 
in combination (Figure 5.3A). This was concordant with previous endpoint and real-time assay 
testing. MCF10A CDH1-/- cells showed a significant G1 arrest phenotype in response to single-
agent atorvastatin and mifepristone treatment across each tested concentration (2.5 and 5 μM), 
with 40-45% of drug treated cells in G1 compared to 33% following vehicle treatment (P < 
0.01; Figure 5.3B). Combined atorvastatin and mifepristone treatment induced a marked G1 
arrest phenotype in the MCF10A CDH1-/- cell line, with G1 arrested cells present at 54, 59, and 
60% in order of increasing drug dose (0.63/0.63, 1.25/1.25, 2.5/2.5 μM; P < 0.01). G1 arrested 
MCF10A CDH1-/- cells were therefore 29% more prominent following 0.63/0.63 μM combined 
atorvastatin and mifepristone treatment relative to 2.5 μM single-agent treatment, supporting 
previous findings of a strong synergistic interaction between these two drugs. Together, these 
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results demonstrated that atorvastatin and mifepristone both exert a synthetic lethal phenotype 
in E-cadherin-deficient MCF10A (MCF10A CDH1-/-) cells via a G1 arrest mechanism and that 
















Figure	   5.3	   Combined	   atorvastatin	   and	  mifepristone	   treatment	   induces	  marked	  G1	   arrest	   phenotype	  
exclusively	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	  (A)	  and	  MCF10A	  CDH1-­‐/-­‐	  (B)	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  complete	  growth	  medium	  
(Cell	  Only),	   vehicle	   (DMSO),	  2.5	   and	  5	  μM	  single-­‐agent	   atorvastatin	   (At)	  or	  mifepristone	   (Mif),	   or	   combined	  
atorvastatin	   and	  mifepristone	   (At+Mif;	   0.63/0.63,	   1.25/1.25,	   2.5/2.5	   μM)	   for	   an	   additional	   24	   h.	   Cells	  were	  
then	  harvested	  and	  assessed	  for	  cell	  cycle	  staging	  via	  propidium	  iodide	  nuclear	  staining	  and	  flow	  cytometry	  
analysis.	  Data	  represents	  averaged	  values	  of	   three	  biological	   replicates	  with	  standard	  error	  shown.	  P-­‐values	  












































































Figure 5.3: Combined atorvastatin and mifepristone treatment induces marked G1 arrest phenotype 
exclusively in MCF10A CDH1-/- cells. 
MCF10A ( ) and MCF10A CD 1-/- (B) cells ere gro n for 24 h and treated ith co plete gro th edium 
(Cell Only), vehicle (DMSO), 2.5 and 5 µM single-agent atorvastatin (At) or mifepristone (Mif), or combined 
atorvastatin + mifepristone (At+Mif; 0.63/0.63, 1.25/1.25, 2.5/2.5 µM) for an additional 24 h. Cells were then 
harvested and assessed for cell cycle staging via propidium iodide nuclear staining and flow cytometry 
analysis. Data represents averaged values of three biological replicates with standard error shown. P-values 
calculated using Student’s t-test compared with vehicle treatment; ns = not significant (P > 0.05); ** P < 0.01.  
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5.2.3 Cell Cycle Inhibitor Treatment 
Following the observation that MCF10A CDH1-/- cells undergo G1 arrest in response to 
atorvastatin and mifepristone treatment, we hypothesised that inhibition of G1-specific cell 
cycle regulation might produce a synthetic lethal response in the MCF10A isogenic pair. To test 
this hypothesis, MCF10A and MCF10A CDH1-/- cells were grown for 24 hours and treated with 
a concentration range of G1-specific cyclin-dependent kinase (CDK) inhibitors; K03861, PHA-
793887, and flavopiridol. Cell viability was then assessed at 48 hours post-treatment using a 
nuclei counting assay. Each tested CDK inhibitor failed to induce a marked synthetic lethal 
phenotype in the MCF10A CDH1-/- cell line, reducing the viability of both MCF10A isogenic 
cell lines relatively equally (Figure 5.4A-C). A statistically significant viability difference was 
seen for 160 nM PHA-793887 treatment (P < 0.01), however, wild-type MCF10A cells 
presented with 47% viability and were thus heavily compromised (Figure 5.4B). Overall, these 











Figure	   5.4	   MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cell	   viability	   following	   cyclin-­‐dependent	   kinase	   (CDK)	  
inhibitor	  treatment	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  either	  K03861	  (A),	  PHA-­‐793887	  (B),	  
or	  flavopiridol	  (C)	  over	  a	  range	  of	  concentrations.	  At	  48	  h	  post-­‐treatment,	  cell	  viability	  was	  assessed	  using	  a	  
Hoechst-­‐stained	   nuclei	   counting	   assay.	   Data	   represents	   averaged	   values	   of	   two	   biological	   replicates	   with	  























































































Figure 5.4: MCF10A and MCF10A CDH1-/- cell viability following cyclin-dependent kinase 
(CDK) inhibitor treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with either K03861 (A), 
PHA-793887 (B), or flavopiridol (C) over a range of concentrations. At 48 h post-treatment, cell 
viability was assessed using a Hoechst-stained nuclei counting assay. Data represents averaged 
values of two biological replicates with standard error shown. P-values calculated using Student’s 
t-test; ** P < 0.01. 
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5.2.4 Combining Lead Combination with Cytotoxic Agent 
As atorvastatin and mifepristone treatment enhanced G1 arrest when co-treated in MCF10A 
CDH1-/- cells, we next hypothesised that the increased proportion of growth-arrested cells may 
be primed for apoptosis and that use of a cytotoxic agent could push these cells to death. Taxol 
was selected as the cytotoxic agent as previous testing had shown its ability to induce cell death 
in the MCF10A isogenic pair (Appendix D.1). The MCF10A isogenic cell lines were grown for 
24 hours and incubated for an additional 48 hours with either taxol, combined atorvastatin and 
mifepristone, or all three drugs (taxol, atorvastatin, and mifepristone) in combination, with cell 
viability assessed using nuclei counting. An isobologram analysis was then performed using 
CompuSyn to assess the impact of taxol in the three-part combination. The endpoint viability 
assay showed that the addition of taxol did not amplify the synthetic lethal differential of 
combined atorvastatin and mifepristone treatment (Figure 5.5A). This was supported by the 
isobologram analysis, which showed a lack of synergy for the three-part combination in both 
MCF10A and MCF10A CDH1-/- cell lines (CI > 0.9; Figure 5.5B-C). Interestingly, a strong 
antagonistic effect was observed for the three-part combination at the calculated ED75 and 
ED90 doses in MCF10A CDH1-/- cells (CI = 2.98 and 4.99, respectively), indicating taxol 
inclusion impeded the performance of combined atorvastatin and mifepristone treatment (Figure 
5.5C). To summarise, atorvastatin and mifepristone treated MCF10A CDH1-/- cells did not 







Figure	   5.5	   Taxol	   co-­‐treatment	   does	   not	   enhance	   atorvastatin	   and	   mifepristone	   induced	   synthetic	  
lethality	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   taxol,	   combined	  
atorvastatin	   and	  mifepristone,	   or	   all	   three	   drugs	   in	   combination	   for	   48	   h.	   Cell	   viabilities	   were	   determined	  
using	  a	  Hoechst-­‐stained	  nuclei	  counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  ED50,	  ED75,	  and	  ED90	  
doses	   via	   CompuSyn	   software	   analysis	   (B,	   C).	   Drug	   synergy	   is	   evaluated	   using	   a	   combination	   index	   (CI),	  
whereby	  CI	  <	  0.9	  indicates	  synergy;	  CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  antagonism.	  Combined	  
atorvastatin	  and	  mifepristone	  and	  taxol	  treatment	  was	  not	  synergistic	  in	  either	  MCF10A	  cell	  line	  (CI	  <	  0.9).	  (A)	  
represents	   averaged	   values	   of	   two	   biological	   replicates	   with	   standard	   error	   shown;	   a	   representative	  



















































































Figure 5.5: Taxol co-treatment does not enhance atorvastatin + mifepristone induced synthetic lethality in 
MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with single-agent taxol, combined 
atorvastatin and mifepristone, or all three drugs in combination for 48 h. Cell viabilities were determined using a 
Hoechst-stained nuclei counting assay (A) and used to assess drug synergy at ED50, ED7 , and ED90 doses via 
CompuSyn software a alysis (B, C). Drug synergy is evaluated using  combinat on index (CI), whereby CI < 0.9 
indicates synergy; CI = 0.9-1.1 indicates additiv ty; CI > 1.1 indicates antagonism. Combi ed atorvastatin + 
mifepristone + taxol treatment was not synergistic in either MCF10A ell line (CI < 0.9). (A) represents averaged 
values of two biological replicates with standard error shown; a representative experiment is shown for (B) and (C). 






5.2.5 Validation in E-cadherin-Deficient Malignant Cell Lines 
As the MCF10A and MCF10A CDH1-/- cell lines are non-malignant, we wished to determine 
whether the synergistic effects of atorvastatin and mifepristone would remain in E-cadherin-
negative malignant cell lines. The ILBC-derived IPH-926 cell line was kindly provided by 
Matthias Christgen (Hannover, Germany). IPH-926 cells were derived from a patient with 
metastatic ILBC and are characteristically similar to the disease (Christgen et al., 2009). These 
features include E-cadherin loss (due to a homozygous CDH1 frameshift mutation), anti-cancer 
drug resistance, and a markedly slow proliferation rate in vitro and in vivo (Christgen et al., 
2009; Mathieu et al., 2004). IPH-926 cells were grown for 24 hours and treated with a range of 
single-agent atorvastatin and mifepristone concentrations and both drugs in combination. Cell 
viability was determined at 96 hours post-treatment using a nuclei counting assay. IPH-926 cell 
viability was analysed over 96 hours post-treatment as drug-induced cytostatic effects were less 
evident in the slow-growing cell line over 48 hours (Appendix D.5). An isobologram analysis 
was then performed using CompuSyn to test for potential synergy between atorvastatin and 
mifepristone in this cell line. Additionally, combined atorvastatin and mifepristone-treated IPH-
926 cells were tracked in the IncuCyte to determine if the combination was capable of reducing 
cell confluence over time. The endpoint assay showed a dose-dependent cell viability reduction 
in IPH-926 cells following atorvastatin and mifepristone treatment, whether given alone or in 
combination (Figure 5.6A-C). The highest tested combination concentration, 40/40 μM, induced 
a 40% viability loss relative to control treatment (Figure 5.6C), whilst 40 μM single-agent 
atorvastatin and mifepristone treatment provided a 26 and 37% viability reduction, respectively 
(Figure 5.6A-B). Furthermore, a dose-dependent inhibitory effect for combined atorvastatin and 
mifepristone treatment was seen in IPH-926 cells in the real-time assay (Figure 5.6D). At 96 
hours post-treatment, the real-time assay showed 2.5/2.5, 10/10, and 40/40 μM combined 
atorvastatin and mifepristone treatment exerted 3, 28, and 45% lower confluence values than 
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vehicle treatment, respectively (Figure 5.6D). The isobologram analysis provided an ED50 
combination index of 0.69, indicating a synergistic interaction for combined atorvastatin and 
mifepristone treatment in IPH-926 cells (CI < 0.9; Figure 5.6E-F). Together, these results show 
that atorvastatin and mifepristone treatment induced a dose-dependent viability loss in the E-
cadherin-negative IPH-926 ILBC-derived cell line. The effect of the two drugs was synergistic, 










Figure	  5.6	  IPH-­‐926	  cell	  viability	  following	  atorvastatin	  and	  mifepristone	  treatment	  
IPH-­‐926	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  with	  single-­‐agent	  atorvastatin	  (A)	  or	  mifepristone	  (B),	  or	  
combined	   atorvastatin	   and	   mifepristone	   (C-­‐D)	   for	   96	   h.	   Cell	   viabilities	   were	   determined	   using	   a	   Hoechst-­‐
stained	  nuclei	  counting	  assay	  (A-­‐C)	  and	  real-­‐time	  confluence	  assay	  (D).	  Drug	  synergy	  was	  assessed	  at	  ED50,	  
ED75,	  and	  ED90	  doses	  via	  CompuSyn	  software	  analysis	  (E-­‐F).	  Drug	  synergy	  is	  evaluated	  using	  a	  combination	  
index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  antagonism.	  
Atorvastatin	  and	  mifepristone	  treatment	  showed	  a	  synergistic	  interaction	  in	  IPH-­‐926	  cells	  at	  ED50	  and	  ED75	  
doses	   (CI	  <	  0.9).	  A	  representative	  experiment	  of	  each	  endpoint	  and	  real-­‐time	  assay	   is	  shown,	  with	  standard	  

































































































Figure 5.6: IPH-926 cell viability following atorvastatin and mifepristone treatment. 
IPH-926 cells were grown for 24 h  tr t  with with single-agent atorv statin (A) or mifepristone (B), or 
combined atorvastatin + mifepristone (C-D) for 96 h. Cell viab lities were determined using a Hoechst-stained 
nuclei counting assay (A-C) and real-time confluence assay (D). Drug synergy was assessed at ED50, D75, and 
ED90 doses via CompuSyn software analysis (E-F). Drug synergy is evaluated using a combination index (CI), 
whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 indicates additivity; CI > 1.1 indicates antagonism. Atorvastatin + 
mifepristone treatment showed a synergistic interaction in IPH-926 cells at ED50 and ED75 doses (CI < 0.9). A 
representative experiment of each endpoint and real-time assay is shown, with standard deviation shown in (A-C). 





























Next we tested the atorvastatin and mifepristone combination in the MDA-MB-231 cell line. 
The MDA-MB-231 cell line is a triple-negative breast cancer (TNBC) cell line derived from a 
pleural effusion that lacks E-cadherin expression due to hypermethylation of the CDH1 
promoter (Cailleau et al., 1974). MDA-MB-231 cells have a reported faster doubling time than 
IPH-926 cells (Cailleau et al., 1974; Christgen et al., 2009; Christgen and Derksen, 2015). Akin 
to MCF10A testing, MDA-MB-231 cells were grown for 24 hours and treated with a range of 
single-agent atorvastatin and mifepristone concentrations and both drugs in combination. 
Cellular confluence was measured in real-time over 48 hours using the IncuCyte FLR, followed 
by a nuclei counting viability assay. The isobologram analysis was then performed using 
CompuSyn to assess potential synergy of combined atorvastatin and mifepristone treatment in 
this cell line. The nuclei counting assay showed a dose-dependent effect on MDA-MB-231 
viability following both single-agent and combined atorvastatin and mifepristone treatment 
(Figure 5.7A-C). Single-agent treatment produced IC50 values of 3.86 and 65 μM for 
atorvastatin and mifepristone, respectively; combined atorvastatin and mifepristone treatment 
produced an IC50 of 2.25/2.25 μM ([atorvastatin]/[mifepristone]). The isobologram analysis 
reported an ED50 combination index of 0.61, supporting a synergistic interaction for the 
combination in MDA-MB-231 cells (CI < 0.9; Figure 5.7E-F). Additionally, a dose-dependent 
inhibitory effect was observed for combined atorvastatin and mifepristone treatment over the 
time-course of the real-time confluence assay (Figure 5.7D). At 48 hours post-treatment, the 
real-time assay showed 0.31/0.31, 1.25/1.25, and 5/5 μM treatment produced 6, 42, and 75% 
lower confluence values than vehicle-treatment (Figure 5.7D). In summary, these findings 
showed combined atorvastatin and mifepristone treatment maintained a synergistic effect in the 





Figure	  5.7	  MDA-­‐MB-­‐231	  cell	  viability	  following	  atorvastatin	  and	  mifepristone	  treatment	  
MDA-­‐MB-­‐231	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  with	  single-­‐agent	  atorvastatin	  (A)	  or	  mifepristone	  
(B),	   or	   combined	   atorvastatin	   and	   mifepristone	   (C-­‐D)	   for	   48	   h.	   Cell	   viabilities	   were	   determined	   using	   a	  
Hoechst-­‐stained	  nuclei	  counting	  assay	  (A-­‐C)	  and	  real-­‐time	  confluence	  assay	  (D).	  Drug	  synergy	  was	  assessed	  at	  
ED50,	   ED75,	   and	   ED90	   doses	   via	   CompuSyn	   software	   analysis	   (E-­‐F).	   Drug	   synergy	   is	   evaluated	   using	   a	  
combination	  index	  (CI),	  whereby	  CI	  <	  0.9	  indicates	  synergy;	  CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  
antagonism.	  Atorvastatin	  and	  mifepristone	   treatment	  showed	  a	  synergistic	   interaction	   in	  MDA-­‐MB-­‐231	  cells	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Figure 5.7: MDA-MB-231 cell viability following torvastatin and mifepristone tre ment. 
MDA-MB-231 cells were grown for 24 h and treated with with single-agent atorvastatin (A) or mifepristone (B), or 
combined atorvastatin + mifepristone (C-D) for 48 h. Cell viabilities were determined using a Hoechst-stained 
nuclei counting assay (A-C) and real-time confluence assay (D). Drug synergy was assessed at ED50, ED75, and 
ED90 doses via CompuSyn software analysis (E-F). Drug synergy is evaluated using a combination index (CI), 
whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 indicates additivity; CI > 1.1 i icat s antag nism. Atorvastatin + 
mifepristone treatment showed a synergistic interaction in MDA-MB-231 cells (CI < 0.9). Data represents averaged 
values of two biological replicates with standard error shown. 
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5.2.6 MDA-MB-231 Cell Cycle Analysis 
The MDA-MB-231 cell line was next analysed for the effect of atorvastatin and mifepristone on 
cell cycle arrest. The MDA-MB-231 cell line was selected over IPH-926 cells due to their 
inherent faster doubling time that enabled cytostatic analysis at 24 hours post treatment. MDA-
MB-231 cells were grown for 24 hours and treated with either single-agent atorvastatin and 
mifepristone, or both drugs in combination. Complete growth medium- and DMSO-treated cells 
were used as untreated and vehicle-treated controls, respectively. 24 hours post-treatment, cells 
were harvested and assessed for cell cycle staging via propidium iodide staining and flow 
cytometry. From this analysis, MDA-MB-231 cells showed a lack of cell cycle arrest in 
response to mifepristone treatment (Figure 5.8). A marked cytostatic effect was seen following 
2.5 and 5 μM atorvastatin treatment, with G1-arrested cells 72 and 71% more abundant than 
vehicle-treated cells, respectively (P < 0.01; Figure 5.8). Combined atorvastatin and 
mifepristone treatment also produced a prominent G1-arrested phenotype in the MDA-MB-231 
cell line, however, this effect was not greater than atorvastatin-only treatment. Combined 
atorvastatin and mifepristone treatment induced G1-arrested cell populations 31, 60, and 63% 
greater than vehicle treatment at concentrations of 0.63/0.63, 1.25/1.25, 2.5/2.5 μM, 
respectively (P < 0.05; Figure 5.8). To summarise, the cell cycle analysis showed combined 
atorvastatin and mifepristone treatment induced a G1-arrest effect in MDA-MB-231 cells, 
concordant with previous MCF10A CDH1-/- testing. However, combination treatment did not 













Figure	  5.8	  MDA-­‐MB-­‐231	  cell	  cycle	  analysis	  following	  atorvastatin	  and	  mifepristone	  treatment	  
MDA-­‐MB-­‐231	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   complete	   growth	   medium	   (cell	   only),	   vehicle	  
(DMSO),	   2.5	   and	   5	   μM	   single-­‐agent	   atorvastatin	   (At)	   or	   mifepristone	   (Mif),	   or	   combined	   atorvastatin	   and	  
mifepristone	  (At+Mif;	  0.63/0.63,	  1.25/1.25,	  2.5/2.5	  μM)	  for	  an	  additional	  24	  h.	  Cells	  were	  then	  harvested	  and	  
assessed	   for	   cell	   cycle	   staging	   via	   propidium	   iodide	   nuclear	   staining	   and	   flow	   cytometry	   analysis.	   Data	  
represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown.	  P-­‐values	  calculated	  using	  















































Figure 5.8: MDA-MB-231 cell cycle analysis following atorvastatin and mifepristone treatment.  
MDA-M -231 cells ere gro n for 24 h and treated ith complete growth medium (cell only), vehicle 
(DMSO), 2.5 and 5 µM single-agent atorvastatin (At) or mifepristone (Mif), or combined atorvastatin + 
mifepristone (At+Mif; 0.63/0.63, 1.25/1.25, 2.5/2.5 µM) for an additional 24 h. Cells were then harvested and 
assessed for cell cycle staging via propidium iodide nuclear staining and flow cytometry analysis. Data 
represents averaged values of two biological replicates with standard error shown. P-values calculated using 
Student’s t-test compared with vehicle treatment; ns = not significant (P > 0.05); * P < 0.05; ** P < 0.01.  
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5.2.7 Targeting the Mevalonate Pathway 
We next aimed to investigate the mevalonate pathway’s role in inducing synthetic lethality in E-
cadherin-deficient MCF10A cells. Inhibitors for various proteins downstream of HMGCR were 
therefore tested in the MCF10A isogenic pair. Zoledronic acid, FTI-277, GGTI-298, 
tunicamycin, and zaragozic acid were used to inhibit FDPS, FTase, GGTase-I, N-glycosylation, 
and SQS, respectively (Figure 5.1). Following a 24 hour incubation, MCF10A and MCF10A 
CDH1-/- cells were incubated with a range of concentrations of each mevalonate pathway 
inhibitor for an additional 48 hours, followed by cell viability assessment using nuclei counting. 
Interestingly, a similar cell viability reduction was seen in both MCF10A cell lines following 
zoledronic acid, FTI-277, GGTI-298, and tunicamycin treatment (Figure 5.9A-D). A minor 
synthetic lethal effect was seen in MCF10A CDH1-/- cells in response to zaragozic acid 
treatment, however, this was only achieved at high concentrations when the drug was also 
highly toxic to the MCF10A cells (Figure 5.9E). The lack of a marked synthetic lethal 
phenotype from these tested inhibitors suggests the mevalonate pathway may not be a targetable 
vulnerability in MCF10A CDH1-/- cells and that statin-mediated synthetic lethality may be 
attributed to pleiotropic effects external to HMGCR inhibition. Additionally, the synergistic 
effects of atorvastatin and mifepristone co-treatment may not be due to interaction of the 
mevalonate metabolite FPP with the glucocorticoid receptor. 
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Figure	   5.9	   MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cell	   viability	   following	   mevalonate	   pathway	   inhibition	  
downstream	  of	  HMGCR	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  either	  zoledronic	  acid	  (A),	  FTI-­‐277	  
(B),	   GGTI-­‐298	   (C),	   tunicamycin	   (D),	   or	   zaragozic	   acid	   (E)	   over	   a	   range	   of	   concentrations.	   At	   48	   h	   post-­‐
treatment,	  cell	  viability	  was	  assessed	  using	  a	  Hoechst-­‐stained	  nuclei	  counting	  assay.	  Data	  represents	  averaged	  

































































































































Figure 5.9: CF10A and MCF10A CDH1-/- cell viability following mevalonate pathway inhibition 
downstream of HMGCR. 
MCF   F10A CDH1-/- cells were grown for 24 h and treated with ither zoledronic acid (A), FTI-277 
(B), G -  ( ), tunicamycin (D), or z ragozic acid (E) over a range f concentrations. At 48 h post-
treatment, cell ia ilit  as assessed using a Hoechst-stained nuclei counting assay. Data represents averaged 
values of two biological replicates with standard error shown. P-values calculated using Student’s t-test; * P < 
0.05. 
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5.2.8 Hippo Pathway Activation 
Atorvastatin and mifepristone have recently been shown to modulate Hippo pathway activation 
in vitro (Sorrentino et al., 2014; Sorrentino et al., 2017). This prompted us to analyse YAP 
regulation as a potential synthetic lethal and synergistic mechanism targeted by atorvastatin and 
mifepristone in our MCF10A isogenic system. MCF10A and MCF10A CDH1-/- cells were 
grown for 24 hours and treated with either single-agent atorvastatin and mifepristone, or both 
drugs in combination. Complete growth medium and DMSO were used for untreated and 
vehicle-treated controls, respectively. 24 hours post-treatment, cell lysates were prepared and 
immunoblotted for levels of YAP and YAP phosphorylated at serine 127 (pYAP(S127)), the 
target amino acid of LATS kinases (Johnson and Halder, 2014). pYAP(S127) is retained in the 
cytoplasm and infers Hippo pathway activation (Johnson and Halder, 2014). The immunoblot 
analysis showed low YAP expression in MCF10A and MCF10A CDH1-/- cells, with no 
difference observed across both isogenic cell lines (Figure 5.10A). Atorvastatin and 
mifepristone treatment, either alone or in combination, did not increase pYAP(S127) levels 
relative to vehicle treatment in either cell line (Figure 5.10B). Additionally, no difference was 
observed in pYAP(S127) levels between drug-treated MCF10A and MCF10A CDH1-/- cell lines 
(Figure 5.10B). Altogether, the western analysis suggested the Hippo pathway was unlikely to 
be differentially regulated in the MCF10A isogenic pair and that atorvastatin and mifepristone, 
whether given alone or in combination, are not exerting synthetic lethality in normalised E-












Figure	   5.10	   Immunoblot	   for	   YAP	   and	   pYAP(S127)	   in	   MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   following	  
single-­‐agent	  and	  combined	  atorvastatin	  and	  mifepristone	  treatment	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  complete	  growth	  medium	  (cell	  only,	  
CO),	  vehicle	  (DMSO),	  2.5	  μM	  atorvastatin	  (At),	  2.5	  μM	  mifepristone	  (Mif),	  or	  combined	  2.5/2.5	  μM	  atorvastatin	  
and	  mifepristone	  (At+Mif)	  for	  an	  additional	  24	  h.	  Cell	  lysates	  were	  collected	  and	  immunoblotted	  for	  YAP	  (A)	  
and	   YAP	  phosphorylated	   at	   serine	   residue	   127	   (pYAP(S127);	   (B),	  with	   α-­‐tubulin	   used	   as	   a	   loading	   control.	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Figure 5.10: Immunoblot for YAP and pYAP(S127) in MCF10A and MCF10A CDH1-/- cells following 
single-agent and combined atorvastatin and mifepristone treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 4 h and trea ed with comp ete grow h medium (cell 
only, CO), vehicle (DMSO), 2.5 µM atorvastatin (At), 2.5 µM mifepristone (Mif), or combined 2.5/2.5 µM 
atorvastatin + mifepristone (At+Mif) for an additional 24 h. Cell lysates were collected and immunoblotted 
for YAP (A) and YAP phosphorylated at serine residue 127 (pYAP(S127); B), with α-tubulin used as a loading 




To confirm the absence of an exploitable Hippo pathway vulnerability in MCF10A CDH1-/- 
cells, we next tested the YAP inhibitor verteporfin in combination with atorvastatin and 
mifepristone in the MCF10A isogenic cell lines. MCF10A and MCF10A CDH1-/- cells were 
grown for 24 hours and treated with a titrated range of single-agent atorvastatin, mifepristone, 
or verteporfin; combined atorvastatin and mifepristone, atorvastatin and verteporfin, 
mifepristone and verteporfin; or all three drugs in combination. Cell viability was determined at 
48 hours post-treatment using nuclei counting and an isobologram analysis was used to 
investigate potential synergistic interactions of the two-part and three-part drug combinations. 
The viability analysis showed single-agent verteporfin treatment did not induce a marked 
synthetic lethal phenotype in the MCF10A CDH1-/- cell line (Appendix D.6). Further, the 
addition of verteporfin to atorvastatin and mifepristone failed to increase the synthetic lethal 
viability differential provided by combined atorvastatin and mifepristone treatment in MCF10A 
and MCF10A CDH1-/- cells (Figure 5.11A). This was supported by a lack of synergy from the 
isobologram analysis, whereby combined atorvastatin and verteporfin treatment produced 
combination indices of 1.00 and 0.97, and combined mifepristone and verteporfin treatment 
produced combination indices of 1.19 and 1.49 for MCF10A and MCF10A CDH1-/- cells, 
respectively (CI > 0.9; Figure 5.11B). To summarise, verteporfin-mediated YAP inhibition 
showed no evidence for a Hippo pathway vulnerability in the MCF10A CDH1-/- cell line. 
 
 135 
Figure	   5.11	   Verteporfin	   co-­‐treatment	   does	   not	   enhance	   atorvastatin	   and	   mifepristone	   induced	  
synthetic	  lethality	  in	  MCF10A	  CDH1-­‐/-­‐	  cells	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   single-­‐agent	   verteporfin,	  
atorvastatin,	  mifepristone;	  combined	  verteporfin	  and	  atorvastatin,	  verteporfin	  and	  mifepristone,	  atorvastatin	  
and	  mifepristone;	  or	  all	  three	  drugs	  in	  combination	  for	  48	  h.	  Cell	  viabilities	  were	  determined	  using	  a	  Hoechst-­‐
stained	  nuclei	  counting	  assay	  (A)	  and	  used	  to	  assess	  drug	  synergy	  at	  the	  ED50	  dose	  via	  CompuSyn	  software	  
polygonogram	   analysis	   (B).	   Drug	   synergy	   is	   evaluated	   using	   a	   combination	   index	   (CI),	   whereby	   CI	   <	   0.9	  
indicates	  synergy;	  CI	  =	  0.9-­‐1.1	  indicates	  additivity;	  CI	  >	  1.1	  indicates	  antagonism.	  Atorvastatin	  and	  verteporfin	  
=	  additive	  (CI	  =	  0.9-­‐1.1);	  verteporfin	  and	  mifepristone	  =	  antagonistic	  (CI	  >	  0.9);	  atorvastatin	  and	  mifepristone	  
=	   synergistic	   (CI	   <	   0.9).	   Data	   represents	   averaged	   values	   of	   two	   biological	   replicates	   with	   standard	   error	  


















































Figure 5.11: Verteporfin co-treatment does not enhance atorvastatin + mifepristone induced synthetic 
lethality in MCF10A CDH1-/- cells. 
MCF10A and MCF10A CDH1-/- cells were g own for 24 h and treated with single-age t vert porfin, atorvastatin, 
mifepristone; combined vert porfin + atorvastatin, verteporfin + mifepristone, atorvastatin + mifepristone; or all 
three drugs in combination for 48 h. Cell viabilities were determined using a Hoechst-stained nuclei counting assay 
(A) and used to assess drug synergy at the ED50 dose via CompuSyn software polygonogram analysis (B). Drug 
synergy is evaluated using a combination index (CI), whereby CI < 0.9 indicates synergy; CI = 0.9-1.1 indicates 
additivity; CI > 1.1 indicates antagonism. Atorvastatin + verteporfin = additive (CI = 0.9-1.1; thin green line); 
verteporfin + mifepristone = antagonistic (CI > 0.9; dashed red line); atorvastatin + mifepristone = synergistic (CI < 
0.9; thick green ine). Dat  represents averaged values of two biological replicates with standard error shown. P-







5.3 DISCUSSION  
In this chapter, the consequences of combined atorvastatin and mifepristone treatment were 
evaluated in the MCF10A isogenic cell lines. A real-time confluence analysis showed a stronger 
proliferation reduction in MCF10A cells lacking E-cadherin expression (MCF10A CDH1-/-) 
than wild-type MCF10A cells following single-agent atorvastatin and mifepristone treatment, 
supporting the findings of our previous endpoint testing. This drug-induced confluence loss was 
enhanced following co-treatment of these drugs, supporting previous findings of a synergistic 
interaction. A complete loss of cellular confluence, however, was not seen in MCF10A CDH1-/- 
cells in response to atorvastatin and mifepristone treatment at the tested concentration range. 
This lack of cell death was later attributed to cytostasis, whereby MCF10A CDH1-/- cells were 
exclusively G1-arrested following drug treatment.  
 
In addition to our normalised MCF10A isogenic cell line model, the atorvastatin and 
mifepristone combination was applied to two malignant cell lines devoid of E-cadherin 
expression, the ILBC-derived IPH-926 and the TNBC-derived MDA-MB-231. Both IPH-926 
and MDA-MB-231 cell lines exhibited a dose-dependent loss in viability in response to 
atorvastatin and mifepristone treatment. A synergistic response was observed following co-
treatment of these drugs in both cell lines, a result similar to our MCF10A isogenic cell line 
findings. The synergistic response of combined atorvastatin and mifepristone in these malignant 
breast cancer cell lines suggests that this combination may be robust to a variety of genetic 
backgrounds. Further studies testing the atorvastatin and mifepristone combination in additional 
cancer cell lines should be undertaken to further extend these initial observations. This could 
include testing in malignant cell lines with intact E-cadherin, to see how specific these findings 
are with respect to E-cadherin loss in a malignant context.  
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The synergistic effect of co-administered atorvastatin and mifepristone was not as potent in 
IPH-926 and MDA-MB-231 cells as MCF10A CDH1-/-, presumably due to background genetic 
differences. This was also evident in the cell cycle analysis, where MDA-MB-231 cells 
exhibited a marked G1-arrested effect in response to single-agent statin treatment, an effect 
unseen using both E-cadherin-expressing and E-cadherin-deficient MCF10A lines, but in line 
with the previous literature (Shen et al., 2015). Interestingly, co-treatment with mifepristone did 
not amplify the growth-arrested phenotype of atorvastatin treatment in the TNBC-derived cell 
line. However, this may be attributed to the low mifepristone concentration used in the 
combination for the MDA-MB-231 cell cycle staging analysis. Mifepristone treatment produced 
a higher IC50 than atorvastatin treatment in MDA-MB-231 endpoint testing, thus a higher 
mifepristone concentration was likely required in the combination instead of the tested 1:1 
(atorvastatin:mifepristone) molar ratio. This effect could be explained by mifepristone targeting 
hormone receptors (PR and/or GR) in a TNBC context and would therefore be worth examining 
in additional TNBC cell lines. 
 
Although differences between the isogenic MCF10A cells were detected following atorvastatin 
and mifepristone treatment, we were unable to confirm a single signalling pathway that 
correlated with the synthetic lethal phenotype and synergistic drug interaction. Inhibition of 
multiple mevalonate pathway nodes did not give rise to a marked synthetic lethal phenotype in 
MCF10A CDH1-/- cells, suggesting statin-exploited vulnerabilities in E-cadherin-deficient cells 
are independent to mevalonate pathway signalling. Additionally, these data suggest that 
interweaving of mevalonate and glucocorticoid signalling pathways via FPP-GR complex 
formation may not explain the synergistic link between atorvastatin and mifepristone co-
inhibition (Das et al., 2007; Pastar et al., 2016; Vukelic et al., 2010). Follow-up studies 
involving targeted knockdown of mevalonate pathway enzymes such as HMGCR and FDPS, 
will likely provide further clarity to this mechanism. Additionally, methodology describing 
 138 
mevalonate metabolite supplementation to cells following HMGCR inhibition could also be 
adapted to this analysis (Andres et al., 2014; Wang et al., 2016).     
 
ILBC exhibits modulated Hippo pathway signalling in addition to E-cadherin loss in vitro and 
in vivo (Vlug et al., 2013). Furthermore, both atorvastatin and mifepristone have been shown to 
induce YAP cytoplasmic sequestration, and thus Hippo activation, in breast cancer cell lines 
(Sorrentino et al., 2014; Sorrentino et al., 2017). This prompted us to investigate the Hippo 
pathway in our isogenic MCF10A system. Much to our chagrin, the Hippo pathway regulator 
YAP was not differentially regulated between MCF10A and MCF10A CDH1-/- cells, either pre- 
or post-treatment with atorvastatin and mifepristone. This infers non-malignant breast cells do 
not rely on nuclear-localised YAP for proliferation following E-cadherin loss. Atorvastatin and 
mifepristone treatment is therefore unlikely to be inhibiting MCF10A CDH1-/- proliferation via 
the Hippo pathway, a finding supported by a lack of synthetic lethality following verteporfin 
(YAP inhibitor) treatment. It is possible that the E-cadherin-deficient cancerous cell lines used 
in this study, IPH-926 and MDA-MB-231, may utilise YAP signalling to a greater extent than 
MCF10A cells, however, this was not tested in the investigation. 
 
MCF10A cells have been shown to enter G1 arrest when in agarose suspension cultures 
(without cell-substratum adhesion) and following knockdown of E-cadherin expression 
(Fournier et al., 2008). This suggests that compromised cell-to-cell adhesion may increase a 
cell’s dependency on basement membrane adhesion (Fournier et al., 2008). Both statin and 
mifepristone treatment are known to alter focal adhesion signalling pathways (Wang et al., 
2008; Yu et al., 2015). It is therefore possible that combined atorvastatin and mifepristone may 
be acting synergistically through integrin adhesion inhibition. In MCF10A CDH1-/- cells, where 
cell-to-cell adhesion is compromised following E-cadherin loss, atorvastatin and mifepristone 
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treatment may be inducing a blockade of integrin signalling, which consequently produces our 
observed G1-arrested synthetic lethal effect. 
 
Additionally, atorvastatin has been shown to reduce the viability of hepatocellular carcinoma 
and colorectal carcinoma cells via AMPK-mediated autophagy induction, a process that was 
independent of HMGCR activity (Yang et al., 2010). Autophagy involves the self-digestion of 
cellular proteins and organelles to prolong viability and is usually initiated in response to 
cellular stress events such as starvation (Meijer and Dubbelhuis, 2004). Atorvastatin-induced 
cellular starvation involves restriction of insulin-mediated Akt pro-proliferative signalling 
pathways (Roudier et al., 2006). Glucocorticoid removal can also induce cellular starvation, an 
effect shown to be more potent than combined EGF and insulin deprivation (Moran et al., 
2000). This may explain mifepristone’s greater synthetic lethal effect in MCF10A CDH1-/- cells 
than that seen post-statin treatment. It is noteworthy that EGF, insulin, and the glucocorticoid 
hydrocortisone are components of MCF10A growth medium. This opens the possibility that 
atorvastatin-mediated EGF and insulin restriction and mifepristone-mediated hydrocortisone 
restriction may explain the synergistic interaction following co-treatment of both drugs. This 
suggests that combining atorvastatin and mifepristone with an autophagy-inducing compound, 
such as the FDA-approved metformin, may further increase the synthetic lethal differential in 
the MCF10A isogenic cell lines. Indeed, a recent study has shown combined statin and 
metformin treatment improves prognosis in gastrointestinal cancer patients (Nimako et al., 
2017). Additionally, metformin treatment reduces metabolic side effects in patients receiving 
glucocorticoid therapy (Seelig et al., 2017). Taken together, these studies suggest a potential 
synergistic interaction for combined atorvastatin, mifepristone, and metformin treatment. 
 
If starvation-induced autophagy is responsible for atorvastatin and mifepristone synergy, an 
impaired autophagic ability must therefore reside in E-cadherin-deficient cells to explain the 
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synthetic lethality in the isogenic MCF10A cell lines. It has been shown that E-cadherin-
mediated cell-to-cell adhesion is required for the formation of an E-cadherin-LKB1-AMPK 
complex at the cell periphery, which facilitates the activation of AMPK and subsequent 
induction of autophagy (Bays et al., 2017; Sebbagh et al., 2009). Interestingly, LKB1 loss-of-
function mutations have been identified in HDGC families who do not harbour CDH1 
mutations (Hansford et al., 2015). This suggests that loss of CDH1 and/or LKB1 may reduce a 
cell’s ability to perform autophagy via AMPK, a process that may be an exploitable synthetic 
lethal vulnerability in HDGC. In breast cancer, autophagy-related proteins show differential 
expression between E-cadherin-negative ILBC and E-cadherin-positive invasive ductal 
carcinoma (IDC) (Cha et al., 2014). Beclin-1 (BECN1) is a key regulator of autophagy 
induction and was identified at lower levels in ILBC than IDC (Cha et al., 2014), suggesting 
ILBC tumours may also have compromised autophagy. Further studies are needed to understand 
the mechanisms underpinning E-cadherin loss and cellular autophagy, and whether this process 
can indeed be exploited across DGC and ILBC tumours.  
 
In summary, this chapter has identified a cytostatic effect following combined atorvastatin and 
mifepristone treatment in both non-malignant and malignant cell lines devoid of E-cadherin 
expression. We have demonstrated that this response is unrelated to mevalonate and Hippo 
signalling pathways in non-malignant cells, a finding that will prompt further investigation 
across a panel of E-cadherin-deficient cancer cell lines. Nonetheless, this study adds further 
support to the use of statins and mifepristone in cancer therapeutics and provides a novel drug 
































6. FUTURE DIRECTIONS  
This thesis characterised a range of real-time and endpoint cell viability assays that were applied 
to a pair of isogenic non-malignant breast cell lines to screen for synergistic and synthetic lethal 
drug combinations in E-cadherin-deficient cells. From this screen, statins were identified as a 
drug class that reduced MCF10A CDH1-/- cell viability whilst leaving wild-type MCF10A cells 
relatively unharmed at concentrations up to 5 μM. Furthermore, statin-induced synthetic lethal 
interactions were synergistic with HDACi (entinostat and vorinostat), saracatinib, and 
mifepristone. Combined atorvastatin and mifepristone treatment produced the strongest 
synthetic lethal and synergistic response via a cytostatic G1-arrest phenotype, and this synergy 
was maintained in the IPH-926 and MDA-MB-231 breast cancer cell lines. This chapter focuses 
on potential future directions of this research, highlighting additional steps that may lead to the 
atorvastatin and mifepristone combination as a chemoprevention and advanced cancer treatment 
option in the clinic. 
 
To further expand this study’s findings, an approach to unravel both the synergistic and 
synthetic lethal mechanisms of atorvastatin and mifepristone treatment would be useful. As 
such, this drug combination could be applied to additional isogenic cell lines that differ by 
CDH1 expression status. We are currently performing drug testing in a gastric cancer cell line 
(NCI-N87) and a CRISPR-generated CDH1 knockout counterpart (unpublished data). 
Additionally, an RNA sequencing analysis could be undertaken using the MCF10A and 
MCF10A CDH1-/- cells treated with single-agent and combined atorvastatin and mifepristone. 
On the proteomic scale, a Reverse Phase Protein Array (RPPA) could be used to identify altered 
phosphoproteome signalling following single-agent and combined drug treatment. Together, 
these methodologies may uncover a pathway that could be further investigated in the context of 
cellular vulnerabilities following loss of E-cadherin.  
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A high-throughput drug screen could also be undertaken to identify additional synthetic lethal 
drug combinations involving statins and/or mifepristone. This could involve treating MCF10A 
and MCF10A CDH1-/- cells that have been pre-treated with statin and/or mifepristone. An 
endpoint viability assay would then be used to find drugs that enhance the synthetic lethal effect 
of statin and mifepristone treatment. Additionally, a caspase assay could be used to discover 
drugs that drive atorvastatin- and mifepristone-treated cells to apoptosis. Findings from this 
screen may identify drugs that are more synergistic with atorvastatin than mifepristone. This 
would provide a better chemoprevention option for female CDH1 mutation carriers of 
childbearing age, as mifepristone is used clinically as an abortifacient agent.  
 
An obvious next move for this research is to apply the atorvastatin and mifepristone 
combination to a more complex system than monolayer cell culture. One such system involves 
growing cell lines in three-dimensional spheres, termed ‘spheroids’.  Spheroids can be produced 
using a number of methods (described in detail by Breslin and O’Driscoll, 2013), with the aim 
of mimicking aspects of tumour growth in vivo (Breslin and O'Driscoll, 2013). Central to this is 
the formation of a hypoxic core, which is a result of poor oxygen diffusion from the spheroid 
exterior to the spheroid centre (Tung et al., 2011). This resembles conditions of low oxygen 
permeability observed in vivo, where approximately 60% of solid tumours exhibit hypoxic cores 
(Vaupel and Mayer, 2005). However, it is noteworthy that hypoxic cores are infrequent in 
lobular carcinomas due to the diffuse and indolent nature of their growth. Hypoxic conditions 
have been shown to change cellular responses to drug treatment by altering the expression of 
survival- and apoptosis-related genes (Wilson and Hay, 2011). In addition, hypoxia may cause 
resistance to drug-induced G1 cell cycle arrest (Wilson and Hay, 2011), an effect that may 
impact the atorvastatin and mifepristone effects described in this study. Further, the MCF10A 
and MDA-MB-231 cell lines used in this study are known to become more resistant to 
doxorubicin-induced cytotoxicity when grown in spheroids versus monolayer cultures (Li et al., 
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2010). Thus, there is a need to assess the synergistic and synthetic lethal effects of combined 
atorvastatin and mifepristone treatment in three-dimensional MCF10A, MDA-MB-231, and 
additional E-cadherin-deficient cell line cultures. 
 
Slightly more complex than spheroids are organoid model systems. Organoids are three-
dimensional cell cultures derived from the stem cells of primary tissue that exhibit similar 
structural and functional properties as the tissue of origin (Clevers, 2016; Fatehullah et al., 
2016). This allows for a more accurate model of tissue pathology in vitro, providing an 
intermediate between cell culture and animal model systems. Of interest to this study is the 
development of gastric and mammary tissue organoids, with the aim of inducing E-cadherin 
loss in these tissues to resemble DGC and ILBC pathologies. Fortunately, the successful 
culturing of gastric organoids has been described in the literature (Barker et al., 2010; Bartfeld 
et al., 2015; McCracken et al., 2014), and the technique is now established in our laboratory 
using neonatal mouse stomachs. Gastric organoids have been developed from both mouse and 
human primary tissue, containing gastric gland- and pit-like domains, proliferative zones, 
mucous cells, and endocrine cells, akin to stomach tissue in vivo (Clevers, 2016). Recently, 
Boelens et al. (2016) generated an ILBC organoid model from mouse mammary tissue 
harbouring Cre-conditional inactivation of Cdh1 and Pten (Boelens et al., 2016). PTEN loss 
induces hyperactive signalling of the PI3K pathway and was additionally inactivated as E-
cadherin loss alone does not produce mammary tumours in a mouse model (Boussadia et al., 
2002; Derksen et al., 2006). 
 
Similar to Boelens et al., we are currently developing a Cre-conditional Cdh1-/- mouse as a DGC 
model. In this model, Cre expression is under a Cd44 promoter and inducible via tamoxifen 
treatment. At the time of writing, this Cd44-Cre/Cdh1-/- mouse is being bred to generate the 
required numbers for a time course study following tamoxifen-induced Cdh1 deletion. It is 
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predicted that lesions akin to T1a signet ring cell carcinoma will develop in the gastric 
epithelium of these mice in under six months. Lead synthetic lethal drugs, such as atorvastatin 
and mifepristone, will be used to treat the DGC model mice with the aim of reducing the 
number of foci in the stomach tissue. Additionally, resected stomach tissue from these mice will 
be used to form organoids, with tamoxifen treatment used to induce E-cadherin loss in vitro. 
Thus, if the mouse model is successful, we will have two powerful drug testing platforms for 
advancing synthetic lethal drug testing. 
 
The performance of statin-based combinations in a patient-derived xenograft (PDX) model 
would also be of interest. PDX models involve the propagation of a patient’s tumour tissue 
inside an immunosuppressed mouse. Following transplantation, PDX models have been found 
to closely resemble the donor tumour tissue, maintaining features such as gland architecture, 
mucin production, and cyst development (Hidalgo et al., 2014). This provides a useful tool for 
translational cancer research, as evidenced by the successful use of PDX models in preclinical 
phase II studies with chemotherapeutic agents (Berger et al., 1990). Of immediate relevance to 
this study would be the testing of atorvastatin and mifepristone in a PDX model consisting of 
DGC- and/or ILBC-derived tumour tissue. The ability of these synthetic lethal drugs to maintain 
a synergistic therapeutic effect in a PDX model may expand the combination’s application from 
chemoprevention to advanced cancer therapeutics. 
 
Finally, proof of a therapeutic benefit from statin-based combinations in CDH1 mutation 
carriers is needed. This would be a worthwhile investigation as statin concentrations used in 
vitro are markedly higher than what is clinically attainable in human serum (Bjorkhem-
Bergman et al., 2011). Prior to undergoing prophylactic total gastrectomy (PTG), CDH1 
mutation carriers can face a waiting period of several months. This presents a window where 
combination treatment could be provided to individuals planning to undergo a PTG. As the 
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stomach tissue of CDH1 mutation carriers contain multiple stage T1a lesions (as detailed in 
Chapter 1.1.2), we would examine the number of foci between the resected stomachs of 
individuals who received drug combination treatment. No foci in a series of stomachs from 
patients who received drug treatment would provide evidence of a successful chemoprevention 
approach. 
 
Overall, co-treatment of atorvastatin and mifepristone is a novel drug combination in cancer 
chemoprevention. The ability of statin-based combinations to reduce E-cadherin-deficient cell 
viability whilst modestly affecting wild-type cells demonstrates an exciting overlap between the 
fields of synergistic drug combination discovery and synthetic lethality. The known safety 
profile and FDA-approval status of atorvastatin and mifepristone should aid translation of this 
research to the clinic, where co-treatment of these drugs can potentially serve as a new 
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Synthetic Lethal Screens IdentifyVulnerabilities in
GPCR Signaling and Cytoskeletal Organization in
E-Cadherin–Deficient Cells
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Cathryn M. Gould2, Andrew Single1, Tanis Godwin1, Kaylene J. Simpson2,3, and
Parry Guilford1
Abstract
The CDH1 gene, which encodes the cell-to-cell adhesion
protein E-cadherin, is frequently mutated in lobular breast
cancer (LBC) and diffuse gastric cancer (DGC). However,
because E-cadherin is a tumor suppressor protein and lost from
the cancer cell, it is not a conventional drug target. To overcome
this, we have taken a synthetic lethal approach to determine
whether the loss of E-cadherin creates druggable vulnerabilities.
We first conducted a genome-wide siRNA screen of isogenic
MCF10A cells with and without CDH1 expression. Gene ontol-
ogy analysis demonstrated that G-protein–coupled receptor
(GPCR) signaling proteins were highly enriched among the
synthetic lethal candidates. Diverse families of cytoskeletal
proteins were also frequently represented. These broad classes
of E-cadherin synthetic lethal hits were validated using both
lentiviral-mediated shRNA knockdown and specific antago-
nists, including the JAK inhibitor LY2784544, Pertussis toxin,
and the aurora kinase inhibitors alisertib and danusertib. Next,
we conducted a 4,057 known drug screen and time course
studies on the CDH1 isogenic MCF10A cell lines and identified
additional drug classes with linkages to GPCR signaling and
cytoskeletal function that showed evidence of E-cadherin syn-
thetic lethality. These included multiple histone deacetylase
inhibitors, including vorinostat and entinostat, PI3K inhibitors,
and the tyrosine kinase inhibitors crizotinib and saracatinib.
Together, these results demonstrate that E-cadherin loss creates
druggable vulnerabilities that have the potential to improve the
management of both sporadic and familial LBC and DGC. Mol
Cancer Ther; 14(5); 1213–23. !2015 AACR.
Introduction
E-cadherin is a cell-to-cell adhesion protein that is localized at
the adherens junction of all epithelial cells (1).Other than its roles
in cell adhesion, E-cadherin is involved in establishing and
maintaining cell polarity and differentiation, the organization of
cell migration and architecture and the mediation of signaling
through various proliferation and survival pathways, including
WNT and EGFR (2, 3).
Abrogation of expression of the E-cadherin gene (CDH1) by
mutation, deletion, or promoter hypermethylation is a feature
common to many epithelial tumors and its downregulation is
the hallmark of both diffuse gastric cancer (DGC) and lobular
breast cancer (LBC; refs. 1, 4–6). Disrupting E-cadherin's
expression or localization has a pronounced impact on a cell's
cytoskeletal structure, with changes including misalignment of
the microtubule and actin cytoskeletons, defects in cell migra-
tion and irregularities in the orientation of the mitotic spindle
(7–9).
Germline CDH1 mutations are responsible for hereditary dif-
fuse gastric cancer (HDGC), a cancer syndrome characterized by
the highly penetrant, early onset of multifocal DGC and an
elevated rate of LBC. In HDGC,CDH1 inactivation is an initiating
event thatmay be related to abnormalmitotic spindle orientation
resulting in daughter cells being displaced into the lamina pro-
pria, outside the epithelial plane (10–12). Inother cancer types, its
downregulation is considered to be a late event that promotes
increased invasive capacity, frequently through association with
the epithelial–mesenchymal transition (13).
Although E-cadherin is a tumor suppressor protein that is lost
from the cancer cell and therefore not a conventional drug target,
the downregulation of such a multifunctional protein during
tumorigenesis would be predicted to create vulnerabilities in the
cell which are targetable using a synthetic lethal approach. In the
context of drug development, synthetic lethality can be defined as
a drug that reduces cell viability or fitness only in cells carrying a
specificmutation. The utility of synthetic lethal targeting of tumor
suppressor genes is well illustrated clinically by olaparib, an
inhibitor of the DNA repair enzyme PARP. Olaparib elicits strong
clinical responses in breast and ovarian cancer patients who
harbor inactivatingmutations in the homologous recombination
dsDNA repair genes BRCA1/2 (14, 15).
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In addition to providing new therapeutic avenues for the
treatment of sporadic epithelial cancers, synthetic lethal targeting
of E-cadherin–deficient cells also has the potential to improve the
clinical management of HDGC. To identify druggable synthetic
lethal vulnerabilities in E-cadherin–deficient cells, we have con-
ducted both a genome-wide siRNA synthetic lethal screen and a
four thousand compound known drug screen on isogenic breast
MCF10A cellswith andwithoutCDH1 expression. Together, these
screens have identified multiple druggable targets that suggest
new therapeutic strategies for the treatment of E-cadherin–defi-
cient cancers and the chemoprevention of HDGC.
Materials and Methods
Cell lines and media
The MCF10A breast cell line and its paired isogenic MCF10A
CDH1!/! line (here designated CDH1!/!) were obtained from
Sigma Aldrich in 2011 (parental line ATCC CRL-10317) and had
beenauthenticated using short terminal repeat analysis.CDH1!/!
hadbeen created byhomozygous deletionof 4bp fromexon11of
the CDH1 gene. The lines were resuscitated within one week of
receipt and early passage cells (passage 3–7) were aliquoted and
frozen. All experiments were conducted with cells between pas-
sages 6–15 inDMEMF12media with glutamate, 5%horse serum,
20 ng/mL EGF, 0.5 mg/mL hydrocortisone, 100 ng/mL cholera
toxin, and 10 mg/mL insulin. Characterization of the cell line pair
is described elsewhere (7).
siRNA high-throughput screen
Cells were transfected with siRNAs from the Dharmacon
SMARTpool whole genome protein-coding siRNA library (RefSeq
27) housed in the VictorianCenter for Functional Genomics. Each
SMARTpool contained four siRNAs that targeted different regions
of each gene in one well. Each reaction, in a white walled, clear-
bottom 384-well plate format, contained 0.125%DharmaFECT 3
(0.05 mL), 27.4% OptiMEM (Invitrogen), and 40 nmol/L of the
siRNA SMARTpool (total volume 37.5 mL). Cells were reverse
transfected and seeded onto the siRNA cocktail at a density of 700
MCF10A cells per well and 900 CDH1!/! cells/well to enable the
two cell lines to reach confluence at the same time point (72 hours
after seeding). The following controls were included in each plate:
the death controls siEGFR and siPLK1 (4 wells each), a synthetic
lethal control siCTNNB1 (6 wells) and two negative controls,
siRISC free andmock (lipid only, 9wells each). After 24 hours, the
media was replaced and at 72 hours 10 mL CellTiter-Glo was
added to eachwell (final concentration 1/5), shaken on an orbital
shaker for 2 minutes and incubated for a further 30 minutes at
room temperature before measuring luminescence using a Syn-
ergy H4 microplate reader (Biotek). siRNA was dispensed using a
Caliper Sciclone ALH3000 (PerkinElmer). All other liquid han-
dling steps were performed using a Biotek406 liquid handling
workstation. Primary screen analysis was performed by normal-
izing genes in each cell line individually to the averagemock value
(across all screen plates) for the respective cell line. The level of
increased kill was determined by the ratio ofCDH1!/! viability to
MCF10A viability. Candidates with MCF10A viability "50% and
a fold change ratio of #0.85 were considered synthetic lethal
candidates. Selection of the final 500 genes chosen for secondary
screening was based on further analysis of druggability and
biologic relevance. Secondary siRNA screening was performed
using four individual siRNAs targeting each gene arrayed in
individual wells, separately using the same transfection condi-
tions described above with a final siRNA concentration of 25
nmol/L. The secondary screen was analyzed using the same
normalization strategy and cutoffs as the primary screen.
Viral knockdown
Dharmacon pGIPZ lentiviral shRNA mir30 plasmids were
prepared from cultures using the Machery Nagel EasyPure Mini-
prep Kit. 293FT cells were cotransfected 24 hours after seeding
with 18.6mg pGIPZ, 9.6mgPAX2, and4.8mg VSVGplasmids using
55.7 mL Lipofectamine 2000 (Invitrogen). Media was changed at
24 hours, and after a further 24 hours, viral particles were
harvested by aspirating media, centrifugation at 3,000 rpm for
15minutes to remove cellular debris and filtration through a 0.45
mmol/L polyvinylidene difluoride filter. Virus was aliquoted and
snap frozen for subsequent use.
Viral titer was determined by seeding MCF10A cells at 4,000
cells per well and transducing with a 1/32 dilution of virus 24
hours later. Media was changed after 24 hours, and after a further
24 hours, GFP-expressing cells were quantitated over 5 fields at
10$ magnification. The average number of transduced cells per
well was used to determine the number of transducing units
per mL.
For knockdown experiments, 1,000 MCF10A and 2,000
CDH1!/! cells per well were seeded in black walled, clear bot-
tomed 96-well plates and allowed to adhere overnight. The
followingday, viruswas addedat amultiplicity of infection (MOI)
of 10. Media were changed at 24 hours and 1 mg/mL puromycin
added. Seventy-four hours after transduction,mediawas aspirated
and 1 mg/mL Hoechst 33342 and 0.5 mg/mL propidium iodide in
PBS added. After 30minutes, incubation plates were imaged with
4 fields per well on the Cytell (GE) at 4$ magnification and 10
fields per well at 10$ magnification using the "Cell Viability
BioApp". CellProfiler (16) was used to quantitate the total nuclei,
as well as the proportion stained with propidium iodide.
RNA was extracted at 72 hours to determine gene knockdown
using the RNAgem-PLUS Kit (ZyGem). cDNA was synthesized
using the Primescript cDNA Synthesis Kit (Takara), and qPCR
performed using Sybr Fast kit (KAPA) on an ABI7900HT with an
enzyme activation step of 95%C for 3 minutes followed by 40
cycles of 95%C for 15 seconds, 57%C for 15 seconds, and 72%C for
15 seconds. GAPDH and PPIA were used as reference genes and
results were analyzed using the efficiency method as described by
Pfaffl (17).
Known drug screen
Assay ready plates containing 20 nL of 4,057 compounds
diluted in DMSO at four concentrations (2, 1, 0.5, and 0.25
mmol/L) were prepared by the Walter and Eliza Hall Institute
(WEHI, Parkville, Victoria, Australia) High-Throughput Chemical
Screening Facility. Cells were seeded directly onto these plates in a
volume of 50 mL at a density of 1,000 cells per well for MCF10A
and 1,200 cells per well for CDH1!/! in 384-well clear bottom
plates. After 48 hours, 20 mL of CellTiter-Glo (Promega) was
added to each well, shaken for 2 minutes on an orbital shaker,
and incubated for 30minutes before reading. Valueswere normal-
ised to the average DMSO control value of the whole screen for
each cell line at each concentration.
The secondary drug screen was performed on 316 compounds
selected from the primary screen. Thesewere provided at 5mmol/L
Telford et al.
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and 11 1:1 dilutions weremadewithDMSO to create a 10 mmol/L
to 10 nmol/L concentration range. Cells were seeded at a density
of 700 cells per well for MCF10A and 900 cells per well for
CDH1!/! for 24 hours before 100 nL of each compound was
added to the plates robotically. Thirty-two DMSO control wells
were included in each plate. Plates were incubated for a further 48
hours before assaying with CellTiter-Glo.
Drug titrations and time course assays
To determine drug EC50, cells were seeded in white walled,
clear-bottom 384 well plates at a density of 800 cells per well in
a volume of 45 mL. After 24 hours incubation, 5 mL of drug
(rehydrated in DMSO to an 80 mmol/L stock and diluted in
complete media) was added to each well. A DMSO control and
a cell only control were used on each plate. The 11 drug
concentrations used were dependent on the individual drug.
After 48 hours of treatment, cell viability was assayed using
either the CellTiter-Glo (Promega) or Alamar blue assay. All
results were normalized to the average DMSO control for
individual cell types. EC50 values were calculated by plotting
viability against the log drug concentration and fitting a non-
linear regression curve using Prism version 6.0 for Mac (Graph-
Pad Software).
Drug time course assays were carried out by seeding equal
numbers of MCF10A or CDH1!/! at 4,000 cells per well in
xCELLigence plates (Roche), except for crizotinib which was
seeded at 2,000 cells per well. The xCELLigence system measures
relative changes in electrical impedance in a well ("cell prolifer-
ation index")which can be used as ameasure of cell number. After
24 hours, three concentrations of each drug were added and
growth followed in real time for a further 72 hours. Assays were
carried out in duplicate and the data averaged. Time course assays
were also performed on the IncuCyte Imaging System (Essen
Bioscience). Cells were seeded at 4,000 cells per well in black
walled clear-bottom 96-well plates. After 24 hours, five concen-
trations of each drugwere added and 3fieldswere imaged perwell
at 4" magnification every 2 hours for 48 hours. Plates were then
removed and cell numbers determined using metabolic assays
and nuclei imaging as described above.
For drug synergy studies, the combination index was deter-
mined using CompuSyn software (ComboSyn Inc) and the
Chou–Talalay method (18). EC50 was estimated for both drugs
and cells treated with each drug alone and in combination at this
concentration and concentrations 2- and 4-fold higher and lower.
Viabilitywas calculated by nuclei counting andnormalized values
imported into CompuSyn.
Results
Genome-wide siRNA screen of CDH1 isogenic MCF10A cells
To identify genes potentially involved in a synthetic lethal
interaction with E-cadherin, we conducted a genome-wide func-
tional screen using the Dharmacon siGENOME SMARTpool
library targeting 18,120 genes in a pooled format, with 4 indi-
vidual siRNAs targeting each gene. Isogenic MCF10A cells with
and without CDH1 expression were screened in parallel, and
viability was assayed 72 hours after transduction using CellTi-
ter-Glo. siPLK1 and siEGFR were used as positive death controls
(Fig. 1A) and siCTNNB1used as apositive synthetic lethal control,
after showing a mild synthetic lethal effect in a pilot screen
(Supplementary Fig. S1). Mock (lipid only) and RISC-free control
(Dharmacon) were included as nontargeting controls. Little var-
iability was observed between these controls; consequently, we
normalized the values of each gene to the average screen-wide
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siRNA screening overview of
outcomes and analysis strategy. A, the
resulting effect on cell viability after
knockdown of each protein-coding
target in MCF10A and CDH1!/! cells.
The positive death controls siPLK1 and
siEGFR both consistently cause death
in both cell lines. B, the analysis
workflow used to select synthetic
lethal candidates based on MCF10A
and CDH1!/! viability. C, correlation
between primary and secondary
screens. The dotted line marks where
CDH1!/! has 15% less viability than
MCF10A. The primary screen identified
500 candidates that were selected for
validation in a secondary screen. Five
percent of these validates aswith 3of 4
or 4 of 4 individual siRNA. D,
candidates tested in the secondary
screen were split into two categories,
based on the decrease in viability of
CDH1!/! compared with MCF10A.
Candidates with a greater differential
were more likely to be validated in the
secondary screen.
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the ratio of cell viability between the MCF10A and CDH1!/!
cells 72 hours after transduction (Fig. 1B). We rejected siRNAs
that were highly toxic to the MCF10A cells (a decrease in
viability of "50%) and selected those for which the viability
of CDH1!/! cells decreased by "15% more than the corre-
sponding knockdown in MCF10A cells. These targets were
classed as CDH1 synthetic lethal candidate genes (List SL1,
2,437 genes; Supplementary Table S1). From this set, 501 genes
were manually selected for secondary screening using criteria,
including predicted druggability of the encoded proteins and
biologic significance. The secondary screen was performed by
deconvoluting the four individual siRNAs that consititute the
SMARTpool. Using the same stringent threshold as the primary
screen (i.e., MCF10A viability "50% and "15% more death in
CDH1!/!), 21 genes (5%) had 3 of 4 or 4 of 4 of the individual
siRNAs show a synthetic lethal effect. One hundred eighty-three
genes (44%) had 1 of 4 or 2 of 4 siRNAs validated. Fifty-one
percent of genes were not validated (0/4) by this approach.
Division of the selected genes into groups based on the strength
of the synthetic lethal phenotype in the primary screen dem-
onstrated that candidates which showed a greater viability
differential between MCF10A and CDH1!/! cells were more
likely to be validated in the secondary screen (Fig. 1C and D).
Of the candidates that reduced CDH1!/! cell number by "25%
more than MCF10A cells, 12% validated with 3 of 4 or 4 of 4
individual siRNAs, a validation rate comparable with other
genome-wide RNAi studies (19, 20).
Functional diversity: gene ontology analysis
To search for functional enrichment in the 2,437 synthetic
lethal candidates identified in the primary screen (List SL1), we
conducted a gene ontology analysis using DAVID (21). Using the
Functional Annotation Clustering tool, the most enriched func-
tional cluster was a group of ten terms associated with G-protein–
coupled receptor (GPCR) signaling (enrichment score ¼ 10.01;
Supplementary Table S2A). Accordingly, the twomost significant
biologic process terms (Supplementary Table S2B) were "G-pro-
tein–coupled receptor protein signaling pathway" (Benjamini-
adjusted P value ¼ 4.1 $ 10!8) and "cell surface receptor linked
signal transduction" (adj. P value ¼ 1.7 $ 10!5). These cell
signaling processes were strongly reflected in the DAVID gene
ontology molecular function terms (Supplementary Table S2C)
which included peptide, neuropeptide, and purinergic nucleotide
receptor activity and protein kinase activity (adj. P value 3.5 $
10!7 to 3.2 $ 10!2).
Because our ultimate goal is to identify targeted drugs for E-
cadherin–deficient tumors that have minimal toxicity against
nonmalignant tissues, we also performed gene ontology analysis
on a subset of genes from List SL1 whose corresponding siRNA
SMARTpools had little or no impact on MCF10A cells (MCF10A
viability "0.85 mock). 1,136 genes met this revised threshold
(List SL2; Supplementary Table S3). Notably, this more stringent
cutoff led to further enrichment of both the GPCR-associated
functional cluster (enrichment score, 12.14) and the biologic
process terms "GPCR protein signaling pathway" (adj. P value
¼ 9.0$ 10!16) and "cell surface receptor linked signal transduc-
tion" (adj. P value ¼ 4.8 $ 10!10; Supplementary Table S2D).
Our earlier observation of abnormal cytoskeletal organization
in E-cadherin–deficientMCF10A cells (7) prompted us to look for
specific cytoskeletal functions associated with synthetic lethality.
Although the adjusted P values for cytoskeletal-like terms in List
SL1 and SL2 did not reach significance, DAVID functional clusters
associated with each of cell motility, cell polarity, and cell adhe-
sion were among the top five clusters observed in the group of
synthetic lethal candidate genes which reduced MCF10A viability
to <0.85 of themock controls (enrichment scores, 2.18, 1.97, and
1.84, respectively; Supplementary Table S2E). This greater repre-
sentation of cytoskeletal genes among synthetic lethal candidates
that seriously affect MCF10A cell viability presumably reflects the
essential role of many cytoskeletal proteins. Cyto- or nucleoske-
letal functions that were represented in List SL1, often bymultiple
family members, includedmicrotubule nucleation, organization,
and function (e.g., TUBA1C, TUBG1, TUBB2A, MZT2A, ARPC3,
NME4, NME7, MAST1, MAST2, MAST3, NEK1, NEK3, NEK4,
NEK10, CLIP1, CLIP2, TEKT3, TEKT4, TEKT5), Rho-mediated
motility (e.g., RHOB, RHOC, RHOH, RAC1, PAK2, TIAM1),
linkages between the cytoskeleton and nucleoskeleton (e.g.,
SUN1, SUN2, SUN5, NSUN3, NSUN6, SYNE1), polarity (e.g.,
DLG1, DLG2, DLG4, DLG5, CELSR1, CELSR3), and actin filament
organization and remodeling (e.g., AVIL, ARF6, CYTH2, CTYH3,
CYTH4).
E-cadherin–deficient MCF10A cells are sensitive to
downregulation of microtubule-associated genes and the
aurora kinase A inhibitor alisertib
To validate the apparent synthetic lethal interaction between
E-cadherin and the microtubule cytoskeleton, we selected three
microtubule-associated genes, MAST2, MAP1B, and MAPRE3
for confirmation using lentiviral shRNA knockdown. MAST2 is
a microtubule-associated serine–threonine kinase (22); MAP1B
is a microtubule-binding and -stabilizing protein that can also
interact with actin microfilaments (23) and MAPRE3 is a
microtubule plus end-binding protein involved in regulating
the dynamics of microtubules and their interactions with
intracellular structures such as the cell cortex or mitotic kinet-
ochore (24). These three genes had previously been validated in
the secondary screen, with 3 of 4, 2 of 4, and 1 of 4 siRNAs,
respectively, decreasing the viability of CDH1!/! cells by at
least 15% more than the MCF10A (Fig. 2A). shRNAs targeting
these three genes resulted in 51%–86% mRNA knockdown in
both cell lines (Fig. 2B). Seventy-two hours after transduction,
cell viability was measured using nuclei counting (Fig. 2C).
Knockdown of each of MAP1B, MAST2, and MAPRE3 resulted
in 15%–29% more cell death in the CDH1!/! cells compared
with the MCF10A cells, confirming the siRNA data.
To determine whether the synthetic lethal phenotype
observed with downregulation of microtubule-associated genes
could be recapitulated using known inhibitors of microtubule
function, we treated the isogenic MCF10A cell line pair with the
microtubule stabilizing drug taxol and inhibitors of the micro-
tubule-associated proteins aurora kinase A and aurora kinase B.
Increasing concentrations of taxol (1–16 nmol/L) led to a
small increase in cell death in CDH1!/! cells compared with
MCF10A cells (Supplementary Fig. S2). The aurora kinase A
inhibitor alisertib and the aurora kinase B inhibitor danusertib
both showed a minor synthetic lethal effect (Fig. 2D and E),
with 18% (at 25 nmol/L) and 12% (50 nmol/L) more death
in the CDH1!/! line, respectively. Together, the RNAi and
aurora kinase inhibitor data demonstrate that E-cadherin–defi-
cient MCF10A cells are more vulnerable to disruption of
specific microtubule-related functions than E-cadherin–expres-
sing MCF10A cells.
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lethal drugs were selected for further characterization if they met
two criteria: (i) modest toxicity to MCF10A cells (a decrease in
viability of no more than 30%) and (ii) a minimum of 15%
greater reduction in CDH1!/! viability compared with the
MCF10A cells at one or more concentrations. Three-hundred
sixteen compounds were selected for secondary analysis using
an 11 point serial dilution from10 mmol/L to 10 nmol/L. Twenty-
one of 316 compounds in this secondary screen had EC50 values
that were 10%–50% lower in the CDH1!/! cells compared with
the MCF10A cells (Table 1). These included multiple histone
deacetylase (HDAC) and PI3K inhibitors, crizotinib (an inhibitor
of receptor tyrosine kinases c-MET, ALK, and ROS1), CGP 71683
hydrochloride (an inhibitor of the neuropeptide receptorNPY5R)
and the guanine nucleotide exchange factor inhibitor Brefeldin A.
The synthetic lethality of the majority of drug classes shown
in Table 1 was supported by the siRNA primary screen data with
one or more targets (or associated proteins) for each being
included in List SL1 (Supplementary Table S4).
The E-cadherin synthetic lethal effects of crizotinib and several
HDAC inhibitors were further characterized in time course and
direct cell counting studies. Saracatinib, a c-SRC kinase inhibitor
not included in the 11-point screen was also further examined
because of a borderline effect in the original four-point screen.
Crizotinib had little effect on the growth of MCF10A cells at 0.63,
1.25, and 2.50 mmol/L up to 48 hours after drug addition, as
observed using the xCELLigence system. The same concentrations,
however, reduced the growth of CDH1!/! cells to 86%, 76%, and
46%ofmock (Fig. 4A).Nuclei counting at 48hours confirmed the
synthetic lethal effect, although an inhibitory effect was observed
on the MCF10A cells at all three concentrations (Fig. 4B). The
difference between the nuclei counting method and the IncuCyte
and xCELLigence methods is primarily due to cell density differ-
ences at full confluency that can only be determined by direct
nuclei counting.
Treatment with saracatinib caused greater growth inhibition in
the CDH1!/! cells compared with the MCF10A cells at three
different concentrations in two different assay systems, cell con-
fluence (IncuCyte) and direct nuclei counting. In the IncuCyte
system, a dose-dependent inhibition was observed in both iso-
genic cells with the CDH1!/! cells demonstrating greater suscep-
tibility (Fig. 4C). At 0.63 mmol/L, saracatinib had negligible effect
on the confluence ofMCF10A cells but caused a26% inhibition of
CDH1!/! cells (relative to DMSO) after 48 hours. Similarly,
differentials of 0.17 (P ¼ 0.06), 0.30 (P ¼ 0.02), and 0.15 (P
¼ 0.10) were observed in normalized cell counts of the CDH1!/!
cells compared with the MCF10A cells at saracatinib concentra-
tions of 0.63, 1.25, and 2.5 mmol/L, respectively (Fig. 4D).
Entinostat selectively targets class I HDACs, in particular
HDAC1–3 (26). The 0.63, 1.25, and 2.5 mmol/L entinostat had
a negligible effect on cell proliferation of MCF10A as determined
using the xCELLigence system. In contrast,CDH1!/! cells showed
18%, 67%, and 78% growth inhibition at these concentrations 48
hours after drug addition (Fig. 4E). Comparable results were
obtained using the IncuCyte (Supplementary Fig. S3). Nuclei
counting also showed a significant synthetic lethal effect across
the three entinostat concentrations, although, as observed previ-
ously for crizotinib, reduced nuclei count was observed in both
cell lineswith increasing drug concentrationusing thismore direct
method. At concentrations of 0.63, 1.25, and 2.5 mmol/L, a cell
viability differential of 0.13 (P¼ 0.04), 0.23 (P¼0.004), and0.14
(P ¼ 0.02) was observed between the CDH1!/! cells and the
MCF10A cells (Fig. 4F).
Vorinostat (SAHA) is a pan-HDAC inhibitor, acting on both
class I and class II HDACs (26). Assays using the IncuCyte system
showed preferential inhibition ofCDH1!/! cells over 48 hours of
drug treatment at 0.63, 1.25, and 2.5 mmol/L, with little effect on
the MCF10A cells (Fig. 4G). This effect was confirmed on the
xCELLigence system (Supplementary Fig. S3). Similar to entino-
stat, direct nuclei counting showed a greater effect of vorinostat on
the MCF10A cells than was observed using the real-time prolif-
eration assay platforms. A significant cell viability differential was
still observed between the CDH1!/! and MCF10A cells with cell
Table 1. Known drugs with greater inhibitory effect on CDH1!/! cells compared with MCF10A cells








Mocetinostat HDAC inhibitor 1.76 1.02 0.58
Entinostat HDAC inhibitor 4.31 2.50 0.58
Quisinostat HDAC inhibitor 0.05 0.04 0.72
Pracinostat HDAC inhibitor 0.73 0.54 0.74
LAQ824 HDAC inhibitor 0.09 0.06 0.76
Panobinostat HDAC inhibitor 0.08 0.07 0.84
Crizotinib ROS1-like tyrosine kinase inhibitor 5.53 3.98 0.72
PI103 PI3K inhibitor 0.75 0.59 0.79
GSK2126458 PI3K inhibitor 0.05 0.04 0.79
PIK-75 hydrochloride PI3K inhibitor 0.08 0.07 0.89
CGP 71683 hydrochloride NPY5R inhibitor 3.92 3.47 0.89
Tyrphostin A9 PDGFR and EGFR inhibitor 1.30 0.65 0.50
AZD8055 mTOR inhibitor 0.22 0.12 0.53
Obatoclax Mesylate BCL2 inhibitor 0.63 0.47 0.74
Brefeldin A Guanine nucleotide exchange factor inhibitor 0.20 0.15 0.76
LY2784544 JAK family inhibitor 5.64 4.70 0.83
FCCP uncoupler of mitochondrial oxidative phosphorylation 3.74 2.90 0.78
JNJ-7706621 CDK and aurora kinase inhibitor 3.37 2.77 0.82
Danusertib Inhibitor of aurora kinases, Bcr-Abl, c-RET, and FGFR 1.25 1.07 0.86
PD-166285 hydrate Broad-spectrum tyrosine kinase inhibitor 0.66 0.58 0.88
10-DEBC hydrochloride AKT/protein kinase B inhibitor 8.10 7.26 0.90
NOTE: EC50 valueswere obtained from 11-point dilution curves carried out in duplicate. Cell viabilitywas determined using the CellTiter-Glo assay 48 hours after drug
addition. The CDH1!/! to MCF10A ratio is a measure of the reduced viability of the CDH1!/! cells in the presence of drug.
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E-cadherin–deficient MCF10A cells show vulnerabilities in
GPCR signaling
Gene ontology analysis (21) identified >200 genes fromour list
of synthetic lethal candidates (List SL1) that were associated with
GPCR protein signaling pathways. These candidates included
several proteins involved in signal transduction from activated
GPCRs such as theG protein subunits GNAS, GNAT1, GNG2, and
GNG5, the membrane bound adenyl cyclase ADCY7 and the
downstream signaling protein JAK2. ADCY7 validated in the
secondary screen with 4 of 4 siRNAs recapitulating the SMART-
pool phenotype (Fig. 3A). The synthetic lethal effect of the JAK2
siRNA SMARTpool was confirmed using lentiviral-mediated
shRNA transduction. Both the siRNA SMARTpool and lentiviral
shRNA knocked down JAK2 mRNA by >44% (Fig. 3B). Normal-
ized cell numbers after transduction were significantly lower in
the CDH1!/! cells compared with the MCF10A cells for both the
siRNA pool and the shRNA (Fig. 3C). To determine whether the
synthetic lethality of JAK2 downregulation could be mimicked
using a JAK2 antagonist, we treated the isogenic CDH1 MCF10A
cell line pair with the JAK inhibitor LY2784544. Using the xCEL-
Ligence system to monitor cell growth in real time, LY2784544
had only a modest effect on MCF10A cells at 0.32, 0.63, and 1.25
mmol/L concentrations; however, the cell proliferation index was
reduced in the CDH1!/! cells in a concentration-dependent
manner. Forty-eight hours after drug addition, the three con-
centrations of LY2784544 resulted in a 15%, 29%, and 51%
reduction in CDH1!/! cell number, respectively (Fig. 3D). In
contrast, the three drug concentrations reduced MCF10A cell
number by 0%, 11%, and 10%, respectively. A second JAK2
inhibitor, AG490, showed a similar synthetic lethal response
in xCELLigence assays (data not shown). Further real-time
assays using the IncuCyte replicated this effect (Supplementary
Fig. S3). Nuclei counting confirmed a significant synthetic
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proteins induces synthetic lethal
effect. A, bar graphs with primary and
secondary screen viability normalized
to mock for MAST2, MAP1B, and
MAPRE3. Each value is the average of
two technical replicates. The
arrowheadsmark siRNAs that reached
the synthetic lethal criteria (15% less
viability in CDH1!/! cells). B, level of
mRNA knockdown 72 hours after
transduction with shRNA lentivirus
constructs. Error bars show SE of two
independent experiments, except for
MAST2 which was only assayed once.
C, nuclei count normalized to
nonsilencing control after knockdown
with MAP1B, MAST2, and MAPRE3
shRNA. Error bars show SE of two
independent experiments. " , P < 0.05
by one-tailed, equal variance Student
t test. D, nuclei count normalized to
DMSO control 48 hours after alisertib
treatment. Error bars showSEMof two
independent experiments. E, nuclei
count normalized to DMSO control
48 hours after danusertib treatment.
A single experiment is shown.
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(P ¼ 0.005) and 0.63 mmol/L (P ¼ 0.03) (Fig. 3E). LY2784544
resulted in cells becoming more spindle shaped, with an
increased number of extended filopodia; this effect was partic-
ularly marked in the CDH1"/" cells (Fig. 3F).
The presence of G protein subunits in list SL1 prompted us
to examine CDH1 synthetic lethality using the Gai and Gao
subunit inhibitor Pertussis toxin (25). Treatment of MCF10A
and CDH1"/" cells with 10, 100, and 200 ng/mL of Pertussis
toxin over a period of 48 hours resulted in growth inhibition of
both MCF10A and CDH1"/" cell lines in a concentration-depen-
dent manner (Fig. 3G). However, the MCF10A cells recovered
and reached the same confluence as the PBS control after 48
hours, whereas the CDH1"/" cells showed 20%–30% less con-
fluence at that time point for the three drug concentrations.
E-cadherin loss sensitizes MCF10A cells to HDAC inhibitors
and other drug classes
To explore how E-cadherin loss alters sensitivity of MCF10A
cells to other knowndrugs, we screened 4,057 compounds against
the CDH1 MCF10A isogenic cell line pair. The compounds
comprised the WEHI known drug library (3,600 compounds
from the Tocriscreen Total library, the Prestwick Chemical Library
and the "Lopac 1280" library), the Selleck Chemistry inhibitor
library (326 compounds consisting of approximately half known
drugs and half kinase inhibitors) and a kinase inhibitor library
(131 compounds supplied by SYNthesis Medicinal Chemistry).
The initial screen covered four drug concentrations ranging from
0.25 to 2 mmol/L, with cell viability measured at 48 hours after
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proteins causes synthetic lethality.
A, bar graphs with primary and
secondary screen viability normalized
to mock for ADCY7. Each value is the
average of two technical replicates. All
siRNA reached the synthetic lethal
criteria. B, normalized mRNA levels
after knockdown by JAK2 shRNA and
siRNA pool. C, nuclei counts
normalized to nonsilencing (shRNA)
or mock (siRNA) controls after
knockdown by JAK2 RNAi. D,
representative xCELLigence
experiment for cells treated with
LY2784544. Arrow marks time when
compound was added. E, nuclei count
normalized to DMSO 48 hours after
LY2784544 treatment. F, images
taken 48 hours after LY2784544
treatment showing reduced
confluence and morphologic changes.
G, representative IncuCyte assay
showing confluence over 48 hours
after Pertussis toxin treatment. Error
bars show SE of at least two
independent experiments. # , P < 0.05;
## , P < 0.01 by the one-tailed, equal
variance Student t test.
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viability differentials of 0.21 (P¼ 0.02), 0.29 (P¼ 0.01), and 0.17
(P ¼ 0.10) between CDH1"/" and MCF10A at concentrations of
0.63, 1.25, and 2.5 mmol/L (Fig. 4H). The HDAC inhibitors
mocetinostat andpracinostat showed comparable synthetic lethal
effects when assayed at 0.63, 1.25, and 2.5 mmol/L on the
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Treatment with various known drugs
causes CDH1 synthetic lethality. A and E,
representative xCELLigence assay of
cells treated with crizotinib (A) and
entinostat (E). Cells were seeded at
4,000 or 2,000 (crizotinib) cells per well
and drug was added at 24 hours. Cells
were grown for an additional 72 hours.
C andG, representative IncuCyte assays of
cells treated with saracatinib (C) and
vorinostat (G). Cellswere seeded at 4,000
cells per well and drug was added at
24 hours. Cells were then grown for an
additional 48 hours. B, D, F and H, nuclei
counts normalized to DMSO after
treatment with crizotinib (B), saracatinib
(D), entinostat (F), and vorinostat (H).
Error bars show SE of at least two
independent experiments. #, P < 0.05;
##, P < 0.01 determined by the one-tailed,
equal variance Student t test.
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I/II HDAC inhibitor valproic acid also showed a minor synthetic
lethal effect when assayed by direct nuclei counting (Supplemen-
tary Fig. S4C).
Previous reports of synergy betweenHDAC inhibitors and taxol
(27–30) prompted us to test combinations of taxol and each of
vorinostat and entinostat in our isogenic cell line pair. CompuSyn
(ComboSyn Inc) was used to calculate EC50 concentrations, and
to determine the Combination Index. In contrast to other studies,
we found no evidence for synergy between taxol and these HDAC
inhibitors (Supplementary Fig. S2).
Discussion
Synthetic lethality provides a potentialmethod to target cancers
carrying inactivatingmutations in tumor suppressor genes such as
the E-cadherin gene, CDH1. To provide an initial survey of E-
cadherin's synthetic lethal interactions, we conducted a genome-
wide functional screen of nonmalignant, isogenic MCF10A cells
with and without E-cadherin expression. Thirteen percent of the
18,120 genes in the siRNA screen met our threshold for synthetic
lethality of at least 15% more death in the CDH1!/! cells than the
wild-type MCF10A cells. Although this threshold is low stringency
and subsequently not highly specific, it is clear that E-cadherin
deficiency creates large numbers of vulnerabilities in nonmalignant
cells which are exposed by genetic knockdown of additional genes.
Gene ontology analysis identified a striking enrichment for
GPCR signaling proteins among the synthetic lethal candidates.
Notably, this enrichment was greater for hits that showed min-
imal impact on the viability of the E-cadherin–expressing
MCF10A cells, suggesting that drug targeting of GPCR signaling
in CDH1-mutant tumors may be a means to obtain clinical gain
whileminimizing collateral damage to normal tissues. The nature
of the synthetic lethal relationship between E-cadherin andGPCR
signaling is not yet known, although the functional diversity of the
candidate synthetic lethal GPCR signaling proteins would suggest
that the interaction involves a common downstream mechanism
such as interplay with the actin and microtubule cytoskeletons
(31–33). The importance of cytoskeletal functions to the E-cad-
herin synthetic lethal phenotype is supported by the abundance of
cytoskeletal genes associated with synthetic lethality in our pri-
mary siRNA screen. These genes were involved in all aspects of
cytoskeletal function, including the nucleation, organization, and
function of microtubules mitotic spindle organization and con-
trol, linkages between the cytoskeleton andnucleoskeleton, polar-
ity, actin filament organization, vesicle transport, focal adhesion
kinase signaling, and Rho-mediated motility (8, 34–36). The
increased vulnerability of E-cadherin–deficient MCF10A cells to
knockdown of so many diverse but inter-related functions is
consistent with the widespread disorganization of cytoskeletal
networks observed in theCDH1!/! cells (7). Notably, afterCDH1
and TP53, RHOA is the most commonly mutated gene in DGC
(37–39), emphasizing the importance of dysregulated cytoskel-
etal function to development of the diffuse phenotype.
The increased vulnerability of E-cadherin–deficient MCF10A
cells to RNAi knockdown of cytoskeletal and GPCR signaling
genes was supported by the increased sensitivity of these cells to
antagonists of multiple protein families associated with GPCR
signaling and cytoskeletal function, including HDACs (40, 41),
JAK (42), aurora kinases (43), c-SRC tyrosine kinase (44), G-
protein subunits and PI3K (45). The enrichment for GPCR sig-
naling genes among our synthetic lethal candidates does not,
however, exclude the possibility that other signaling functions,
such as the cytokine responses of JAK2, may also be associated
with synthetic lethality. EC50 differences between MCF10A and
CDH1!/! cells for these known drugs were on average only
approximately 25% less in the CDH1!/! cells. This small differ-
ential is to be expected as neither MCF10A or CDH1!/! cells are
tumorigenic and therefore these lines cannot be distinguished by
the presence/absence of addiction to the targeted pathways.
Synthetic lethal drugs which are significantly more potent in E-
cadherin–deficient cells will be more readily identified using fit-
for-purpose, high-throughput compound screens across the
MCF10A and other CDH1 isogenic cell line pairs. Differences
between the E-cadherin–expressing and E-cadherin–deficient
cells may also be more pronounced in phenotypes other than
cell viability, such as invasive capability.
This research demonstrates for the first time that loss of the
tumor suppressor protein E-cadherin creates druggable vulner-
abilities in cells. It remains to be determined whether any of the
observed drug sensitivities in CDH1!/! cells will be robust to the
genetic dysregulation of advanced tumors, and therefore able to
provide additional clinical benefit in the treatment of sporadic
CDH1-mutant tumors. Instead, the observed sensitivities may
havemore near termapplication toHDGCchemoprevention. The
natural history of cancer development in CDH1 germline muta-
tion carriers involves the development of multifocal lobular
carcinoma in situ (46, 47) and tens to hundreds of gastric stage
T1asignet ring cell carcinomasbefore theonsetof advanceddisease
(11, 48, 49). The high multiplicity of these early stage foci argues
against additional genetic hits being required for their initiation.
These early breast and gastric cancers are therefore relatively
genetically homogenous and distinguished from normal tissue
predominantly by the cellular changes associated with deficiency
of E-cadherin. As a consequence, the E-cadherin synthetic lethal
interactions identified in the nonmalignant breast MCF10A cells
provide strong leads for drugs that may eliminate early-stage
disease in germlineCDH1mutation carriers, potentially providing
a new clinical management option for HDGC families.
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In vitro viability assays are essential tools for drug develop-
ment, allowing for the assessment of drug efficacy prior 
to subsequent in vivo analyses. Whether performed as a 
single-plate experiment or as part of a high-throughput screen, 
the concept remains the same—cells are incubated with a 
particular compound(s), then assessed for viability to quan-
tify drug-induced cell toxicity.
Numerous commercial cell viability assays that exploit dif-
ferent cellular processes to quantify cytotoxicity are now avail-
able, each highlighting the variability that can be obtained 
from different methodologies.1–3 Consequently, the selection 
and application of an effective assay(s) should be a major con-
sideration in any drug-based experimental design.
A widely used approach to determine drug-induced cyto-
toxicity involves measuring cellular metabolic activity at the 
conclusion of an experiment. Such approaches include the 
3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bro-
mide (MTT) assay, resazurin reduction, and the CellTiter-Glo 
assay, each using a different aspect of cellular metabolism as 
a means of quantifying live cells. The MTT assay relies on 
the mitochondrial activity of live cells to convert a yellow 
MTT substrate into purple formazan crystals, detectable via 
spectrophotometry.4 The resazurin reduction assay, used in 
alamarBlue and CellTiter-Blue assays, is a more sensitive 
alternative to MTT and uses the intracellular reduction poten-
tial of living cells to convert resazurin to the fluorescent 
product resorufin.5 CellTiter-Glo adopts the use of firefly 
luciferase, which reacts with available cellular adenosine tri-
phosphate (ATP) to produce a bioluminescent signal propor-
tional to the number of live cells present in the assay.6 The 
nuclei counting method, which is a direct measure of viabil-
ity, is considered to be the most accurate;1 however, the ease 
of mix-and-measure metabolic-based approaches makes 
them a common feature in high-throughput drug screens.
Unlike endpoint approaches, real-time assay systems 
allow for the tracking of cellular growth over the entire time 
course of an experiment. This is particularly effective for 
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A Comparison of Real-Time and Endpoint 
Cell Viability Assays for Improved Synthetic 
Lethal Drug Validation
Andrew Single1, Henry Beetham1, Bryony J. Telford1,  
Parry Guilford1, and Augustine Chen1
Abstract
Cell viability assays fulfill a central role in drug discovery studies. It is therefore important to understand the advantages 
and disadvantages of the wide variety of available assay methodologies. In this study, we compared the performance of 
three endpoint assays (resazurin reduction, CellTiter-Glo, and nuclei enumeration) and two real-time systems (IncuCyte 
and xCELLigence). Of the endpoint approaches, both the resazurin reduction and CellTiter-Glo assays showed higher 
cell viabilities when compared directly to stained nuclei counts. The IncuCyte and xCELLigence real-time systems were 
comparable, and both were particularly effective at tracking the effects of drug treatment on cell proliferation at sub-
confluent growth. However, the real-time systems failed to evaluate contrasting cell densities between drug-treated and 
control-treated cells at full growth confluency. Here, we showed that using real-time systems in combination with endpoint 
assays alleviates the disadvantages posed by each approach alone, providing a more effective means to evaluate drug 
toxicity in monolayer cell cultures. Such approaches were shown to be effective in elucidating the toxicity of synthetic 
lethal drugs in an isogenic pair of MCF10A breast cell lines.
Keywords
cell-based assays, imaging technologies, label-free technologies, multiplex assays and technology
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assessing the impact of cytostatic compounds, where subtle 
growth inhibitory effects are easily noticeable but may be 
missed using endpoint-based methods. Real-time assays are 
typically performed using equipment capable of capturing 
images at regular intervals and quantifying cellular surface 
area coverage as a measure of proliferation (e.g., IncuCyte 
FLR; Essen BioScience, Ann Arbor, MI). Such methods 
also facilitate visualization of drug-induced cell morphol-
ogy changes. Alternatives to this approach include the 
xCELLigence (ACEA Biosciences, San Diego, CA), which 
uses electrical impedance to measure both cellular adhesion 
strength and surface area coverage as a combined proxy of 
cellular proliferation.
In this study, we compared the performance of five dif-
ferent cell-based viability assays. Three endpoint assays 
(resazurin reduction, CellTiter-Glo, and nuclei enumera-
tion) and two real-time assays (IncuCyte and xCELLigence) 
were used to investigate the effectiveness of each approach 
for the validation of candidate synthetic lethal drugs in an 
isogenic pair of MCF10A breast cell lines.
Materials and Methods
Cell Culture
MCF10A and the derived CDH1-negative isogenic line 
(MCF10A CDH1−/−) were purchased from Sigma-Aldrich (St. 
Louis, MO). Cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM)/F12 (1:1; Life Technologies, 
Carlsbad, CA) with 5% horse serum (Life Technologies), 10 
µg/ml insulin (Novo Nordisk Pharmaceuticals Ltd, Bagsvaerd, 
Denmark), 20 ng/ml human epidermal growth factor 
(Peprotech, Rocky Hill, NJ), 100 ng/ml cholera toxin (Sigma-
Aldrich), and 500 ng/ml hydrocortisone (Sigma-Aldrich).7 The 
cells were cultured in exponential growth phase at 37 °C and 
5% CO2.
7,8 An isogenic MCF10A cell line pair was selected to 
demonstrate drug-induced synthetic lethal phenotypes against 
CDH1 in a nonmalignant cell background.
Vorinostat was purchased from SelleckChem (Houston, 
TX), and paclitaxel (Taxol) was purchased from Sigma-
Aldrich. Both drugs were reconstituted in 100% DMSO, stored 
at −80 °C, and individual aliquots were diluted to working 
stocks in complete growth medium prior to use in an experi-
ment. Vorinostat, a histone deacetylase inhibitor, was selected 
because it has previously demonstrated selective lethality 
toward CDH1-deficient MCF10A cells.9 Taxol was chosen as 
a chemotherapeutic agent that demonstrated nondiscriminate 
lethality in the MCF10A isogenic cell line pair.
Endpoint Assays
MCF10A and MCF10A CDH1−/− cells were seeded 
at 4×103 cells per well in 96-well, black-walled, clear- 
bottomed tissue culture plates (Corning, Corning, NY) in 
100 µL complete growth medium and left to equilibrate at 
room temperature for 30 min before incubation at 37 °C. 
After overnight incubation, cells were treated in triplicate 
with drug or DMSO for controls. Endpoint assays were per-
formed at 48 h post drug treatment. For resazurin reduction 
assays, resazurin (Sigma-Aldrich) was made to 440 µM 
stock solutions in phosphate buffered saline (PBS) and ali-
quoted for storage at −20 °C. Resazurin solution was added 
to cells at 20% final concentration, and plates were incu-
bated for 3 h at 37 °C prior to reading fluorescence at 550 
nm excitation and 590 nm emission using a POLARstar 
Optima (BMG Labtech, Ortenberg, Germany). For lumi-
nescent assays, CellTiter-Glo (Promega, Madison, WI) was 
added at 20% final concentration. Earlier optimization had 
shown this concentration to consistently reproduce the 
manufacturer’s recommended 1:1 vol/vol ratio (results not 
shown). Luminescent readings were obtained using a 
POLARstar Optima after 10 min incubation at room tem-
perature with shaking. For nuclei counting assays, Hoechst 
33342 (Life Technologies) was added at 1 µg/mL final con-
centration and incubated for 30 min in the dark at 37 °C 
with shaking. Plates were then imaged at four fields per 
well under 4× magnification using the Cytell Cell Imaging 
System (GE Healthcare, Buckinghamshire, United 
Kingdom), and imaged nuclei were enumerated using 
CellProfiler10 to obtain a total cell count. For direct com-
parison between total cell count and measured confluency 
performed in the IncuCyte FLR, SYTOX (Life Technologies) 
was used in place of Hoechst for nuclei enumeration 
because this IncuCyte model only has a single, green fluo-
rescence filter. A one-step, no-wash, mild permeabilization 
and fixation protocol was adopted from Chan et al. (2013),1 
using a final concentration of 0.25% paraformaldehyde, 
0.075% saponin, and 10 nM SYTOX. Because the SYTOX 
dye stains only membrane-compromised cells, permeabili-
zation was required to obtain a total cell count.
xCELLigence Assays
Experiments conducted on the RTCA-MP xCELLigence 
system (ACEA Biosciences, San Diego, CA) were per-
formed in accordance with the instructions of the supplier. 
Complete growth medium (100 µL) was added into each 
well of the E-plate 96 (ACEA Biosciences), followed by a 
brief background impedance measurement on the RTCA-MP 
station. MCF10A and MCF10A CDH1−/− cells were seeded 
at 4×103 cells per well in 100 µL complete growth medium, 
and, after 30 min equilibration at room temperature, the 
E-plate was placed in the RTCA-MP station. The RTCA-MP 
station was housed in a humidified cell culture incubator at 
37 °C and 5% CO2. Cell proliferation, as determined by 
electrical impedance, was recorded at 15-min intervals. 
After overnight incubation, the assay was paused, 10 µL 
medium was removed from each well, and cells were treated 
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with 10 µL drug or 0.1% DMSO for controls. The assay was 
then resumed, taking impedance measurements every 15 
min for a further 48 h. All xCELLigence experiments were 
performed in duplicate.
IncuCyte Assays
MCF10A and MCF10A CDH1−/− cells were seeded at 
4×103 cells per well in 96-well, black-walled, clear- 
bottomed, tissue culture plates in 100 µL complete growth 
medium and left to equilibrate at room temperature for 30 
min before 37 °C, 5% CO2 incubation. After overnight incu-
bation, cells were treated with 10 µL drug or 0.1% DMSO 
for controls, and the plate was inserted into the IncuCyte 
FLR for real-time imaging, with three fields imaged per 
well under 4× magnification every 2 h for a total of 48 h. 
Data were analyzed using the IncuCyte Confluence version 
1.5 software, which quantified cell surface area coverage as 
confluence values. All IncuCyte experiments were per-
formed in triplicate.
Results and Discussion
Metabolic and Nuclei-Counting Endpoint Assays
First, we compared the performance of two metabolic-based 
assays alongside a nuclei-counting one. The resazurin reduc-
tion and CellTiter-Glo assays were chosen ahead of the MTT 
assay because previous studies have reported reduced sensitiv-
ity with MTT compared to other endpoint methods.11,12 To 
compare the efficacy of each assay, MCF10A and MCF10A 
CDH1−/− cells were treated with vorinostat for 48 h 
and assessed for cell viability using each method. A dose-
dependent effect was observed in all three methods with 
increasing vorinostat concentration in both cell lines. In both 
MCF10A and MCF10A CDH1−/− cells, 0.63 µM vorinostat 
treatment showed negligible viability inhibition with no 
marked differences observed between the two metabolic 
assays. At dosages of 1.25 and 2.5 µM vorinostat, however, the 
CellTiter-Glo assay gave significantly higher viabilities than 
the resazurin reduction assay (P < 0.05; Fig. 1A). Both meta-
bolic-based approaches gave significantly higher viabilities 
than the nuclei-counting approach for all three vorinostat con-
centrations in both cell lines (P < 0.05; Fig. 1A), suggesting 
that resazurin reduction and CellTiter-Glo were overrepresent-
ing cell viability. In addition, viability as measured by nuclei 
counting was more comparable to that measured using resa-
zurin reduction, suggesting CellTiter-Glo gave less sensitivity 
to the other endpoint methodologies for cells treated with vori-
nostat. This is contrary to previous literature reports, which 
indicate that CellTiter-Glo can provide higher sensitivity than 
resazurin-based assays.13,14
In addition to reduced sensitivity, the two metabolic 
assays also have other potential limitations. For example, 
the resazurin reduction assay requires a 37 °C incubation 
step of several hours, which has been reported to cause mor-
phological changes in cells.13 However, we did not observe 
resazurin-induced morphology changes in both cell lines 
(data not shown). In comparison, CellTiter-Glo, which has 
a shorter incubation phase to permeabilize cells and release 
their ATP for measurement, has a considerably greater cost, 
which can be a drawback in high-throughput screening. 
Furthermore, it is possible that drugs affecting cellular met-
abolic processes could interfere with the performance of 
both the resazurin reduction and CellTiter-Glo assays, giv-
ing rise to inaccurate viability measurements.2
Overall, the nuclei-counting method is still considered to 
be the most accurate measure of cell viability.1 However, its 
application to high-throughput screening requires efficient 
automated imaging systems with built-in enumeration soft-
ware, which can be cost prohibitive. Fortunately, more 
affordable entry-level systems, such as the Cytell (GE 
Healthcare, Buckinghamshire, UK), Cytation 5 (BioTek, 
Winooski, VT), and EVOS (Thermo, Waltham, MA), are 
available to provide such technologies at a reduced cost. 
Alternatively, more standard imaging systems without 
accompanying enumeration software can be used with free 
open-sourced applications such as ImageJ15 or CellProfiler.10
Real-Time Assays
To complement the endpoint assays, real-time IncuCyte and 
xCELLigence assays were performed on MCF10A and 
MCF10A CDH1−/− cell lines treated with vorinostat over 48 
h (Fig. 1B and 1C). The IncuCyte uses automated imaging 
to determine cellular confluence at designated intervals 
over the time course of an experiment as a measure of via-
bility. The xCELLigence uses gold-plated plates to measure 
cell surface area coverage and adhesion strength via electri-
cal impedance, combining these factors as a measurement 
of cell viability.
From the IncuCyte and xCELLigence platforms, both 
cell lines showed a dose-dependent inhibitory response to 
vorinostat, although this effect was more pronounced in 
MCF10A CDH1−/− cells (Fig. 1B and 1C). To compare the 
two real-time systems, we determined the proliferation rate 
at logarithmic growth phase (taken from 12 to 36 hours post 
drugging in Fig. 1B and 1C) between control and drug 
treatment within the respective MCF10A and MCF10A 
CDH1−/− cells. In both systems, the proliferation rates of 
vorinostat-treated MCF10A cells were quite comparable 
and differed by no more than 10% across each tested con-
centration (Fig. 1D). MCF10A CDH1−/− cells showed 
slower proliferation rates in the xCELLigence than in the 
IncuCyte. From 0.63 and 1.25 µM vorinostat doses, 24% 
and 53% smaller measurements were observed, respec-
tively (Fig. 1D). This difference could possibly be attrib-
uted to the compromised adhesion previously characterized 
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in MCF10A CDH1−/− cells,8 which may have been further 
exacerbated by vorinostat treatment. As a result, the xCEL-
Ligence, which measures adhesion impedance, would have 
registered a greater reduction in MCF10A CDH1−/− cell 
viability compared to the IncuCyte, which is incapable of 
detecting adhesion strength. MCF10A cells showed no 
marked difference between the two systems, presumably 
because this cell line does not exhibit compromised cellular 
adhesion.8 Unfortunately, the gold-plated xCELLigence 
plates used in this study lacked clear bottoms, which pre-
vented imaging analysis. Newer E-plates with partially 
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Figure 1. Comparison 
of endpoint and real-time 
cell viability assays. (A) 
A comparison of three 
different endpoint assays 
(resazurin reduction, 
CellTiter-Glo, and 
Hoechst stained nuclei 
counting) based on their 
cell viability measurements 
normalized to their 
respective DMSO-treated 
controls in MCF10A and 
MCF10A CDH1−/− cells. A 
comparison of real-time 
viability measurements 
in MCF10A and 
MCF10A CDH1−/− cells 
as determined using (B) 
the IncuCyte system, 
which uses cell surface 
confluence, and (C) the 
xCELLigence system, 
which measures cellular 
surface area coverage and 
adherence strength. (D) A 
comparison of proliferation 
rates between the two 
real-time systems as 
determined at logarithmic 
growth phase (between 
12 to 36 hours post 
treatment from B and C). 
The depicted proliferation 
rates are normalized to 
DMSO-treated controls. 
Endpoint assays represent 
averaged values of three 
biological replicates with 
standard error shown; a 
representative experiment 
of each real-time assay is 
shown. P-values calculated 
using Student’s t-test; * P < 
0.05; ** P < 0.01.
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available; however, these were not released prior to our 
investigation. Conversely, the IncuCyte system was able to 
provide images that showed no substantial morphological 
changes over the time course of vorinostat treatment in both 
cell types (Fig. 2A). Overall, both real-time platforms 
showed comparable performance, except for measuring 
MCF10A CDH1−/− cells treated with 0.63 µM vorinostat.
At the conclusion of each assay, both real-time platforms 
showed that vorinostat-treated MCF10A cells had achieved 
viability values very similar to those of DMSO-treated con-
trols (Fig. 1B and 1C). This was contrary to data from our 
endpoint methods (Fig. 1A), which had shown that each vori-
nostat concentration had produced lower viabilities than con-
trol-treated cells, particularly in the nuclei-counting assay. A 
closer inspection of representative phase-contrast and fluo-
rescent images from the IncuCyte revealed an observable 
difference in cell density between control and vorinostat-
treated MCF10A cells (Fig. 2A and 2C). Even though both 
control and vorinostat (1.25 µM) treated MCF10A cells 
showed full growth confluence covering the entire surface 
area of each respective well (Fig. 2B), subsequent nuclei 
counting confirmed significant differences in cell num-
bers, whereby 39% fewer cells were present following 
drug treatment compared to control treatment (Fig. 2C). 
This key observation demonstrated the IncuCyte’s inabil-
ity to discriminate between differing cellular densities 
when cells had covered the entire surface area of their respec-
tive wells. As such, caution should be taken when analyzing 
data at full cellular confluence because further validation is 
required from direct cell counting. Nevertheless, the IncuCyte 
still produced valuable data during sub-confluent growth 
phases, which was comparable to nuclei-counting data (data 
not shown). These results demonstrate that a combination 
of distinct methodologies provides a more comprehensive 
and accurate assessment of drug efficacy than singular 
assays.
Real-Time Assay and Endpoint Assay 
Multiplexing
To mitigate the shortfalls observed in the endpoint and real-
time assays, we combined the IncuCyte real-time assay 
with both the resazurin reduction and nuclei-counting 
assays. The resazurin reduction and nuclei-counting meth-
ods were selected as endpoint assays because they have 
been reported to multiplex together effectively.16 This mul-
tiplexed approach also allowed for more data to be gathered 
from one drug-treated experiment. We also wanted to inves-
tigate if the combined approach was capable of evaluating 
synthetic lethal properties of two different drugs, in which 
assay sensitivity is essential to distinguish preferential tar-
geting of one cell type over another. In this case, a synthetic 
lethal effect would involve the selective growth inhibition 
of MCF10A CDH1−/− cells but not MCF10A cells. To test 
this, we subjected MCF10A and MCF10A CDH1−/− cells to 
either vorinostat or Taxol treatment over 48 hours, with cel-
lular growth being tracked in the IncuCyte, followed by 
resazurin reduction and nuclei counting at the conclusion of 
the real-time analysis.
At 48 h following vorinostat treatment (0.63, 1.25, 2.5 
µM), the confluence measurements from the IncuCyte 
showed that MCF10A cells were marginally inhibited and 
proliferated similarly to control treated cells (Fig. 3A). 
However, in MCF10A CDH1−/− cells, a significant dose-
dependent inhibitory response was observed in which drug-
treated cells did not reach the confluency of control-treated 
cells (Fig. 3B). Following the IncuCyte assay, the same 
plate was then subjected to the resazurin reduction assay. 
Increasing vorinostat treatment caused a more marked 
reduction in MCF10A CDH1−/− cell viabilities (93%, 71%, 
and 43%; Fig. 3E) compared to the corresponding MCF10A 
treated cells (98%, 83%, 55%; Fig. 3E). Similarly, the 
nuclei-counting analysis, performed immediately after the 
resazurin reduction assay, also showed increasing vorino-
stat treatment causing a more marked effect on MCF10A 
CDH1−/− cell viabilities (77%, 47%, and 26%; Fig. 3F) 
compared to MCF10A cells (79%, 57%, and 37%; Fig. 3F). 
These results infer synthetic lethality, which in the context 
of cancer therapeutics allows for greater target specificity 
toward tumor cells with reduced side effects.
As another measure of synthetic lethality, we calculated 
the viability ratio of MCF10A CDH1−/− cells to MCF10A 
cells, whereby a ratio of less than 1 indicated an increased 
susceptibility of MCF10A CDH1−/− cells to drug treatment, 
concordant with a drug-induced synthetic lethal phenotype. 
Both the resazurin reduction and nuclei-counting assays 
produced comparable viability ratios for 0.63, 1.25, and 2.5 
µM vorinostat treatment between the isogenic cell lines 
(resazurin reduction: 0.95, 0.85, 0.78; nuclei counting: 0.97, 
0.82, 0.70). This result is consistent with the IncuCyte 
confluence analysis, although the extent of this differential 
was more marked in real time. Overall, the combined 
assays demonstrated an increased susceptibility of MCF10A 
CDH1−/− cells compared to MCF10A cells with increasing 
vorinostat dose.
IncuCyte analysis showed that MCF10A cells treated 
with 1 and 2 nM Taxol exhibited negligible inhibition. 
When treated with 4 nM Taxol, MCF10A cell viability was 
affected within the first 36 hours but eventually attained 
confluence measurements similar to those of controls at the 
conclusion of the real-time assay (Fig. 3C). A similar effect 
was seen in Taxol-treated MCF10A CDH1−/− cells, although 
the highest concentration (4 nM) gave rise to growth inhibi-
tion that prevented full confluency observed in control 
treatment (Fig. 3D). The resazurin reduction and nuclei-
counting assays showed that Taxol treatment also produced 
a dose-dependent effect in both MCF10A and MCF10A 
CDH1−/− cells, without showing preferential inhibition in 
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either cell type at the tested concentration range (Fig. 3G 
and 3H). Furthermore, the viability ratios determined from 
both the resazurin reduction and nuclei-counting assays 
were not less than 1 (resazurin reduction: 1.00, 1.02, and 
1.05; nuclei counting: 1.02, 1.03, and 1.03), indicating no 
synthetic lethality. Taxol treatment at higher concentrations 
(up to 16 nM) yielded a dose-dependent effect in both iso-
genic cells lines, although no synthetic lethal phenotype 
was observed at these concentrations (data not shown). 
Here, we have shown that our combined real-time and end-
point assay approach reliably identified drug-induced 
synthetic lethal effects in the tested MCF10A isogenic cell 
lines. We have also previously used the combined IncuCyte 
and endpoint method to uncover other drugs that induce 
synthetic lethality in MCF10A CDH1−/− cells.9 The 
IncuCyte and nuclei counting were used to show that drugs 
such as crizotinib, LY2784544, and saracatinib each caused 
significantly reduced viabilities in MCF10A CDH1−/− cells 
compared to MCF10A cells.9
Our current study has shown that the IncuCyte system is 
well suited for tracking sub-confluent cell growth phases, 





































DMSO Vorinostat DMSO Vorinostat
DMSO Vorinostat
Figure 2. Cellular confluence 
measurements do not reflect 
cell densities at full surface area 
coverage. (A) Phase-contrast 
images of MCF10A cells at 48 h 
post DMSO and 1.25 µM vorinostat 
treatment (4× magnification; scale 
bars = 400 µm in length). A more 
distinct difference in cell density 
was observed in SYTOX-stained 
cell nuclei compared to the phase-
contrast images from the same field 
(fluorescent images captured using 
IncuCyte under 4× magnification). 
(B) Negligible cell viability difference 
observed between DMSO- and 
vorinostat-treated MCF10A cells 
as determined using IncuCyte’s cell 
surface confluence measurement of 
phase-contrast images in A. (C) A 
significant difference in cell density as 
quantified from nuclei enumeration 
of control and drug-treated MCF10A 
cells shown in A.
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efficacy when cells are at full confluence. In the absence of 
a real-time system like the IncuCyte, nuclei counting should 
be performed because it provided the most accurate 
measurement of viable cells in our analysis. Overall, we 
have demonstrated the utility and strengths of five viability 





































































































































































Figure 3. Combined real-time and endpoint assays facilitate the evaluation of drugs for synthetic lethal properties in MCF10A 
isogenic cells. (A–D) IncuCyte real-time confluence measurements demonstrating a selective proliferation inhibition by vorinostat 
and, to a lesser extent, by Taxol in MCF10A CDH1−/− cells compared to MCF10A cells across a range of concentrations over 48 h. 
Endpoint resazurin reduction (E, G) and Hoechst stained nuclei-counting (F, H) assays, performed immediately after the real-time 
assay (A–D), showed a greater and selective inhibition in MCF10A CDH1−/− cells across three concentrations of vorinostat but not 
Taxol. Endpoint assays show cell viabilities normalized to respective controls, representing the averaged values of three biological 
replicates with standard error shown. P-values calculated using Student’s t-test; ** P < 0.01.
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multiplexed method for the investigation of synthetic lethal 
drugs.
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C.1 Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was made by dissolving 1 PBS tablet per 100 mL mQH
2
O, 
then autoclaving to sterilise.  
 
C.2 0.05% trypsin solution 
0.05% trypsin solution was made by diluting 0.5% trypsin at a 1:10 ratio with PBS. 
 
C.3 Cell culture freezing medium 
Cell culture freezing medium was made with a final concentration of 70% complete growth 
medium, 20% horse serum or FBS (respective to serum in complete growth medium), and 10% 
DMSO. 
 
C.4 Resazurin solution 
Resazurin solution was prepared by dissolving resazurin in PBS to create a 440 μM stock 
solution. Stock solutions were aliquoted and stored at -20 °C.  
 
C.5 Laemmli buffer 
A 5x laemmli buffer stock consisted of 164.5 mM Tris-HCl (pH 6.8), 65.75% (w/v) glycerol, 
6.25% SDS, and 0.025% bromophenol blue mixed in mQH2O.  
 
C.6 SDS-PAGE 
Gels were cast in pairs using the Mini-PROTEAN II casting stand and a 15 tooth comb.  
 
Two resolving gels consisted of: 6.6 mL 30% acrylamide/bis solution, 5 mL 1.5 M Tris-HCl 
containing 0.4% SDS (pH 8.8), 26 μL TEMED, 120 μL 10% APS, and 8.26 mL mQH2O. This 
was poured to below the comb level and covered with 1 mL isopropanol while setting.  
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Two stacking gels consisted of: 1.4 mL 30% acrylamide/bis solution, 2.5 mL 0.5 M Tris-HCl 
contacting 0.4% SDS (pH 6.8), 40 μL TEMED, 50 μL 10% APS, and 6 mL mQH
2
O added. 
Following isopropanol removal, stacking gel solution was added on top of each set resolving 
gel. 
 
C.7 Running buffer 










C.8 Transfer buffer 





A 1 L 1x transfer buffer solution with 20% methanol consisted of: 100 mL 10x transfer buffer 
stock, 200 mL methanol, and 700 mL mQH2O. 
 
C.9 Tris buffered saline (TBS) 
A 10x Tris buffered saline (TBS) stock consisted of 200mM Tris and 1.5 M NaCl mixed 
thoroughly in 900 mL mQH
2
O. This was adjusted to pH 7.6 and made to 1 L with mQH2O.  
 





C.10 Tris buffered saline and 0.1% Tween-20 (TBST) 
A 1 L 1x working stock of Tris-buffered saline and 0.1% Tween-20 (TBST) solution consisted 
of 100 mL 10x TBS, 900 mL mQ H2O, and 1 mL Tween-20. 
 
C.11 Protease inhibitor cocktail 
A 25x protease inhibitor stock consisted of 1 cOmplete mini (EDTA-free) tablet dissolved in 2 
mL mQH2O. 
 
C.12 Cell culture lysis buffer containing protease inhibitors 
A 1.5 mL 1x cell culture lysis buffer containing protease inhibitors consisted of: 60 μL 25x 
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Figure	  D.1	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  	  cells	  following	  taxol	  treatment	  
MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  taxol	  over	  a	  range	  of	  concentrations.	  
At	   48	   h	   post-­‐treatment,	   cell	   viability	   was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	   assay.	   Data	  






















Figure D.1: MCF10A and MCF10A CDH1-/- cells following taxol treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with taxol over a range of 
concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained nuclei 































Figure	  D.2	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  	  cells	  following	  olaparib	  treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   olaparib	   over	   a	   range	   of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	  was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	  



























Figure D.2: MCF10A and MCF10A CDH1-/- cells following olaparib treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with olaparib over a range 
of concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained nuclei 































Figure	  D.3	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  following	  sorafenib	  treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   sorafenib	   over	   a	   range	   of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	  was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	  






















Figure D.3: MCF10A and MCF10A CDH1-/- cells following sorafenib treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with sorafenib over a range 
of concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained nuclei 






























Figure	  D.4	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  cells	  following	  PD0325901	  treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   PD0325901	   over	   a	   range	   of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	  was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	  
assay.	  Data	  represents	  averaged	  values	  of	  two	  biological	  replicates	  with	  standard	  error	  shown.	   	  
Figure D.4: MCF10A and MCF10A CDH1-/- cells following PD0325901 treatment. 
MCF10A and MCF10A CDH1-/- cells w re grown for 24 h and treated with PD0325901 over a 
range of concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained 















































Figure	  D.5	  IPH-­‐926	  cell	  viability	  following	  atorvastatin	  and	  mifepristone	  treatment	  over	  48	  hours	  
IPH-­‐926	  cells	  were	  grown	  for	  24	  h	  and	  treated	  with	  either	  atorvastatin	  (A)	  or	  mifepristone	  (B)	  over	  a	  range	  of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	  was	   assessed	   using	   a	   Hoechst-­‐stained	   nuclei	   counting	  

















































Figure D.5: IPH-926 cell viability following atorvastatin and mifepristone treatment over 48 hours. 
IPH-926 cells were grown for 24 h and treated w th either atorvastatin (A) or mifepristone (B) over a range of 
concentrations. At 48 h post-treatment, cell viability was assessed using a Hoechst-stained nuclei counting assay. 







Figure	  D.6	  MCF10A	  and	  MCF10A	  CDH1-­‐/-­‐	  	  cells	  following	  verteporfin	  treatment	  
MCF10A	   and	   MCF10A	   CDH1-­‐/-­‐	   cells	   were	   grown	   for	   24	   h	   and	   treated	   with	   verteporfin	   over	   a	   range	   of	  
concentrations.	   At	   48	   h	   post-­‐treatment,	   cell	   viability	   was	   assessed	   using	   a	   Hoechst-­‐stainednuclei	   counting	  


























Figure D.6: MCF10A and MCF10A CDH1-/- cells following verteporfin treatment. 
MCF10A and MCF10A CDH1-/- cells were grown for 24 h and treated with verteporfin over a 
range of concentrations. At 48 h post-treatment, cell viability as assessed using a Hoechst-stained 




























Adzhubei, A. A., Sternberg, M. J., and Makarov, A. A. Polyproline-II helix in proteins: 
structure and function. J Mol Biol, 425, 2100-32 (2013). 
Al-Haidari, A. A., Syk, I., and Thorlacius, H. HMG-CoA reductase regulates CCL17-induced 
colon cancer cell migration via geranylgeranylation and RhoA activation. Biochem 
Biophys Res Commun, 446, 68-72 (2014). 
Andres, A. M., Hernandez, G., Lee, P., Huang, C., Ratliff, E. P., Sin, J., Thornton, C. A., 
Damasco, M. V., and Gottlieb, R. A. Mitophagy is required for acute cardioprotection 
by simvastatin. Antioxid Redox Signal, 21, 1960-73 (2014). 
Arpino, G., Bardou, V. J., Clark, G. M., and Elledge, R. M. Infiltrating lobular carcinoma of the 
breast: tumor characteristics and clinical outcome. Breast Cancer Res, 6, R149-56 
(2004). 
Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors 
for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 
26, 3785-90 (2008). 
Barber, M., Murrell, A., Ito, Y., Maia, A. T., Hyland, S., Oliveira, C., Save, V., Carneiro, F., 
Paterson, A. L., Grehan, N., et al. Mechanisms and sequelae of E-cadherin silencing in 
hereditary diffuse gastric cancer. J Pathol, 216, 295-306 (2008). 
Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H. J., van Es, J. H., Sato, T., 
Stange, D. E., Begthel, H., van den Born, M., et al. Lgr5(+ve) stem cells drive self-
renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell, 6, 25-
36 (2010). 
Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begthel, H., Kujala, P., Vries, R., 
Peters, P. J., and Clevers, H. In vitro expansion of human gastric epithelial stem cells 
and their responses to bacterial infection. Gastroenterology, 148, 126-136 e6 (2015). 
Batlle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J., and Garcia De 
Herreros, A. The transcription factor snail is a repressor of E-cadherin gene expression 
in epithelial tumour cells. Nat Cell Biol, 2, 84-9 (2000). 
Bays, J. L., Campbell, H. K., Heidema, C., Sebbagh, M., and DeMali, K. A. Linking E-cadherin 
mechanotransduction to cell metabolism through force-mediated activation of AMPK. 
Nat Cell Biol, 19, 724-731 (2017). 
Bender, A., and Pringle, J. R. Use of a screen for synthetic lethal and multicopy suppressee 
mutants to identify two new genes involved in morphogenesis in Saccharomyces 
cerevisiae. Mol Cell Biol, 11, 1295-305 (1991). 
Berger, D. P., Fiebig, H. H., Winterhalter, B. R., Wallbrecher, E., and Henss, H. Preclinical 
phase II study of ifosfamide in human tumour xenografts in vivo. Cancer Chemother 
Pharmacol, 26 Suppl, S7-11 (1990). 
 182 
Bergstrom, J. D., Kurtz, M. M., Rew, D. J., Amend, A. M., Karkas, J. D., Bostedor, R. G., 
Bansal, V. S., Dufresne, C., VanMiddlesworth, F. L., Hensens, O. D., and et al. 
Zaragozic acids: a family of fungal metabolites that are picomolar competitive 
inhibitors of squalene synthase. Proc Natl Acad Sci U S A, 90, 80-4 (1993). 
Bertucci, F., Orsetti, B., Negre, V., Finetti, P., Rouge, C., Ahomadegbe, J. C., Bibeau, F., 
Mathieu, M. C., Treilleux, I., Jacquemier, J., et al. Lobular and ductal carcinomas of the 
breast have distinct genomic and expression profiles. Oncogene, 27, 5359-72 (2008). 
Biglia, N., Maggiorotto, F., Liberale, V., Bounous, V. E., Sgro, L. G., Pecchio, S., D'Alonzo, 
M., and Ponzone, R. Clinical-pathologic features, long term-outcome and surgical 
treatment in a large series of patients with invasive lobular carcinoma (ILC) and 
invasive ductal carcinoma (IDC). Eur J Surg Oncol, 39, 455-60 (2013). 
Bjorkhem-Bergman, L., Lindh, J. D., and Bergman, P. What is a relevant statin concentration in 
cell experiments claiming pleiotropic effects? Br J Clin Pharmacol, 72, 164-5 (2011). 
Bodo, J., Zhao, X., Sharma, A., Hill, B. T., Portell, C. A., Lannutti, B. J., Almasan, A., and Hsi, 
E. D. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically 
potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis 
through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br 
J Haematol, 163, 72-80 (2013). 
Boelens, M. C., Nethe, M., Klarenbeek, S., de Ruiter, J. R., Schut, E., Bonzanni, N., Zeeman, A. 
L., Wientjens, E., van der Burg, E., Wessels, L., et al. PTEN loss in E-cadherin-
deficient mouse mammary epithelial cells rescues apoptosis and results in development 
of classical invasive lobular carcinoma. Cell Rep, 16, 2087-101 (2016). 
Boggon, T. J., and Eck, M. J. Structure and regulation of Src family kinases. Oncogene, 23, 
7918-27 (2004). 
Boussadia, O., Kutsch, S., Hierholzer, A., Delmas, V., and Kemler, R. E-cadherin is a survival 
factor for the lactating mouse mammary gland. Mech Dev, 115, 53-62 (2002). 
Brandhagen, B. N., Tieszen, C. R., Ulmer, T. M., Tracy, M. S., Goyeneche, A. A., and Telleria, 
C. M. Cytostasis and morphological changes induced by mifepristone in human 
metastatic cancer cells involve cytoskeletal filamentous actin reorganization and 
impairment of cell adhesion dynamics. BMC Cancer, 13, 35 (2013). 
Breslin, S., and O'Driscoll, L. Three-dimensional cell culture: the missing link in drug 
discovery. Drug Discov Today, 18, 240-9 (2013). 
Brown, M. T., and Cooper, J. A. Regulation, substrates and functions of src. Biochim Biophys 
Acta, 1287, 121-49 (1996). 
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., 
Meuth, M., Curtin, N. J., and Helleday, T. Specific killing of BRCA2-deficient tumours 
with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913-7 (2005). 
Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. Breast tumor cell lines from pleural 
effusions. J Natl Cancer Inst, 53, 661-74 (1974). 
 183 
Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F., 
Kumar, A. S., Adduci, K., Marx, C., et al. Breast cancer growth prevention by statins. 
Cancer Res, 66, 8707-14 (2006). 
Canaani, D. Application of the concept synthetic lethality toward anticancer therapy: A promise 
fulfilled? Cancer Lett,  (2013). 
Cha, Y. J., Kim, Y. H., Cho, N. H., and Koo, J. S. Expression of autophagy related proteins in 
invasive lobular carcinoma: comparison to invasive ductal carcinoma. Int J Clin Exp 
Pathol, 7, 3389-98 (2014). 
Chan, G. K., Kleinheinz, T. L., Peterson, D., and Moffat, J. G. A simple high-content cell cycle 
assay reveals frequent discrepancies between cell number and ATP and MTS 
proliferation assays. PLoS One, 8, e63583 (2013). 
Chao, O. S., and Goodman, O. B. Synergistic loss of prostate cancer cell viability by 
coinhibition of HDAC and PARP. Mol Cancer Res, 12, 1755-1766 (2014). 
Charlton, A., Blair, V., Shaw, D., Parry, S., Guilford, P., and Martin, I. G. Hereditary diffuse 
gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal 
stomach and transitional zone. Gut, 53, 814-20 (2004). 
Charlton-Menys, V., and Durrington, P. N. Squalene synthase inhibitors: clinical pharmacology 
and cholesterol-lowering potential. Drugs, 67, 11-6 (2007). 
Chen, A., Beetham, H., Black, M. A., Priya, R., Telford, B. J., Guest, J., Wiggins, G. A., 
Godwin, T. D., and Guilford, P. J. E-cadherin loss alters cytoskeletal organization and 
adhesion in non-malignant breast cells but is insufficient to induce an epithelial-
mesenchymal transition. BMC Cancer, 14, 552 (2014a). 
Chen, C. H., Chen, M. C., Wang, J. C., Tsai, A. C., Chen, C. S., Liou, J. P., Pan, S. L., and 
Teng, C. M. Synergistic interaction between the HDAC inhibitor, MPT0E028, and 
sorafenib in liver cancer cells in vitro and in vivo. Clin Cancer Res, 20, 1274-87 
(2014b). 
Chou, T. C. Comparison of dose-effect relationships of carcinogens following low-dose chronic 
exposure and high-dose single injection: an analysis by the median-effect principle. 
Carcinogenesis, 1, 203-13 (1980). 
Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay 
method. Cancer Res, 70, 440-446 (2010). 
CompuSyn software for drug combinations and for general dose-effect analysis, and user's 
guide., ComboSyn, Inc., Paramus, NJ. 
Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined 
effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55 (1984). 
Christgen, M., Bruchhardt, H., Hadamitzky, C., Rudolph, C., Steinemann, D., Gadzicki, D., 
Hasemeier, B., Römermann, D., Focken, T., Krech, T., et al. Comprehensive genetic 
and functional characterization of IPH-926: a novel CDH1-null tumour cell line from 
human lobular breast cancer. J Pathol, 217, 620-632 (2009). 
 184 
Christgen, M., and Derksen, P. Lobular breast cancer: molecular basis, mouse and cellular 
models. Breast Cancer Res, 17, 16 (2015). 
Christgen, M., Noskowicz, M., Schipper, E., Christgen, H., Heil, C., Krech, T., Langer, F., 
Kreipe, H., and Lehmann, U. Oncogenic PIK3CA mutations in lobular breast cancer 
progression. Genes Chromosomes Cancer, 52, 69-80 (2013). 
Christgen, M., Steinemann, D., Kuhnle, E., Langer, F., Gluz, O., Harbeck, N., and Kreipe, H. 
Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol 
Res Pract, 212, 583-97 (2016). 
Clevers, H. Modeling development and disease with organoids. Cell, 165, 1586-97 (2016). 
Cooper, A. L., Greenberg, V. L., Lancaster, P. S., van Nagell, J. R., Jr., Zimmer, S. G., and 
Modesitt, S. C. In vitro and in vivo histone deacetylase inhibitor therapy with 
suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol 
Oncol, 104, 596-601 (2007). 
Cooper, J. A., Gould, K. L., Cartwright, C. A., and Hunter, T. Tyr527 is phosphorylated in 
pp60c-src: implications for regulation. Science, 231, 1431-4 (1986). 
Coppock, H. A., Gilham, D. E., Howell, A., and Clarke, R. B. Cyclin-dependent kinase 
inhibitors and basement membrane interact to regulate breast epithelial cell 
differentiation and acinar morphogenesis. Cell Prolif, 40, 721-40 (2007). 
Crouch, S. P., Kozlowski, R., Slater, K. J., and Fletcher, J. The use of ATP bioluminescence as 
a measure of cell proliferation and cytotoxicity. J Immunol Methods, 160, 81-8 (1993). 
Das, S., Schapira, M., Tomic-Canic, M., Goyanka, R., Cardozo, T., and Samuels, H. H. 
Farnesyl pyrophosphate is a novel transcriptional activator for a subset of nuclear 
hormone receptors. Mol Endocrinol, 21, 2672-86 (2007). 
Derksen, P. W., Liu, X., Saridin, F., van der Gulden, H., Zevenhoven, J., Evers, B., van 
Beijnum, J. R., Griffioen, A. W., Vink, J., Krimpenfort, P., et al. Somatic inactivation 
of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through 
induction of anoikis resistance and angiogenesis. Cancer Cell, 10, 437-49 (2006). 
Dietrich, C. S., 3rd, Greenberg, V. L., DeSimone, C. P., Modesitt, S. C., van Nagell, J. R., 
Craven, R., and Zimmer, S. G. Suberoylanilide hydroxamic acid (SAHA) potentiates 
paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol, 116, 126-30 
(2010). 
Do, R., Kiss, R. S., Gaudet, D., and Engert, J. C. Squalene synthase: a critical enzyme in the 
cholesterol biosynthesis pathway. Clin Genet, 75, 19-29 (2009). 
Dobzhansky, T. Genetics of Natural Populations. Xiii. Recombination and Variability in 
Populations of Drosophila Pseudoobscura. Genetics, 31, 269-90 (1946). 
Dowdy, S. C., Jiang, S., Zhou, X. C., Hou, X., Jin, F., Podratz, K. C., and Jiang, S. W. Histone 
deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and 
microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther, 
5, 2767-76 (2006). 
 185 
Dutta, A., Parikh, B., Maben, R., and Melnykovych, G. Increased dolichol content in 
glucocorticoid-sensitive human T-cell leukemia line grown in the presence of 
dexamethasone. Biochem Biophys Res Commun, 158, 163-9 (1989). 
Ekstrom, A. M., Hansson, L. E., Signorello, L. B., Lindgren, A., Bergstrom, R., and Nyren, O. 
Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma--a 
population-based study in Sweden. Br J Cancer, 83, 391-6 (2000). 
Ercan, C., van Diest, P. J., van der Ende, B., Hinrichs, J., Bult, P., Buerger, H., van der Wall, E., 
and Derksen, P. W. B. p53 mutations in classic and pleomorphic invasive lobular 
carcinoma of the breast. Cell Oncol (Dordr), 35, 111-118 (2012). 
Erlich, R. B., Kherrouche, Z., Rickwood, D., Endo-Munoz, L., Cameron, S., Dahler, A., Hazar-
Rethinam, M., de Long, L. M., Wooley, K., Guminski, A., and Saunders, N. A. 
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors 
in head and neck squamous cell carcinoma. Br J Cancer, 106, 107-15 (2012). 
Etienne-Manneville, S., and Hall, A. Rho GTPases in cell biology. Nature, 420, 629-35 (2002). 
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, 
M., Dillon, K. J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in 
BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-21 (2005). 
Fatehullah, A., Tan, S. H., and Barker, N. Organoids as an in vitro model of human 
development and disease. Nat Cell Biol, 18, 246-54 (2016). 
Fournier, A. K., Campbell, L. E., Castagnino, P., Liu, W. F., Chung, B. M., Weaver, V. M., 
Chen, C. S., and Assoian, R. K. Rac-dependent cyclin D1 gene expression regulated by 
cadherin- and integrin-mediated adhesion. J Cell Sci, 121, 226-33 (2008). 
Fukata, M., and Kaibuchi, K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat 
Rev Mol Cell Biol, 2, 887-897 (2001). 
Gan, Y., Wang, J., Coselli, J., and Wang, X. L. Synergistic induction of apoptosis by HMG-
CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochem 
Biophys Res Commun, 365, 386-92 (2008). 
Glozak, M. A., Sengupta, N., Zhang, X., and Seto, E. Acetylation and deacetylation of non-
histone proteins. Gene, 363, 15-23 (2005). 
Glozak, M. A., and Seto, E. Histone deacetylases and cancer. Oncogene, 26, 5420-32 (2007). 
Gobel, A., Thiele, S., Browne, A. J., Rauner, M., Zinna, V. M., Hofbauer, L. C., and Rachner, 
T. D. Combined inhibition of the mevalonate pathway with statins and zoledronic acid 
potentiates their anti-tumor effects in human breast cancer cells. Cancer Lett, 375, 162-
71 (2016). 
Guggenheim, D. E., and Shah, M. A. Gastric cancer epidemiology and risk factors. J Surg 
Oncol, 107, 230-6 (2013). 
 186 
Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., 
Scoular, R., Miller, A., and Reeve, A. E. E-cadherin germline mutations in familial 
gastric cancer. Nature, 392, 402-5 (1998). 
Guilford, P., Humar, B., and Blair, V. Hereditary diffuse gastric cancer: translation of CDH1 
germline mutations into clinical practice. Gastric Cancer, 13, 1-10 (2010). 
Gul, I. S., Hulpiau, P., Saeys, Y., and van Roy, F. Evolution and diversity of cadherins and 
catenins. Exp Cell Res, 358, 3-9 (2017). 
Gupta, P., Reid, R. C., Iyer, A., Sweet, M. J., and Fairlie, D. P. Towards isozyme-selective 
HDAC inhibitors for interrogating disease. Curr Top Med Chem, 12, 1479-99 (2012). 
Haataja, L., Groffen, J., and Heisterkamp, N. Characterization of RAC3, a novel member of the 
Rho family. J Biol Chem, 272, 20384-8 (1997). 
Hamid, R., Rotshteyn, Y., Rabadi, L., Parikh, R., and Bullock, P. Comparison of alamar blue 
and MTT assays for high through-put screening. Toxicol In Vitro, 18, 703-10 (2004). 
Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., Schrader, K. A., 
Schaeffer, D. F., Shumansky, K., Zogopoulos, G., et al. Hereditary diffuse gastric 
cancer syndrome: CDH1 mutations and beyond. JAMA Oncol, 1, 23-32 (2015). 
Harvey, K. F., Zhang, X., and Thomas, D. M. The Hippo pathway and human cancer. Nat Rev 
Cancer, 13, 246-57 (2013). 
Haselsberger, K., Peterson, D. C., Thomas, D. G., and Darling, J. L. Assay of anticancer drugs 
in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye 
assay in short-term cultures derived from human malignant glioma. Anticancer Drugs, 
7, 331-8 (1996). 
Head, J., and Johnston, S. R. New targets for therapy in breast cancer: farnesyltransferase 
inhibitors. Breast Cancer Res, 6, 262-8 (2004). 
Hegde, M., Mantelingu, K., Pandey, M., Pavankumar, C. S., Rangappa, K. S., and Raghavan, S. 
C. Combinatorial study of a novel poly (ADP-ribose) polymerase inhibitor and an 
HDAC inhibitor, SAHA, in leukemic cell lines. Target Oncol, 11, 655-665 (2016). 
Hennequin, L. F., Stokes, E. S., Thomas, A. P., Johnstone, C., Ple, P. A., Ogilvie, D. J., Dukes, 
M., Wedge, S. R., Kendrew, J., and Curwen, J. O. Novel 4-anilinoquinazolines with C-
7 basic side chains: design and structure activity relationship of a series of potent, orally 
active, VEGF receptor tyrosine kinase inhibitors. J Med Chem, 45, 1300-12 (2002). 
Henney, J. E. From the Food and Drug Administration. JAMA, 283, 2779 (2000). 
Henson, D. E., Dittus, C., Younes, M., Nguyen, H., and Albores-Saavedra, J. Differential trends 
in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: 
increase in the signet ring cell type. Arch Pathol Lab Med, 128, 765-70 (2004). 
Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., Clarke, R. B., 
de Jong, S., Jonkers, J., Maelandsmo, G. M., et al. Patient-derived xenograft models: an 
 187 
emerging platform for translational cancer research. Cancer Discov, 4, 998-1013 
(2014). 
Hollestelle, A., Peeters, J. K., Smid, M., Timmermans, M., Verhoog, L. C., Westenend, P. J., 
Heine, A. A., Chan, A., Sieuwerts, A. M., Wiemer, E. A., et al. Loss of E-cadherin is 
not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast 
Cancer Res Treat, 138, 47-57 (2013). 
Huber, M. A., Kraut, N., and Beug, H. Molecular requirements for epithelial-mesenchymal 
transition during tumor progression. Curr Opin Cell Biol, 17, 548-58 (2005). 
Humar, B., Blair, V., Charlton, A., More, H., Martin, I., and Guilford, P. E-cadherin deficiency 
initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res, 69, 2050-6 
(2009). 
Humar, B., Fukuzawa, R., Blair, V., Dunbier, A., More, H., Charlton, A., Yang, H. K., Kim, W. 
H., Reeve, A. E., Martin, I., and Guilford, P. Destabilized adhesion in the gastric 
proliferative zone and c-Src kinase activation mark the development of early diffuse 
gastric cancer. Cancer Res, 67, 2480-9 (2007). 
Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-87 (2002). 
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, 
L. C., and Brugge, J. S. Breast cancer-associated PIK3CA mutations are oncogenic in 
mammary epithelial cells. Cancer Res, 65, 10992-1000 (2005). 
Johnson, R., and Halder, G. The two faces of Hippo: targeting the Hippo pathway for 
regenerative medicine and cancer treatment. Nat Rev Drug Discov, 13, 63-79 (2014). 
Kalluri, R., and Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest, 
119, 1420-8 (2009). 
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., 
Clardy, J., Sellers, W. R., and Silver, P. A. A chemical genetic screen identifies 
inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-
deficient tumor cells. Cancer Cell, 4, 463-76 (2003). 
Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., and Kroemer, G. Cell death assays for drug 
discovery. Nat Rev Drug Discov, 10, 221-37 (2011). 
Kim, M. J., Kim, D. E., Jeong, I. G., Choi, J., Jang, S., Lee, J. H., Ro, S., Hwang, J. J., and Kim, 
C. S. HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell 
carcinoma cells. Anticancer Res, 32, 3161-8 (2012). 
Kirsch, C., Eckert, G. P., and Mueller, W. E. Statin effects on cholesterol micro-domains in 
brain plasma membranes. Biochem Pharmacol, 65, 843-56 (2003). 
Klein, E. A., Campbell, L. E., Kothapalli, D., Fournier, A. K., and Assoian, R. K. Joint 
requirement for Rac and ERK activities underlies the mid-G1 phase induction of cyclin 
D1 and S phase entry in both epithelial and mesenchymal cells. J Biol Chem, 283, 
30911-8 (2008). 
 188 
Kmiecik, T. E., and Shalloway, D. Activation and suppression of pp60c-src transforming ability 
by mutation of its primary sites of tyrosine phosphorylation. Cell, 49, 65-73 (1987). 
Koea, J. B., Karpeh, M. S., and Brennan, M. F. Gastric cancer in young patients: demographic, 
clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol, 7, 346-51 
(2000). 
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J., Wass, E., and Khabele, D. 
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting 
homologous recombination DNA repair in ovarian cancer. Gynecol Oncol, 133, 599-
606 (2014). 
Korhonen, T., Kuukasjarvi, T., Huhtala, H., Alarmo, E. L., Holli, K., Kallioniemi, A., and 
Pylkkanen, L. The impact of lobular and ductal breast cancer histology on the 
metastatic behavior and long term survival of breast cancer patients. Breast, 22, 1119-
24 (2013). 
Kovacs, E. M., Ali, R. G., McCormack, A. J., and Yap, A. S. E-cadherin homophilic ligation 
directly signals through Rac and phosphatidylinositol 3-kinase to regulate adhesive 
contacts. J Biol Chem, 277, 6708-18 (2002). 
Kovacs, J. J., Murphy, P. J., Gaillard, S., Zhao, X., Wu, J. T., Nicchitta, C. V., Yoshida, M., 
Toft, D. O., Pratt, W. B., and Yao, T. P. HDAC6 regulates Hsp90 acetylation and 
chaperone-dependent activation of glucocorticoid receptor. Mol Cell, 18, 601-7 (2005). 
La Vecchia, C., Negri, E., Franceschi, S., and Gentile, A. Family history and the risk of stomach 
and colorectal cancer. Cancer, 70, 50-5 (1992). 
Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, 
B., Tsai, H. W., Ward, S. C., Thung, S., et al. Combination therapy for hepatocellular 
carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with 
sorafenib. J Hepatol, 56, 1343-50 (2012). 
Lamprecht, M. R., Sabatini, D. M., and Carpenter, A. E. CellProfiler: free, versatile software for 
automated biological image analysis. Biotechniques, 42, 71-5 (2007). 
Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called 
intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol 
Microbiol Scand, 64, 31-49 (1965). 
Lechler, T., and Fuchs, E. Asymmetric cell divisions promote stratification and differentiation 
of mammalian skin. Nature, 437, 275-80 (2005). 
Lecuit, T., and Yap, A. S. E-cadherin junctions as active mechanical integrators in tissue 
dynamics. Nat Cell Biol, 17, 533-9 (2015). 
Lehmann, U. Lobular breast cancer--the most common special subtype or a most special 
common subtype? Breast Cancer Res, 17, 99 (2015). 
Li, Q., Chow, A. B., and Mattingly, R. R. Three-dimensional overlay culture models of human 
breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase 
inhibitors. J Pharmacol Exp Ther, 332, 821-8 (2010). 
 189 
Lin, Y. C., Lin, J. H., Chou, C. W., Chang, Y. F., Yeh, S. H., and Chen, C. C. Statins increase 
p21 through inhibition of histone deacetylase activity and release of promoter-
associated HDAC1/2. Cancer Res, 68, 2375-83 (2008). 
Lin, Z., Zhang, Z., Jiang, X., Kou, X., Bao, Y., Liu, H., Sun, F., Ling, S., Qin, N., Jiang, L., and 
Yang, Y. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced 
cell death in triple-negative breast cancer cells. Oncotarget, 8, 17833-17848 (2017). 
Liu, B. A., Engelmann, B. W., and Nash, P. D. The language of SH2 domain interactions 
defines phosphotyrosine-mediated signal transduction. FEBS Lett, 586, 2597-605 
(2012). 
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S. J., Anders, R. A., Liu, J. O., and 
Pan, D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses 
the oncogenic activity of YAP. Genes Dev, 26, 1300-5 (2012). 
Liwosz, A., Lei, T., and Kukuruzinska, M. A. N-glycosylation affects the molecular 
organization and stability of E-cadherin junctions. J Biol Chem, 281, 23138-49 (2006). 
Manal, M., Chandrasekar, M. J., Gomathi Priya, J., and Nanjan, M. J. Inhibitors of histone 
deacetylase as antitumor agents: A critical review. Bioorg Chem, 67, 18-42 (2016). 
Mathers, C. D., and Loncar, D. Projections of Global Mortality and Burden of Disease from 
2002 to 2030. PLoS Med, 3, e442 (2006). 
Mathieu, M. C., Rouzier, R., Llombart-Cussac, A., Sideris, L., Koscielny, S., Travagli, J. P., 
Contesso, G., Delaloge, S., and Spielmann, M. The poor responsiveness of infiltrating 
lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their 
biological profile. Eur J Cancer, 40, 342-51 (2004). 
McCracken, K. W., Cata, E. M., Crawford, C. M., Sinagoga, K. L., Schumacher, M., Rockich, 
B. E., Tsai, Y. H., Mayhew, C. N., Spence, J. R., Zavros, Y., and Wells, J. M. 
Modelling human development and disease in pluripotent stem-cell-derived gastric 
organoids. Nature, 516, 400-4 (2014). 
Meijer, A. J., and Dubbelhuis, P. F. Amino acid signalling and the integration of metabolism. 
Biochem Biophys Res Commun, 313, 397-403 (2004). 
Mills, A. A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. 
Nat Rev Cancer, 10, 669-82 (2010). 
Miranti, C. K., and Brugge, J. S. Sensing the environment: a historical perspective on integrin 
signal transduction. Nat Cell Biol, 4, E83-90 (2002). 
Moran, T. J., Gray, S., Mikosz, C. A., and Conzen, S. D. The glucocorticoid receptor mediates a 
survival signal in human mammary epithelial cells. Cancer Res, 60, 867-72 (2000). 
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63 (1983). 
Mottamal, M., Zheng, S., Huang, T. L., and Wang, G. Histone deacetylase inhibitors in clinical 
studies as templates for new anticancer agents. Molecules, 20, 3898-941 (2015). 
 190 
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., and Penn, L. Z. The interplay between cell 
signalling and the mevalonate pathway in cancer. Nat Rev Cancer, 16, 718-731 (2016). 
Mutze, K., Langer, R., Becker, K., Ott, K., Novotny, A., Luber, B., Hapfelmeier, A., Gottlicher, 
M., Hofler, H., and Keller, G. Histone deacetylase (HDAC) 1 and 2 expression and 
chemotherapy in gastric cancer. Ann Surg Oncol, 17, 3336-43 (2010). 
Nakagawa, M., Fukata, M., Yamaga, M., Itoh, N., and Kaibuchi, K. Recruitment and activation 
of Rac1 by the formation of E-cadherin-mediated cell-cell adhesion sites. J Cell Sci, 
114, 1829-38 (2001). 
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., 
Gibbons, J. J., Wu, H., and Sawyers, C. L. Enhanced sensitivity of PTEN-deficient 
tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A, 98, 10314-9 (2001). 
Nimako, G. K., Wintrob, Z. A., Sulik, D. A., Donato, J. L., and Ceacareanu, A. C. Synergistic 
benefit of statin and metformin in gastrointestinal malignancies. J Pharm Pract, 30, 
185-194 (2017). 
Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Huntsman, D. G., 
Chun, N., Kurian, A. W., and Ford, J. M. CDH1 truncating mutations in the E-cadherin 
gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann 
Surg, 245, 873-9 (2007). 
Novotny-Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., 
Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. SB939, a novel potent and 
orally active histone deacetylase inhibitor with high tumor exposure and efficacy in 
mouse models of colorectal cancer. Mol Cancer Ther, 9, 642-52 (2010). 
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., 
Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. A phase Ib 
multiple ascending dose study of the safety, tolerability, and central nervous system 
availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther, 7, 
35 (2015). 
O'Brien, J., Wilson, I., Orton, T., and Pognan, F. Investigation of the Alamar Blue (resazurin) 
fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem, 267, 
5421-6 (2000). 
Oliveira, C., Sousa, S., Pinheiro, H., Karam, R., Bordeira-Carrico, R., Senz, J., Kaurah, P., 
Carvalho, J., Pereira, R., Gusmao, L., et al. Quantification of epigenetic and genetic 2nd 
hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. 
Gastroenterology, 136, 2137-48 (2009). 
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., and Weinberg, R. A. Loss of E-
Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways. 
Cancer Res, 68, 3645-3654 (2008). 
Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C. X., Brugge, 
J. S., and Haber, D. A. Transforming properties of YAP, a candidate oncogene on the 
chromosome 11q22 amplicon. Proc Natl Acad Sci U S A, 103, 12405-10 (2006). 
 191 
Owonikoko, T. K., Ramalingam, S. S., Kanterewicz, B., Balius, T. E., Belani, C. P., and 
Hershberger, P. A. Vorinostat increases carboplatin and paclitaxel activity in non-small-
cell lung cancer cells. Int J Cancer, 126, 743-55 (2010). 
Parsons, J. T., Slack-Davis, J., Tilghman, R., and Roberts, W. G. Focal adhesion kinase: 
targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res, 14, 
627-32 (2008). 
Pastar, I., Stojadinovic, O., Sawaya, A. P., Stone, R. C., Lindley, L. E., Ojeh, N., Vukelic, S., 
Samuels, H. H., and Tomic-Canic, M. Skin metabolite, farnesyl pyrophosphate, 
regulates epidermal response to inflammation, oxidative stress, and migration. J Cell 
Physiol, 231, 2452-63 (2016). 
Pece, S., and Gutkind, J. S. Signaling from E-cadherins to the MAPK pathway by the 
recruitment and activation of epidermal growth factor receptors upon cell-cell contact 
formation. J Biol Chem, 275, 41227-33 (2000). 
Pei, Y., Liu, K. W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. 
T., Murad, N., Morrissy, S., et al. HDAC and PI3K antagonists cooperate to inhibit 
growth of MYC-driven medulloblastoma. Cancer Cell, 29, 311-23 (2016). 
Pestalozzi, B. C., Zahrieh, D., Mallon, E., Gusterson, B. A., Price, K. N., Gelber, R. D., 
Holmberg, S. B., Lindtner, J., Snyder, R., Thurlimann, B., et al. Distinct clinical and 
prognostic features of infiltrating lobular carcinoma of the breast: combined results of 
15 International Breast Cancer Study Group clinical trials. J Clin Oncol, 26, 3006-14 
(2008). 
Peternel, L., Kotnik, M., Prezelj, A., and Urleb, U. Comparison of 3 cytotoxicity screening 
assays and their application to the selection of novel antibacterial hits. J Biomol Screen, 
14, 142-50 (2009). 
Pharoah, P. D., Guilford, P., and Caldas, C. Incidence of gastric cancer and breast cancer in 
CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. 
Gastroenterology, 121, 1348-53 (2001). 
Piao, J., Chen, L., Quan, T., Li, L., Quan, C., Piao, Y., Jin, T., and Lin, Z. Superior efficacy of 
co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase 
inhibitor Trichostatin A against NSCLC. Oncotarget, 7, 60169-60180 (2016). 
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., 
Yang, L., Gibbons, J., et al. An inhibitor of mTOR reduces neoplasia and normalizes 
p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A, 98, 10320-5 (2001). 
Quent, V. M., Loessner, D., Friis, T., Reichert, J. C., and Hutmacher, D. W. Discrepancies 
between metabolic activity and DNA content as tool to assess cell proliferation in 
cancer research. J Cell Mol Med, 14, 1003-13 (2010). 
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., and Grant, S. Apoptosis induced by the kinase 
inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 
through inhibition of translation. J Biol Chem, 280, 35217-27 (2005). 
 192 
Rakha, E. A., El-Sayed, M. E., Powe, D. G., Green, A. R., Habashy, H., Grainge, M. J., 
Robertson, J. F., Blamey, R., Gee, J., Nicholson, R. I., et al. Invasive lobular carcinoma 
of the breast: response to hormonal therapy and outcomes. Eur J Cancer, 44, 73-83 
(2008). 
Rana, A., Alex, J. M., Chauhan, M., Joshi, G., and Kumar, R. A review on pharmacophoric 
designs of antiproliferative agents. Med Chem Res, 24, 903-920 (2015). 
Rasmussen, R. D., Gajjar, M. K., Jensen, K. E., and Hamerlik, P. Enhanced efficacy of 
combined HDAC and PARP targeting in glioblastoma. Mol Oncol, 10, 751-63 (2016). 
Ratheesh, A., Gomez, G. A., Priya, R., Verma, S., Kovacs, E. M., Jiang, K., Brown, N. H., 
Akhmanova, A., Stehbens, S. J., and Yap, A. S. Centralspindlin and alpha-catenin 
regulate Rho signalling at the epithelial zonula adherens. Nat Cell Biol, 14, 818-28 
(2012). 
Riss, T. L., Moravec, R. A., Niles, A. L., Benink, H. A., Worzella, T. J., and Minor, L. 2004. 
Cell viability assays. In Assay Guidance Manual, eds. Sittampalam, G. S., Gal-Edd, N., 
Arkin, M., Auld, D., Austin, C., Bejcek, B., Glicksman, M., Inglese, J., Lemmon, V., 
Li, Z., McGee, J., McManus, O., Minor, L., Napper, A., Riss, T., Trask, O. J. & 
Weidner, J. Bethesda MD. 
Roberts, A. W., Kim, C., Zhen, L., Lowe, J. B., Kapur, R., Petryniak, B., Spaetti, A., Pollock, J. 
D., Borneo, J. B., Bradford, G. B., et al. Deficiency of the hematopoietic cell-specific 
Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and 
host defense. Immunity, 10, 183-96 (1999). 
Rodriguez-Boulan, E., and Macara, I. G. Organization and execution of the epithelial polarity 
programme. Nat Rev Mol Cell Biol, 15, 225-42 (2014). 
Roskoski Jr, R. Src protein–tyrosine kinase structure and regulation. Biochem Biophys Res 
Commun, 324, 1155-1164 (2004). 
Roskoski, R., Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule 
inhibitors. Pharmacol Res, 94, 9-25 (2015). 
Roudier, E., Mistafa, O., and Stenius, U. Statins induce mammalian target of rapamycin 
(mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to 
cytostatic drugs. Mol Cancer Ther, 5, 2706-15 (2006). 
Sahai, E., and Marshall, C. J. RHO-GTPases and cancer. Nat Rev Cancer, 2, 133-42 (2002). 
Sanchez, C. A., Rodriguez, E., Varela, E., Zapata, E., Paez, A., Masso, F. A., Montano, L. F., 
and Loopez-Marure, R. Statin-induced inhibition of MCF-7 breast cancer cell 
proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated 
by an enhanced oxidative stress. Cancer Invest, 26, 698-707 (2008). 
Sawyer, J. M., Harrell, J. R., Shemer, G., Sullivan-Brown, J., Roh-Johnson, M., and Goldstein, 
B. Apical constriction: a cell shape change that can drive morphogenesis. Dev Biol, 341, 
5-19 (2010). 
 193 
Schackmann, R. C., van Amersfoort, M., Haarhuis, J. H., Vlug, E. J., Halim, V. A., Roodhart, J. 
M., Vermaat, J. S., Voest, E. E., van der Groep, P., van Diest, P. J., et al. Cytosolic 
p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated 
anoikis resistance. J Clin Invest, 121, 3176-88 (2011). 
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. NIH Image to ImageJ: 25 years of image 
analysis. Nat Meth, 9, 671-675 (2012). 
Schroeder, M. C., and Halder, G. Regulation of the Hippo pathway by cell architecture and 
mechanical signals. Semin Cell Dev Biol, 23, 803-11 (2012). 
Sebbagh, M., Santoni, M. J., Hall, B., Borg, J. P., and Schwartz, M. A. Regulation of 
LKB1/STRAD localization and function by E-cadherin. Curr Biol, 19, 37-42 (2009). 
Seelig, E., Meyer, S., Timper, K., Nigro, N., Bally, M., Pernicova, I., Schuetz, P., Muller, B., 
Korbonits, M., and Christ-Crain, M. Metformin prevents metabolic side effects during 
systemic glucocorticoid treatment. Eur J Endocrinol, 176, 349-358 (2017). 
Semb, H., and Christofori, G. The Tumor-Suppressor Function of E-Cadherin. The American 
Journal of Human Genetics, 63, 1588-1593 (1998). 
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., and Sweet, M. J. Histone 
deacetylases as regulators of inflammation and immunity. Trends Immunol, 32, 335-43 
(2011). 
Shen, Y. Y., Yuan, Y., Du, Y. Y., and Pan, Y. Y. Molecular mechanism underlying the 
anticancer effect of simvastatin on MDA-MB-231 human breast cancer cells. Mol Med 
Rep, 12, 623-30 (2015). 
Shi, Y.-k., Li, Z.-h., Han, X.-q., Yi, J.-h., Wang, Z.-h., Hou, J.-l., Feng, C.-r., Fang, Q.-h., 
Wang, H.-h., Zhang, P.-f., et al. The histone deacetylase inhibitor suberoylanilide 
hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in 
breast cancer. Cancer Chemoth Pharm, 66, 1131-1140 (2010). 
Simpson, P. T., Reis-Filho, J. S., Lambros, M. B., Jones, C., Steele, D., Mackay, A., Iravani, 
M., Fenwick, K., Dexter, T., Jones, A., et al. Molecular profiling pleomorphic lobular 
carcinomas of the breast: evidence for a common molecular genetic pathway with 
classic lobular carcinomas. J Pathol, 215, 231-44 (2008). 
Singhai, R., Patil, V. W., Jaiswal, S. R., Patil, S. D., Tayade, M. B., and Patil, A. V. E-Cadherin 
as a diagnostic biomarker in breast cancer. N Am J Med Sci, 3, 227-33 (2011). 
Single, A., Beetham, H., Telford, B. J., Guilford, P., and Chen, A. A comparison of real-time 
and endpoint cell viability assays for improved synthetic lethal drug validation. J 
Biomol Screen, 20, 1286-93 (2015). 
Sonnemann, J., Bumbul, B., and Beck, J. F. Synergistic activity of the histone deacetylase 
inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid 
against prostate cancer cells in vitro. Mol Cancer Ther, 6, 2976-84 (2007). 
 194 
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., 
Ingallina, E., Sommaggio, R., Piazza, S., et al. Metabolic control of YAP and TAZ by 
the mevalonate pathway. Nat Cell Biol, 16, 357-66 (2014). 
Sorrentino, G., Ruggeri, N., Zannini, A., Ingallina, E., Bertolio, R., Marotta, C., Neri, C., 
Cappuzzello, E., Forcato, M., Rosato, A., et al. Glucocorticoid receptor signalling 
activates YAP in breast cancer. Nat Commun, 8, 14073 (2017). 
Stiekema, J., Cats, A., Kuijpers, A., van Coevorden, F., Boot, H., Jansen, E. P., Verheij, M., 
Balague Ponz, O., Hauptmann, M., and van Sandick, J. W. Surgical treatment results of 
intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic 
approach? Eur J Surg Oncol, 39, 686-93 (2013). 
Stojadinovic, O., Lee, B., Vouthounis, C., Vukelic, S., Pastar, I., Blumenberg, M., Brem, H., 
and Tomic-Canic, M. Novel genomic effects of glucocorticoids in epidermal 
keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing 
along with promotion of terminal differentiation. J Biol Chem, 282, 4021-34 (2007). 
Sugihara, K., Nakatsuji, N., Nakamura, K., Nakao, K., Hashimoto, R., Otani, H., Sakagami, H., 
Kondo, H., Nozawa, S., Aiba, A., and Katsuki, M. Rac1 is required for the formation of 
three germ layers during gastrulation. Oncogene, 17, 3427-33 (1998). 
Tang, Y., Yacoub, A., Hamed, H. A., Poklepovic, A., Tye, G., Grant, S., and Dent, P. Sorafenib 
and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biol Ther, 13, 567-74 
(2012). 
Tangutoori, S., Baldwin, P., and Sridhar, S. PARP inhibitors: A new era of targeted therapy. 
Maturitas, 81, 5-9 (2015). 
Tansey, T. R., and Shechter, I. Structure and regulation of mammalian squalene synthase. 
Biochim Biophys Acta, 1529, 49-62 (2000). 
Tapon, N., Harvey, K. F., Bell, D. W., Wahrer, D. C., Schiripo, T. A., Haber, D., and Hariharan, 
I. K. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated 
in human cancer cell lines. Cell, 110, 467-78 (2002). 
Telford, B. J., Chen, A., Beetham, H., Frick, J., Brew, T. P., Gould, C. M., Single, A., Godwin, 
T., Simpson, K. J., and Guilford, P. Synthetic lethal screens identify vulnerabilities in 
GPCR signaling and cytoskeletal organization in E-cadherin-deficient cells. Mol 
Cancer Ther, 14, 1213-23 (2015). 
Thomas, S. M., and Brugge, J. S. Cellular functions regulated by Src family kinases. Annu Rev 
Cell Dev Biol, 13, 513-609 (1997). 
Thurnher, M., Nussbaumer, O., and Gruenbacher, G. Novel aspects of mevalonate pathway 
inhibitors as antitumor agents. Clin Cancer Res, 18, 3524-31 (2012). 
Torre, L. A., Siegel, R. L., Ward, E. M., and Jemal, A. Global cancer incidence and mortality 
rates and trends—an update. Cancer Epidemiol Biomarkers Prev, 25, 16-27 (2016). 
 195 
Tung, Y. C., Hsiao, A. Y., Allen, S. G., Torisawa, Y. S., Ho, M., and Takayama, S. High-
throughput 3D spheroid culture and drug testing using a 384 hanging drop array. 
Analyst, 136, 473-8 (2011). 
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., 
Caldas, C., Schreiber, K. E., Hardwick, R. H., Ausems, M. G., et al. Hereditary diffuse 
gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 
mutation carriers. J Med Genet, 52, 361-74 (2015). 
van Roy, F., and Berx, G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci, 65, 
3756-88 (2008). 
Varley, J. M., McGown, G., Thorncroft, M., Tricker, K. J., Teare, M. D., Santibanez-Koref, M. 
F., Martin, J., Birch, J. M., and Evans, D. G. An extended Li-Fraumeni kindred with 
gastric carcinoma and a codon 175 mutation in TP53. J Med Genet, 32, 942-5 (1995). 
Vasen, H. F., Wijnen, J. T., Menko, F. H., Kleibeuker, J. H., Taal, B. G., Griffioen, G., 
Nagengast, F. M., Meijers-Heijboer, E. H., Bertario, L., Varesco, L., et al. Cancer risk 
in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation 
analysis. Gastroenterology, 110, 1020-7 (1996). 
Vaupel, P., and Mayer, A. Hypoxia and anemia: effects on tumor biology and treatment 
resistance. Transfus Clin Biol, 12, 5-10 (2005). 
Vincent, S., Jeanteur, P., and Fort, P. Growth-regulated expression of rhoG, a new member of 
the ras homolog gene family. Mol Cell Biol, 12, 3138-48 (1992). 
Vlug, E. J., van de Ven, R. A., Vermeulen, J. F., Bult, P., van Diest, P. J., and Derksen, P. W. 
Nuclear localization of the transcriptional coactivator YAP is associated with invasive 
lobular breast cancer. Cell Oncol (Dordr), 36, 375-84 (2013). 
Vos, C. B., Cleton-Jansen, A. M., Berx, G., de Leeuw, W. J., ter Haar, N. T., van Roy, F., 
Cornelisse, C. J., Peterse, J. L., and van de Vijver, M. J. E-cadherin inactivation in 
lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer, 76, 
1131-3 (1997). 
Vukelic, S., Stojadinovic, O., Pastar, I., Vouthounis, C., Krzyzanowska, A., Das, S., Samuels, 
H. H., and Tomic-Canic, M. Farnesyl pyrophosphate inhibits epithelialization and 
wound healing through the glucocorticoid receptor. J Biol Chem, 285, 1980-8 (2010). 
Wang, C. Y., Liu, P. Y., and Liao, J. K. Pleiotropic effects of statin therapy: molecular 
mechanisms and clinical results. Trends Mol Med, 14, 37-44 (2008). 
Wang, J., Yao, X., and Huang, J. New tricks for human farnesyltransferase inhibitor: cancer and 
beyond. Med Chem Commun, 8, 841-854 (2017). 
Wang, M., and Casey, P. J. Protein prenylation: unique fats make their mark on biology. Nat 
Rev Mol Cell Biol, 17, 110-22 (2016). 
Wang, T., Seah, S., Loh, X., Chan, C. W., Hartman, M., Goh, B. C., and Lee, S. C. Simvastatin-
induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK 
 196 
signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget, 
7, 2532-44 (2016). 
Warita, K., Warita, T., Beckwitt, C. H., Schurdak, M. E., Vazquez, A., Wells, A., and Oltvai, Z. 
N. Statin-induced mevalonate pathway inhibition attenuates the growth of 
mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. 
Sci Rep, 4, 7593 (2014). 
Welti, M. Regulation of dolichol-linked glycosylation. Glycoconj J, 30, 51-6 (2013). 
Wennerberg, K., and Der, C. J. Rho-family GTPases: it's not only Rac and Rho (and I like it). J 
Cell Sci, 117, 1301-12 (2004). 
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., and Lynch, M. 
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and 
VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 7, 3129-40 
(2008). 
Wilson, W. R., and Hay, M. P. Targeting hypoxia in cancer therapy. Nat Rev Cancer, 11, 393-
410 (2011). 
Wong, W. W., Dimitroulakos, J., Minden, M. D., and Penn, L. Z. HMG-CoA reductase 
inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific 
apoptosis. Leukemia, 16, 508-19 (2002). 
Wozniak, M. B., Villuendas, R., Bischoff, J. R., Aparicio, C. B., Martinez Leal, J. F., de La 
Cueva, P., Rodriguez, M. E., Herreros, B., Martin-Perez, D., Longo, M. I., et al. 
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and 
synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. 
Haematologica, 95, 613-21 (2010). 
Wu, Y., Connors, D., Barber, L., Jayachandra, S., Hanumegowda, U. M., and Adams, S. P. 
Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal 
tubule injury potential of compounds. Toxicol In Vitro, 23, 1170-8 (2009). 
Yamada, T., Horinaka, M., Shinnoh, M., Yoshioka, T., Miki, T., and Sakai, T. A novel HDAC 
inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via 
the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol, 43, 1080-6 
(2013). 
Yang, J., and Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Dev Cell, 14, 818-29 (2008). 
Yang, P. M., Liu, Y. L., Lin, Y. C., Shun, C. T., Wu, M. S., and Chen, C. C. Inhibition of 
autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer 
Res, 70, 7699-709 (2010). 
Yap, A. S., Gomez, G. A., and Parton, R. G. Adherens junctions revisualized: Organizing 
cadherins as nanoassemblies. Dev Cell, 35, 12-20 (2015). 
Yoshioka, T., Yogosawa, S., Yamada, T., Kitawaki, J., and Sakai, T. Combination of a novel 
HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically 
 197 
induces apoptosis in human endometrial carcinoma cells due to increase of Bim with 
accumulation of ROS. Gynecol Oncol, 129, 425-32 (2013). 
Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., and Adjei, A. 
A. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase 
inhibitor BAY 43-9006. Oncogene, 24, 6861-9 (2005). 
Yu, S., Yang, X., Zhu, Y., Xie, F., Lu, Y., Yu, T., Yan, C., Shao, J., Gao, Y., Mo, F., et al. 
Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: 
comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci 
Rep, 5, 7830 (2015). 
Yu, X., Pan, Y., Ma, H., and Li, W. Simvastatin inhibits proliferation and induces apoptosis in 
human lung cancer cells. Oncol Res, 20, 351-7 (2013). 
Zhang, H., Liu, G., Dziubinski, M., Yang, Z., Ethier, S. P., and Wu, G. Comprehensive analysis 
of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast 
Cancer Res Treat, 112, 217-27 (2008). 
Zhang, J. X., Li, D. Q., He, A. R., Motwani, M., Vasiliou, V., Eswaran, J., Mishra, L., and 
Kumar, R. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting 
chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology, 55, 
1840-51 (2012). 
Zhang, X., George, J., Deb, S., Degoutin, J. L., Takano, E. A., Fox, S. B., Bowtell, D. D., and 
Harvey, K. F. The Hippo pathway transcriptional co-activator, YAP, is an ovarian 
cancer oncogene. Oncogene, 30, 2810-22 (2011). 
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., and Matthias, P. HDAC-6 
interacts with and deacetylates tubulin and microtubules in vivo. EMBO J, 22, 1168-79 
(2003). 
Zhao, B., Li, L., Wang, L., Wang, C. Y., Yu, J., and Guan, K. L. Cell detachment activates the 
Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev, 26, 54-68 
(2012). 
Zhao, H., Liang, Y., Xu, Z., Wang, L., Zhou, F., Li, Z., Jin, J., Yang, Y., Fang, Z., Hu, Y., et al. 
N-glycosylation affects the adhesive function of E-Cadherin through modifying the 
composition of adherens junctions (AJs) in human breast carcinoma cell line MDA-
MB-435. J Cell Biochem, 104, 162-75 (2008). 
Zhao, X., and Guan, J. L. Focal adhesion kinase and its signaling pathways in cell migration and 
angiogenesis. Adv Drug Deliv Rev, 63, 610-5 (2011). 
Zilberman, Y., Ballestrem, C., Carramusa, L., Mazitschek, R., Khochbin, S., and Bershadsky, 
A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase 
HDAC6. J Cell Sci, 122, 3531-41 (2009). 
Zuco, V., De Cesare, M., Cincinelli, R., Nannei, R., Pisano, C., Zaffaroni, N., and Zunino, F. 
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in 
vivo. PLoS One, 6, e29085 (2011). 
 
